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ABSTRACT
Our understanding of glycosaminoglycan (GAG) biology has been limited by a lack of sensitive and
efficient analytical tools designed to deal with these complex molecules. GAGs are heterogeneous and
often sulfated linear polys accharides found throughout the extracellular environment, and available to
researchers only in limited mixtures. A series of sensitive label-free analytical tools were developed to
provide sequence information and to quantify whole epitopes from GAG mixtures.
Three complementary sets of tools were developed to provide GAG sequence information. Two novel
exolytic sulfatases from Flavobacterium heparinum that degrade heparan/heparan sulfate
glycosaminoglycans (HSGAGs) were cloned and characterized. These exolytic enzymes enabled the exo-
sequencing of a HSGAG oligosaccharide. Phenylboronic acids (PBAs) were specifically reacted with
unsulfated chondroitin sulfate (CS) disaccharides from within a larger mixture. The resulting cyclic esters
were easily detected in mass spectrometry (MS) using the distinct isotopic abundance of boron.
Electrospray ionization tandem mass spectrometry (ESI-MSn) was employed to determine the
fragmentation patterns of HSGAG disaccharides. These patterns were used to quantify relative amounts of
isomeric disaccharides in a mixture. Fragmentation information is valuable for building methods for
oligosaccharide sequencing, and the general method can be applied to quantify any isomers using MSn.
Three other tools were developed to quantify GAG epitopes. Two microfluidic devices were characterized
as HSGAG sensors. Sensors were functionalized either with protamine to quantify total HSGAGs or with
antithrombin-III (AT-III) to quantify a specific anticoagulant epitope. A charge sensitive silicon field
effect sensor accurately quantified clinically relevant anticoagulants including low molecular weight
heparins (LMWH), even out of serum. A mass sensitive suspended microchannel resonator (SMR)
measured the same clinically relevant HSGAGs. When these two sensors were compared, the SMR proved
more robust and versatile. The SMR signal is more stable, it can be reused ad infinitum, and surface
modifications can be automated and monitored. The field effect sensor provided an advantage in
selectivity by preferentially detecting highly charged HSGAGs instead of any massive, non-specifically
bound proteins. Lastly, anti-HSGAG single chain variable fragments (scFv) were evolved using yeast
surface display towards generating antibodies for HSGAG epitope sensing and clinical GAG neutralization.
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Title: Professor of Biological Engineering
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Part I
Motivation: Needs and Aims
This thesis is motivated by the lack of analytical tools designed to deal with the
unique complexities in glycosaminoglycan (GAG) analysis, which have led to the
inability to answer complex questions in GAG biology. Glycosaminoglycans (GAGs) are
heterogeneous linear polysaccharides that are ubiquitous in the extracellular environment.
GAGs in general, and heparin/heparan sulfate glycosaminoglycans (HSGAGs)
specifically, have diverse roles in physiological and pathological processes (1-7). Present
both in the extracellular milieu and on the cell surface of virtually every cell type as part
of proteoglycans, HSGAGs serve as important control switches in a number of critical
processes, including angiogenesis (8-13) and development (14-17). HSGAGs also play a
role in mediating disease progression, such as viral invasion (18-21), tumor metastasis,
and cancer growth (22-29). The emerging view is that unique sequences of extracellular
GAGs bind specifically to proteins, including morphogens, growth factors, cytokines,
chemokines, and many other signaling molecules, influencing cell and tissue function
through these interactions (30).
The structural complexity that makes GAGs such versatile regulators also makes
them extremely challenging to study. An additional confounding factor in GAG analysis
is that they are synthesized in vivo via non-template based biosynthesis, resulting in small
heterogeneous samples (5, 31). Unlike other biopolymers (i.e. polynucleotides or
polypeptides), GAG samples cannot be amplified due to the complex nature of their
biosynthesis (i.e. there is no GAG equivalent to PCR for polynucleotides or cloning and
recombinant expression for polypeptides). As a result, the specific sequences that bind to
a given protein or signaling molecule must be purified from tissues. Studies investigating
these molecules haw been hindered by the arduous techniques needed to purify samples
to homogeneity--if and when that purification is even possible. Even the most widely
used HSGAG-based drugs, anticoagulant preparations of heparin, have not yet been fully
characterized.
These and other issues have seriously limited the use of traditional analytical
methods such as nuclear magnetic resonance (NMR), capillary electrophoresis (CE), and
high-performance liquid chromatography (HPLC), and have impeded the discovery of
GAG sequences that may have physiological significance. Recent developments in
separation techniques and mass spectrometry have increased the repertoire of analytical
techniques useful in GAG analysis, and some research has been directed at developing
techniques to rapidly study GAG mixtures. However, most of these techniques require
the sequential use of several different tools to analyze a mixture and are not suited for
high-throughput analysis or analysis of mixtures available in small amounts.
My research aims to provide higher-throughput, label- free, and sensitive tools to
analyze small amounts of GAG mixtures, to allow future analysis of physiologically and
pathologically relevant sequences and epitopes in scarce samples.
My research aims are to:
1. Develop analytical tools to enable analysis from a small sample amount
(< 10tg, a reasonable amount that can be purified from tissue culture), without
any labeling reactions;
2. Develop label-free analytical tools that increase efficiency in the use of time
and material in microsequence analysis; and
3. Develop analytical tools to enable direct analysis of specific epitopes from a
mixture utilizing specific proteins-GAG interactions.
This thesis is organized into four parts. Part one will continue onward to deal with
the background of glycan analysis,including GAG analysis, and current unmet needs in
the field. Part two will cover the techniques I developed for sensitive microsequence
analysis (aims 1-2) in three chapters: one, novel F.Heparinum exo-sequencing enzymes;
two, phenylboronic acid complexation for sulfation analysis; and three, tandem mass
spectrometry for structure determination Part three will cover the techniques I
developed for direct epitope quantification from mixtures (aims 1,3), also divided into
three chapters: one, a charge based microfluidic sensor for GAG sensing; two, a mass
based microfluidic sensor for GAG analysis; and three, single chain antibody fragment
development for epitope analysis. The fourth and final part of the thesis will detail the
implications and possible future directions for this research.
These tools should be helpful in understanding basic biology and in the development
of GAG based therapeutics; in the case of the single chain antibodies, it may be feasible
to develop these tools as GAG binding therapeutics. The techniques I have developed
may also be generally developed for heparan sulfate (HS), chondroitin sulfate (CS),
dermatan sulfate (DS), or keratan sulfate (KS) GAGs. Given the high sensitivity of these
techniques, they may also be used to analyze samples from tissue culture or animal
models, or in the clinic as diagnostics. While this thesis is intended to be read as a whole,
and these tools are meant to be used in concert, each chapter and tool also stand s alone.
Chapter 1
Integrated Approach to Glycan Structure-Function
Relationships
Understanding the complete picture of glycobiology will help develop the glycan
component of glycoprotein biologicals, therapeutics that target glycans, and stand-alone
saccharide drugs. However, the understanding of glycobiology has lagged behind other
fields due to the complexity of glycans and their interactions, and a lack of adequate tools
to investigate them. Therefore, new tools should be developed. This section details the
complex roles and varieties of glycans, created by stochastic biosynthetic machinery,
which make the structure- function relationships so difficult to elucidate. This chapter
motivates and provides context for this thesis by explaining the analytical problems
facing glycobiologists, and the current efforts to develop the new experimental and
computational tools needed solve them.
In glycobiology, it is becoming incredibly important to generate and integrate new
datasets in order to determine the bblogically relevant glycan structure-function
relationships. The complexities of glycan mixtures and the multitude of individually
limited methods currently applied to sequence these molecules necessitates this
integration. Thereafter, the structure-function relationship for these glycans needs to be
determined. In order to make this information accessible, there needs to be a system for
describing and presenting these structures in terms of the properties that lead to their
functions. In addition, the structure-function relationships for glycans are determined by
a greater number of factors than just the glycan fine structure, such as the expression and
functions of related genes and proteins. Therefore, in order to understand the complete
biological relevance of glycans, datasets should be interpreted in a systems biology
framework (i.e. within the dynamic networks of multiple types of interacting biological
elements).
1.1. Introduction to Glycobiology
The functional changes imparted by post-translational modifications (PTM) seem
to explain how human and other mammalian cells have such diverse phenotypes even
with far fewer genes than other organisms. These PTM include phosphorylation,
ubiquitination, glycosylation, and others. Glycosylated proteins dominate the
extracellular space, both as secreted and cell surface proteins. At the interface between
cells and their environment, glycoproteins have been shown to interact with many
important extracellular proteins including signaling molecules, adhesion molecules, and
immune receptors. It is through interactions with proteins such as these that glycans
impact biological processes from development to viral pathogenesis to cancer progression
(25, 32, 33). Therefore, glycoproteins are potentially important therapeutic targets.
There are two broad categories of glycans, linear and branched (34, 35).
Glycosaminoglycans (GAGs) are the major linear sugars, and the four types of GAGs in
this class are all formed of disaccharide repeat units of alternating uronic acids linked to
hexosamines. These chains may be variably sulfated, and they are O-linked to a core
protein, forming a proteoglycan aggregate (Figure 1.1A) (36). Branched glycans are
composed of a multitude of different monosaccharide building blocks, that may be O-
linked or N-linked to glycoproteins or glycolipids (Figure 1.1B) (37). Due to the various
building blocks, linkages, and patterns of sulfation, glycans are information dense (38).
Determining the structure- function relationships for these sugar structures is the key
challenge in glycobiology.
Glycosaminoglycans can further be subdivided into hyaluronic acid,
chondroitin/dermatan sulfate, keratan sulfate, and heparin/heparan sulfate based on their
monosaccharide building blocks, linkages, and modifications. The most structurally
diverse family of these molecules is the sulfated GAGs (Figure 1.2), and the subset with
the best-characterized interactions with proteins is heparin/heparan sulfate GAGS
(HSGAGs).
Unlike amino acid chains whose sequences are encoded on a nucleic acid
template, glycans are manufactured stochastically based on the coordinated expression of
synthetic and modifying enzymes and the substrates present (5, 31, 35, 39). These
enzymes are expressed in a temporal and tissue-specific manner, allowing a cell to
dynamically change its glycoprofile based on its environment (37). The function of these
enzymes has been investigated via cloning and knockout organisms, but the number of
synthetic enzymes involved complicates these studies (40-42). By virtue of the non-
template based biosynthesis, and the complexity of the glycan structures, glycans isolated
from cells and tissues are always heterogeneous mixtures of different chemical structures.
GAGs are synthesized as linear acidic polysaccharide polymers from disaccharide
units. The 10-200 disaccharide units that form each HSGAGs chain are D-glucosamine
(1--4) linked to hexuronic acid (43, 44). In its simplest form, the glucosamine (or
hexosamine, H) is N-acetylated and the uronic acid is J3-D-glucuronic acid (G).
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Figure 1.1 - Structures ofglycans
This figure has illustrative examples of linear and branched sugars. (A) Linear
glycosaminoglycans are polymers of repeated disaccharide units of uronic acids linked to
hexosamines, attached to a core tetrasaccharide. Heparin/heparan sulfate (HS) is formed
of glucuronic acid 1-4 linked to N-acetyl-glucosamine, while chondroitin/dermatan
sulfate (CS/DS) is formed of glucuronic acid 1-4 linked to N-acetyl-galactosamine. In
HS and DS the glucuronic acids may undergo C5 epimerization to iduronic acid, and then
be sulfated at the 2-0 position. HS can undergo further O-sulfation at the 3-0 and 6-0
positions of the glucosamine, while CS/DS can be 0-sulfated at the 4-0 and 6-0
positions of the galactosamine. In HS, the N-acetyl groups can be removed and replaced
with a sulfate, or left as free amines. (B) Branched glycans can be divided into N-linked
and O-linked glycans. N-linked glycans can be further subdivided into high mannose,
hybrid, and complex (such as the example shown) sugars. O-linked glycans can be
further subdivided by core type. These subdivisions of branched sugars can differ in the
number of branches, and the types of monsaccharide units present and their linkages.
* Xylose
# Uronic acid
N N-Acetyl Hexosamine
0 N-acetyl glucosamine
* Mannose
* N-acetyl neuraminic acid
A Fucose
o Galactose
0 N-acetyl galactosamine
Heparin/Heparin Sulfate
(HS)
Chondroitin Sulfate
(CS)
Dermatan Sulfate
(DS)
Keratan Sulfate
(KS)
OH NAc
Figure 1.2 - Monomer Units of Sulfated Glycosaminoglycans
This figure demonstrates the typical repeat units of the four main types of sulfated GAGs.
The key to the variable functional groups is as follows: X = H or SO4- ; Y = SO4- or Ac
or H2
OH
H20X
Modifications to this basic unit include N and O-sulfation (6-0 and 3-0 sulfation of the
glucosamine and 2-0 sulfation of the uronic acid) and epimerization of 13-D-glucuronic
acid (G) to cx-L-iduronic acid (I).
In heparin, where the number of glucosamines with free amines is insignificant,
there are 32 possible disaccharide units that can produce many combinations of linear
structures, consistent with the variety of heparin's biological function (7, 30). With these
building blocks, it is theoretically possible to have more than one million octasaccharides
and over 30 million decasaccharides. In heparan sulfate, which is expressed on many
more cell types than heparin, the addition of the free amine epitopes (31) increases the
theoretical number of disaccharide building blocks to 48, the number of possible
octasaccharides to over five million, and the number of decassaccharides to over 250
million. Furthermore, these calculations do not take into account the structural
differences created by the differences in the ring geometry of uronic acids between
iduronic and glucuronic acids. Unlike most pyranose rings, iduronate can adopt a range
of different ring conformations, including such as 1C4, 4C1, or 2So, depending on the
adjacent residues and the environmental conditions (45-47).
The heterogeneity of glycan structures allows them to interact with a wide
assortment of proteins. The aforementioned biological effects of glycans are due to their
interactions with a variety of enzymes, growth factors, cytokines, cell adhesion
molecules, and pathogens. Detailed studies have shown that in most cases, several
biological glycans can interact with graded affinities with the same protein (36, 48). The
few solved crystal structures of glycan-protein interactions show that while some
functional groups on the glycan may be critical for specificity, many others are tertiary to
the glycanrprotein interaction, allowing for considerable diversity among glycan binding
partners (36). This structural and functional overlap may be partly necessitated by the
stochastic biosynthesis of the glycan molecules, which generates an ensemble of
glycotypes for each glycoprotein.
In summary, there are several challenges to determining the structure-function
relationships for glycans. First, the chemical complexity of each glycan molecule means
that it has high information content and is difficult to analyze. Second, the norn-template
based biosynthesis means that researchers are always dealing with mixtures. The relative
abundance of each species is needed, but the easily obtained molecular weight
distribution and monosaccharide compositional analysis are not sufficient to describe
these mixtures. Third, as the samples are purified from biological sources, with no
possible amplification process, the samples will be scarce and limited. Fourth, these
glycans act in a complex and often multivalent manner in the extracellular space, so in
vitro data obtained using purified glycans is often misleading. All of these confounding
issues may be dealt with by integrating multiple data sets across various organizational
levels (49).
The rest of this chapter and this thesis will describe new tools being developed to
deal with the fundamental challenges of glycan research. New experimental procedures
aim to measure structure and sequence aspects of scarce glycans with minimal or no prior
separation from a mixture. Simultaneously, new computational tools are becoming
available to analyze and integrate these datasets to obtain the structure-function
relationships of bioactive glycans. Finally, new frameworks are being created to present
these structures in terms of the properties that lead to their functions, to better enable
expansion and utilization of this knowledge.
1.2. Analytical Techniques for Glycobiology
1.2.1. Glycan Analysis
Any detailed investigation into the structure- function relationship of glycans
involves the application of multiple techniques and the integration of multiple data sets.
Glycans are so chemically complex that single techniques are usually not capable of
sequencing these molecules. These techniques include, but are not limited to, enzymatic
or chemical digests, HPLC, CE, MS, NMR, and "hyphenated" techniques combining the
above (Table 1.3). Combining the information provided by all of the different
techniques provides its own set of challenges. Once the structures are known, the
problem of relating these structures to their functions can be tackled.
One method to deal with mixtures of glycans, and to analyze fine structure, is to
separate them during analysis. HPLC and CE have evolved as methods of choice to
separate and analyze glycans due to their increased sensitivity over traditional gel
electrophoresis and gravity column chromatography (50-52). Fine structure analysis
generally begins with the selection of a single chromogenic or mass peak (if a MS
detector is being used), followed by depolymerization or fragmentation and analysis. A
limitation of these separation methods is that they require some sort of label (radioactive,
fluorescent, or chromogenic) on the glycans.
Analytical Use Sensitivity
Technique
MALDI-MS Mass-composition relationships 
- pg-fg
ESI-MS n  Mass-composition relationships and structural - ng-pg
information from tandem fragmentation patterns
CE Electrophoretic mobility, may identify glycans with - ng-pg
properly characterized standards
HPLC Separation and preparation, may identify glycans with - mg-ng
properly characterized standards
NMR Monosaccharide composition and linkage information - mg-ug
Enzymatic Structural constraints at cleavage points based on
Digests enzyme specificities, may enable exosequencing
Table 1.3 - Analysis techniques
A brief summary of common analytical techniques used to analyze glycan structure,
along with the typical sample amounts required to utilize the techniques.
Depolymerization is frequently performed chemically or enzymatically to gain
structural information or to add labels. Some chemical digests only cut between certain
residues, or provide chemical handles for labeling, such as nitrous acid degradation of
heparan sulfate (30). Libraries of glycan-degrading enzymes (such as exo-glycosidases
or lyases) with various specificities also allow for fine structure analysis, while lyases
simultaneously leave behind double bonds that can be used as chromogenic labels (30,
51). These chemical or enzymatic digests can be complete, to gain a compositional
analysis of mixtures or individual glycans, or partial, to gain information about linkages
or moieties of a single glycan. Chromatographic shifts indicate various structures
depending on the specificities of the chemicals or enzymes used. HPLC does have the
added advantage of allowing collection of fractionated samples for later fine structure
analysis.
There are other high throughput techniques that can give information on glycan
structures without prior separation. MS has been used extensively to get the profile of
masses present in a mixture of glycans (53-57). MALDI-MS allows high throughput
glycoprofiling utilizing a minimum amount of sample. Recently, computational tools
have been developed to annotate these spectra for N-glycans while incorporating domain
knowledge from other sources (58). ESI-MSn and other tandem MS methods allow for
some structural information to be gleaned during the MS process, through isolation and
fragmentation of the glycans in the MS after ionization. Computational tools are also
being developed to sequence glycans from these spectra (59-63) (Figure 1.4). In the case
of heparan oligosaccharides, the fragment ions are compared to theoretical fragments
generated from known glycan structures, and other information gained from enzymatic
MSRitt0inLg sLLILULLA0Sn s l SALLCU
MS' fitting mass and sample history
MSn In silicofragmentation
Compare
and score
Figure 1.4 - Informatic techniques for MS" sequencing
The figure shows a paradigm for determining glycan structures using tandem mass
spectrometry (MSn). All possible glycan structures fitting the mass from the MS1 spectra
and known sample history (composition, modifications, method of generation) are
computationally generated. Known fragmentation patterns are then applied to generate
theoretical MSn fragments for each possible structure. These theoretical fragments are
compared to those actually observed, and a score is generated for each potential
sequence. Computation tools to apply this paradigm include the web accessible
GylcoFragment and GlycoSearch MS from the Glycomics Initiative of the German
Cancer Research Institute (62), and the EXCEL based Heparin Oligosaccharide
Sequencing Tool (HOST) available from researchers at UC Davis (59).
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digests is also incorporated. Cutting edge techniques such as Fourier Transform Ion
Cyclotron Resonance Mass Spectrometry (FTICR-MS) and chip-based electrospray
interface have also been applied to glycan analysis. The highly sensitive FTICR-MS can
characterize glycans, glycopeptides, and glycolipids with incredible accuracy (64-66).
Nanoscale liquid delivery from chip interfaces reduces the sample consumption by orders
of magnitude, and has been coupled to tandem MS and FTICR-MS to gain structural
information from minute amounts of glycans (67, 68). Unfortunately, this high
throughput fragmentation often does not allow unambiguous assignment of many
complex structures following MS, but much effort is being made to advance this
technique.
NMR can be used with larger amounts of glycans to obtain sequence information
from mixtures. The monosaccharide contents of glycans can be quantified by combining
the information from the one-dimensional proton and carbon spectra along with the
coupling constants from the homonuclear (gCOSY and TOCSY) and heteronuclear
spectra (HMQC, and HMBC) (69-71). This is useful to obtain ratios of sugars such as
glucose to galactose to mannose in branched glycans, or iduronic to glucuronic acid in
GAGs. Besides characterizing the ratios of specific monosaccharides, reducing-end
linkage information can be determined based on the anomeric chemical shifts. This
information is highly useful to determine linkage information for terminal sialic acids,
which can be a2-3- or a2-6-linked at the reducing terminus of the chain. To facilitate
NMR analysis, the relevant chemical shifts have been catalogued in databases (Table
1.5).
Table 1.5 - Web databases of glycan information
This table contains web accessible databases and tools relating to glycan structures and
glycan binding proteins. Resources include those available through the large Consortium
for Functional Glycomics, Glycomics Initiative of the German Cancer Research Institute,
and the Kyoto Encyclopedia of Genes and Genomes.
httn ://www.functionalelvcomics.or2/lcmc/Dbidt/hoe 1S
Glycan Profiling (catalogues the presence of N- and O-linked glycans in human and mouse tissues)
Gene Microarray (mRNA microarray data from glycogene chip)
Mouse Phenotyping (histology, hematology, immunology, and metabolism data for knockout mice)
Glycan Array (results from high-throughput screening for identifying lectin-ligand interactions)
GBP Database
http://www.functionalglycomics.org/glvcomics/molecule/isp/gbpMolecule-home. sp
GBP Molecule Page (an integrated presentation of public database and Consortium information)
Glycan Database
httD ://www.functionalglycomics.org/glycomics/molecule/isp/carbohydrate/carbMoleculeHome.jsp
Glycan Database (database containing structural and chemical information as well as related references)
Glycosyltransferase Database
http://www.functionalglycomics.org/static/gt/gtdb.shtml
tth ://www l coscien 
h
Structure Database (searchable by structures, molecular formula, composition, classification, or motif)
NMR Database (glycan NMR proton and carbon chemical shift database, searchable by atom or by peak)
MS Database (searchable by mass, will compute theoretical fragments)
KE(.i Uilycan Database Search Program: KcaM
http://www.genome.ij/ligand/kcam/
KEGG GLYCAN Database (a collection of experimentally determined glycan structures from CarbBank, recent
publications, and structures present in KEGG pathways)
KEGG Pathway Database
http://www.genome.in/keg,/pathway/map/map0 1170.html
KEGG Pathway (glycan biosynthesis and metabolism pathways with links to relevant enzymes)
Composite Structure Map: CSM
http://www.genome.jp/kegg-bin/draw csm
CSM (visual representation of all possible glycan structures generated from the KEGG GLYCAN database)
ht:/ w fucinl1c mc MI ist " -
i
Carbohydrate Active Enzymes: CAZy
http://www.cazy.org/CAZY/
CAZy (database of families of enzymes that degrade, modify, or create glycosidic bonds)
Complex Carbohydrate Structure Database: CarbBank
http://www.boc.chem.uu.nl/sugabase/carbbank.html
CarbBank (web interface to carbohydrate structure database)
Sugabase
http://www.boc.chem.uu.nl/sugabase/sugabase.html
Sugabase (glycan NMR proton and carbon chemical shift database)
Animal Lectins Database
http://www.imperial.ac.uk/research/animallectins/
information about animal lectins involved in various sugar-recognition processes
GlycoSuite Database
https://tmat.proteomesystems.com/elvcosuite/
Commercial glycan database and analysis tools
Bioinformatic techniques have the potential to improve glycan analysis by
integrating multiple complimentary data sets in an aim to get sample fine structure. It
generally takes data from several orthogonal methods to uniquely determine a sample's
fine structure. To increase throughput, analysis techniques can be combined into so
called "hyphenated" techniques or informatics-based sequencing techniques can be used
to efficiently process and combine data. At the collection level, HPLC-MS and CE-MS
have both been used successfully to get mass profiles of mixtures of glycans (57, 72, 73).
At the analysis level, several informatics-based methodologies have been developed to
use the constraints provided from data gained using multiple methodologies to converge
on the unique glycan sequence (38, 59, 74).
In order to get a structure- function relationship, the fine structure information is
combined with data about how the structure is produced and with which proteins it
interacts. But many of these analytical techniques are still limited because they remove
the glycans from their biological contexts. Frequently glycans are analyzed as mixtures
from multiple proteins (or even from whole cell or whole tissue extracts), making
interpretation of the biologically relevant functions of these glycans difficult. Glycans
may also be fragmented prior to analysis, separating epitopes on the same glycan that
may influence each other. These two factors make it difficult to determine the
biologically relevant structure- function relationships that may require intact
proteoglycans, such as multivalent interactions, allosteric interactions, and mixed protein-
glycan interactions (75). Tools that increase sensitivity and throughput (by integrating
orthogonal data sets, and utilizing the strengths of each) may allow analysis of glycans
from single protein preparations. Computational techniques, especially those that
incorporate knowledge of biosynthetic pathways, may also be able to reassemble whole
glycan structures from sequenced fragments or from partial sequence data. In these
ways, bioinformatic techniques may overcome many of the major limitations of glycan
analysis.
1.2.2. Glycogene and Glycoprotein Analysis
A systems biology approach to glycan structure-function analysis must include
the proteins that synthesize or interact with the glycans, and the genes that encode them.
Analysis of glycogene expression is being undertaken to try and relate protein levels to
glycobiology. At the same time, investigations of glycan-protein interactions are also
being completed to understand the structure- function relationships of glycans.
Understanding these components is critical to determine the full picture of how glycans
are utilized in biology, and how cells regulate their influence.
One of the more powerful tools in systems biology is the gene chip, which allows
for the simultaneous analysis of the mRNA expression levels of thousands of genes.
Although there are advanced commercial gene expression chips available, most notably
those from Affymetrix, glyco- gene specific DNA microarrays have been developed.
These arrays focus on overcoming the challenges of using whole genome chips, such as
limited representations of glycan synthesis enzymes and limited sensitivity of these
measurements compared to other proteins (76). While RT-PCR techniques can analyze
any glycan related transcripts with the highest specificity and sensitivity, this lower
throughput technique can only analyze a handful of transcripts simultaneously.
Customized glyco-gene microarrays, based on the Affymetrix technology, have been
designed for the NIGMS funded Consortium for Functional Glycomics (CFG) and have
been used to analyze hundreds of samples (76). These microarrays simultaneously
provide information on the expression of biosynthetic enzymes and glycan binding
proteins. These data can then be combined with data gained from analyzing the actual
glycan structures purified from the same samples.
Since glycans affect biology through their interactions with proteins, it is critical
to understand the specificity of glycan-protein interactions. The term glycan binding
protein (GBP) can be used to describe proteins involved in cell adhesion, as well as
trafficking and signaling events, that interact with either N- or O-linked glycans (34, 35,
77). GBPs also include foreign proteins that act as receptors for pathogens to attach to
host-cell glycans. Three major classes of GBPs are C-type lectins, galectins, and siglecs.
Each binding site on these GBPs usually binds to tetrasaccharide or smaller epitopes,
with relatively low (micro- to millimolar) affinity. Some sulfated glycosaminoglycan
binding proteins can bind to slightly longer epitopes with slightly higher affinities. Low
affinities to epitopes can be overcome in vivo by the multivalent binding of glycans to a
multimeric association of GBPs. These multivalent units can be soluble or membrane-
bound, dispersed or localized (48).
GBPs have been used to analyze the glycans present in a mixture based on their
specific affinities. On the other hand, various strategies have been used to construct
glycan ligands to investigate the binding affinity of GBPs. The specificities of
recombinant or purified GBPs, including lectins, have been used in column or array
format to analyze glycosylation patterns (78). Solid phase and chemo-enzymatic
synthesis techniques have allowed the construction of diverse glycan structures (79, 80).
These structures have been used in assays to determine binding affinities of GBPs to
various ligands (48), and to devise inhibitors of the physiological glycan-protein
interactions.
The CFG has developed two types of glycan arrays; one array has soluble glycan
ligands in a well-based assay and a second array has a solid phase glycan printed onto an
NHS-activated glass slide (81). The printed array mimics the surface distribution of
glycans exhibited on cell surfaces, and may be more physiologically relevant. The GBPs
are then presented at high enough concentrations so that they can be present in their
multimeric states. Detection schemes for protein- glycan binding include using primary
antibodies to the GBPs followed by labeled secondary antibodies, similar to standard
ELISA setups, or by directly labeling the proteins (Figure 1.6). These glycan arrays
have been successfully utilized to investigate the ligand specificities of physiologically
important GBPs such as Dendritic Cell-Specific ICAM Grabbing Nonintegrin (DC-
SIGN) and DC-SIGN related (DC-SIGNR) protein (82). We anticipate developing
glycan arrays with differing GAG epitopes for characterization of GAG binding GBPs.
When analyzing GBPs, and the genes that code for them, one must be careful in
determining the relationships between the data and the biology. For example, the
connection between relative gene expression changes in synthetic enzymes and actual
glycan structures is not proven or deterministic. Also, in vitro experiments investigating
interactions between GBP and glycans must be carefully designed and accurately
scrutinized with regards to how well they reflect biologically relevant interactions.
Interaction assay formats that may limit the freedom of movement of glycans or GBPs
could misrepresent the biology where these components are free to move and interact in a
(D)
Figure 1.6 - Glycochips
Glycochips developed by the Consortium for Functional Glycomics can be used to
determine glycan-binding specificities for GBPs. (A) Libraries of biological and
synthesized glycans are generated, with attached linkers (magenta). (B-C) These glycans
(cyan) can be assayed for binding to a GBP (red) presented in monomeric or multimeric
forms either in a soluble well-based format or attached to a surface. (B) Glycans with a
biotin linker can be attached to a well surface through streptavidin molecules (blue). (C)
Glycans with an amine linker can directly be printed onto an NHS activated glass slide.
Relative binding can be detected via a primary/labled secondary antibody system (black
and green in A) or by directly fluorescently labeling the GBP (green in B). (D) During
data analysis, the data for each well is linked back to the original glycan structure in the
database, and to other data sets.
multivalent manner. Our increasing body of knowledge on these biologies should inform
our assay design and data interpretation in the future.
1.3. Bioinformatics platforms for glycomics
Multiple datasets, spanning from fine structure analysis to gene expression data to
GBP binding data, need to be integrated to completely understand the biology of glycans.
In order to integrate, process, and present this data in the most meaningful manner a
bioinformatic framework must be developed. One of the most important potential use of
the tools discussed herein is to be able to link and integrate orthogonal data sets generated
from identical or similar samples, generated at different times or by different
investigators. While many techniques for analyzing other biopolymers, such as DNA or
proteins, have been transferred to analyzing glycans, the chemical complexity and
branching nature of some glycans presents unique challenges for integrating and
presenting relevant data. The field has been steadily progressing, from early attempts at
glycan structure databases and analysis such as the failed Complex Carbohydrate
Structures Database (CCSD) to ongoing current efforts such as the Glycosuite database
(83), KEGG Glycan database (84), and other tools for representing and analyzing glycan
structures (85-87) (Table 1.5).
It would be a great aid to investigators to present data in a manner where
relationships between different entries in the database are clear. In order to achieve this,
an object-based relational database was developed by CFG. The three primary objects in
this glycomics database are the biosynthetic enzymes, the glycan structures, and the
GBPs. The datasets generated by the aforementioned techniques are then organized into
other levels of objects that have defined relationships to each other and to the primary
objects. The ontology diagram that encompasses the definitions and relationships is
exceedingly complex - but software has been developed to facilitate data input and
analysis without the investigators being weighed down by this complexity. The user
interface is separated from the back-end database by middleware that communicates
between the two. Therefore the investigator's data are automatically organized and
integrated after input, allowing investigators to see how different proteins or glycans
relate to each other.
An important aspect of the data- integration process is to link orthogonal data sets
from identical or similar samples. For example the compositional analysis and NMR data
from a GAG sample from a tumor type would need to be integrated and then associated
with any gene expression data or immunological profiles from the same tumor type. This
integration is critical for understanding the complete picture of how the glycans are
influenced or are influencing the pathology or biology of the tumor, and therefore tools
need to be developed to integrate these data sets.
Another aid to investigators would be to present the data in a useful, familiar, and
searchable manner. The CFG has introduced a molecule page, becoming standard in
genomics and proteomics (88), that presents information on a single molecule from the
molecular to organism level. The CFG molecule pages can automatically acquire
information from other public databases, interface with CFG data, and show
contributions from a group of experts. This easy to use and familiar interface enables
faster assimilation of data by the investigator. In addition, the bioinformatics platforms
need to allow data mining from the stored data sets. For example, the availability of
diverse datasets via relational databases may allow computational identification of the
structural determinants that allow multivalent high-affinity glycan interactions with
specific GBPs, analogous to computational analysis of genomes to identify promoters or
computational analysis of protein sequences to find conserved functional domains.
1.4. Applications
Glycans and glycoconjugates have inherent advantages over protein or nucleotide
based drugs that give them great potential as therapeutics. In general, glycans are
smaller, more stable, and more easily formulated for drug delivery than protein based
drugs (49). In addition, glycans are potentially less immunogenic than protein and
nucleotide based therapies (89). Unfortunately, the manufacture of complex glycans is
far more difficult than other biopolymers because glycans cannot be easily synthesized
chemically or by using molecular biology tools. The identification of target glycan based
drugs is also hindered by the lack of known structure- function relationships. In order to
harness the potential of glycans as therapeutics, these hurdles need to be overcome.
Advancing the use of glycans in biotechnological applications requires knowledge
of their structure-function relationships. The GAG heparin was first used as an
anticoagulant before its mechanism of action was understood. But as our understanding
of heparin's mode of action has advanced (90), new and better heparinoids have been
developed that are more potent and have fewer side effects than the original
unfractionated heparin (91). More recently, glycan related genetic disorders (such as
Gaucher's disease and Mucopolysaccharidosis type 1) have been treated by replacement
therapy with enzymes that modify glycan structures. These therapies required a detailed
understanding of protein effects on glycan structure and the role of glycan structure in
disease. In contemporary drug development, glycoprotein drugs such as the anti-anemia
glycoprotein drug erythropoeitin have been modified to change their glycosylation
patterns (which resulted in Aranesp)-and these modifications have changed the
pharmacokinetic properties of these proteins (92). These examples illuminate different
areas where glycans are involved in drug development- either as stand-alone
saccharides, as targets themselves, or as components of glycoproteins (Table 1.7).
Several bioactive saccharides, either synthesized or purified from biological
sources, are already in use in the clinic. The first strategy for manufacturing glycan-
based drugs involves isolating and modifying natural glycans. This approach is
technologically less challenging and scales easily, so it has been widely used to create the
largest class of glycan drugs, the low molecular-weight heparins (LMWHs) (91). The
currently used LMWHs are derived from unfractionated heparin purified from animal
sources, with each LMWH then being degraded into smaller pieces using different
degradative methods. While these drugs are more controlled than the starting material,
they remain heterogeneous mixtures. In order to understand their composition, to design
better LMWH, and to recreate generics of these drugs, various orthogonal datasets
needed to be integrated to come up with a complete description of the mixture. Multiple
rationally designed LMWH are in development to take advantage of our continually
improving understanding of the mechanisms of action of these molecules (93). The first
Disease /Drug Name Use Drug Clinical Status Manufacturer
Lovenox Thrombosis LMWH generated by Market Aventis
chemical
depolymerization
Fragmin Thrombosis LMWH generated by Market Pfizer
chemical
depolymerization
Arixtra Thrombosis Synthetic Market Sanofi
oligosaccharide
Healon Cataracts High molecular weight Market Pfizer
sodium hyaluronate
Seprafim Anti- Chemically modified Market Genzyme
adhesive sodium hyaluronate and
carboxymethyl cellulose
Aranesp Anaemia Glycoprotein Market Amgen
genetically engineered
for increased
glycosylation
Aldurazyme MPS I Lysosomal glycan Market Genzyme
degrading enzyme
PI-88 Cancer Heparan sulfate mimetic Phase II Progen
Table 1.7 - Glycan based therapeutics
This table lists representative glycan-based therapies, focusing on those already
approved.
pure glycan pharmaceutical, the pentasaccharide fondaparinux (Arixtra), was created by
de novo chemo-enzymatic synthesis for use as an anticoagulant (94). Although synthesis
of complex glycans is difficult, new solid-phase synthetic techniques for linear and
branched sugars analogous to those in use for peptide and nucleic acids are in continuous
development, and have been used already for carbohydrate-based vaccines.
Although the only prevalent uses of HSGAGs in the clinic take advantage of their
anti-coagulant function, many other biological activities have been demonstrated (95).
Extracellular GAGs bind specifically to many important proteins, including morphogens,
growth factors, cytokines, chemokines and many other signaling molecules, and
influence cell and tissue function through these interactiors. Outside of anticoagulation,
these proteins are involved in angiogenesis, wound healing, viral entry, development, and
cancer (30). There may be a direct role of HSGAGs in the potent anti-angiogenic activity
of endostatin (9). HSGAGs are involved in cell migration and wound healing by binding to
fibronectin and promoting focal adhesion formation by activating PKC (101). Two herpes virus
glycoproteins bind HSGAG, mediating the entry of the virus into the host cell (20, 102, 103).
Various pathways crucial in development are affected by HSGAGs, including Wingless
signaling in Drosophila (14, 104, 105) and FGF signaling in neuronal development (106).
Recent studies have shown that the cell surface heparan sulfate of tumor cells changes as
a function of tumor status (107, 108), and may act as a barrier to tumor metastasis (9,
109, 110). The number and type of known HSGAG-protein interactions is continually
increasing.
A good example of a growth factor that interacts with HSGAG is basic fibroblast
growth factor (bFGF). bFGF binds specifically to a tetrasaccharide with the sequence of
(I2S-HNS,6s)2 . Co-crystal structures of tetra and hexasaccharides with bFGF indicate the
presence of a high affinity and a low-affinity binding site on HSGAGs with different
iduronate ring conformations (Appendix 3) (96, 97). Like AT-III inhibiting thrombin,
longer oligosaccharides (10-12 saccharides) are required for FGF signaling (98).
Differences in cell surface HSGAGs have been implicated in modulating the specificity
of FGF-FGFR interactions, demonstrating another sequence specific activity (99). In
addition to the specific sequence requirement for FGF-FGFR complexes, there is
evidence that different FGFs have distinct HSGAG requirements with respect to HSGAG
sequence and length (100). This interaction provides a snapshot of how specific GAG
structures can mediate cellular function.
Since most circulating proteins in the body are glycoproteins, many therapeutic
proteins derived from antibodies, growth factors, and cytokines are also glycoproteins.
The glycan component of these proteins has been shown to influence protein function,
immunogenicity, and pharmacokinetic properties such as half-life and stability. Since, in
general, proteins are expressed with various glycoforms, there is the opportunity to
influence the quality of a protein therapeutic by influencing its natural glycosylation
(111, 112). The glycan components can also be rationally modified beyond the natural
glycoforms. To return to the erythropoietin example, not only does adding glycoslyation
sites increase the erythropoietic activity and serum half life, but removing the capping
sialic acids from the glycans decouples broad neuroprotective activities from the
erythropoietic activity (92, 113).
Researchers have attempted to modulate the glycosylation of proteins by either
adding chemicals to influence biosynthesis, by genetically manipulating the cells in
which the proteins are produced, by modifying the proteins in vitro after their translation,
or by modifying the protein backbones themselves. While proteins are being synthesized,
the affects of changing cell culture conditions or adding specific natural monosaccharides
have been investigated (111, 112, 114). More recently non-natural amino acids or
monosaccharides with chemical handles, which can be incorporated with the native
machinery, have been added for later use in analyzing or in tailoring the glycosylation
(115-119). Mammalian and insect cell lines have been successfully genetically modified
to simplify the variety of glycoforms produced, and various efforts have been made to
accomplish the gargantuan task of replicating the mammalian glycosylation machinery in
yeast cells (120). Another strategy is to attach specific saccharides after the proteins are
made, either chemically or using exogenous glycosyltransferases. Development of
chemoselective and chemoenzymatic techniques to modify proteins in vitro has
demonstrated success (121). Finally, the gene for the protein itself can be modified to
change glycosylation sites, as mentioned before in the erythropoietin example.
New analytical and bioinformatic techniques that advance our understanding of
the structure-function relationships in glycans are essential to the use of glycan-based
therapies in two important ways. First, understanding the structure- function relationships
in normal and pathological situations allows for the targeted design of new therapeutics.
Second, understanding the structure- function relationships of existing drugs allows the
complete description of their activities enabling the design of generics, as well as the
modification of existing drugs to create new tailored molecules with differing activities.
1.5. Conclusions
The growing success of glycan and glycoprotein pharmaceuticals, based on
increased understanding of the structure- function relationships of specific glycans, is
motivating increasing amounts of research into glycobiology at the basic science,
translational and clinical research levels. Simultaneously, new analytical methods are
generating larger and more diverse data sets about glycans and their functions. These
developments present challenges and opportunities, including the need to integrate
several types of measurements that yield complementary data sets, the need to represent
data in a meaningful way, and the need to allow data mining to answer relevant
questions. These challenges include explaining glycan diversity regulation as a function
of glycan biosynthesis, explaining the basis for specificity and the effect of valency in
glycan-protein interactions, and explaining how extracellular glycans regulate cell-cell
communication and signal transduction Understanding glycan biology should guide
researchers aiming to create new and better glycan, glycan modifying, and glycoprotein
research products and pharmaceuticals. Tools are continually being developed to address
these challenges, including those tools presented in this thesis. The perfection,
standardization, and adoption of these new tools should is key to advancing this field.
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Part II
Tools for Glycosaminoglycan Sequence Analysis
There is a significant need for GAG microsequencing tools in order to help
elucidate the structure-function relationships for GAG-protein interactions. Sequence
analysis is generating data on the identity and order of the disaccharides making up an
oligosaccharide-analogous to the amino acid sequence of a protein. Sequence analysis
is performed both to understand which GAG structures interact with which proteins and
to analyze GAG samples to see which active structures they may contain. With this
information, in combination with protein sequence and structure data, one may be able to
predict which GAG sequences and proteins interact with one another. One may also use
this knowledge to help design synthetic GAGs (or biosynthetic GAGs) for use as
therapeutics.
Part two of this thesis is divided into three chapters. Each chapter contains a
novel toolor tools, for providing sequence and structural data on scarce amounts of
unlabeled GAGs. The first chapter in this section details the addition of two new
Flavobacterium heparinum GAG degrading enzymes to the enzymatic toolbox. These
enzymes are useful for exo-sequencing of small oligosaccharides, determining the
presence or absence of a single sulfate at a time, when applied downstream of the earlier
enzymes in the F. heparinum pathway. The second chapter in this section deals with
proof of principle experiments showing the utility of boronic acid complexation with
GAGs, in combination with a mass spectrometery based readout, for the determination of
specific unsulfated disaccharide units within GAG mixtures. The third chapter in this
section deals with a method for performing disaccharide compositional analysis on
HSGAGs without separation. This method involves establishing fragmentation patterns
for specific epitopes in tandem mass spectrometry; this didactic chapter teaches generic
methods to quantify any set of isomers from a mixture. The information learned from the
fragmentation patterns of small saccharides may be used to generate methods of
sequencing larger saccharides.
Chapter 2
Novel F. Heparinum Exo-sequencing enzymes
The molecular cloning and biochemical
characterization of two additional sulfohyrolases from
F. heparinum involved in the sequential degradation of
heparin/heparan sulfate.
2.1.
Heparan sulfate glycosaminoglycans (HSGAGs) comprise an important
polysaccharide constituent of many proteoglycans (1). These glycans are linear polymers
based on the variably repeating disaccharide unit (uronic acid a/f1-*4 glucosamine)n
where n represents a variable number of repeats (typically 10-200). As present in nature,
these sugars possess an extensive chemical heterogeneity which is largely attributed to
the mosaic arrangement of 0- and N- linked sulfates present at different positions along
each sugar chain (2, 3). Additional structural variations include the presence of N-linked
acetates at the glucosamine C2 position as well as the epimerization of the uronic acid C5
carboxylate that distinguishes 8-D-glucuronic acid from a-L-iduronic acid. Fundamental
to understarding HSGAG structure-activity relationships is the appreciation that the
polydispersity of glycan fine structure is not random. Instead, it is the end product of a
complex and concerted biosynthetic pathway involving numerous modifying enzymes,
whose relative expression levels and specific activities are regulated in a cell and tissue
specific fashion. This programmed diversity of HSGAG structure (4) ultimately plays
out at a functional level, namely through the dynamic regulation of numerous
biochemical signaling pathways (2) relating to such processes as cell growth and
differentiation (5), cell death (6, 7), intercellular communication, adhesion, and tissue
morphogenesis (8). HSGAGs (present as structurally-defined binding epitopes on the
cell surface) also play an important role in microbial pathogenesis (9, 10).
In contrast to the complex enzymatic process by which these polysaccharides are
made, it appears that their catabolism is considerably more straightforward, both in the
scope of its purpose and the means by which it is carried out at the biochemical level. In
the mammalian lysosome for example, GAG degradation follows an obligatory sequence
of depolymerization steps, using enzymes which follow a predominantly exolytic mode
of action. As such, the substrate specificity of one enzyme is largely predicated on the
activity of the enzymes which precede it. Essential to this sequence are several
sulfohydrolases which desulfate the sugar backbone as a prerequisite to the ensuing
glycosidase step. These sulfatases are structure-specific enzymes, each one hydrolyzing
a unique sulfate position within the heparin disaccharide repeat unit present at the non-
reducing end.
Sequential GAG degradation is not unique to the eukaryotic lysosome, however.
This process has been demonstrated in several microorganisms as well (11-13), which
depend on these sulfated polysaccharides not only as a carbon source but often as a
means of scavenging inorganic sulfate (14). The gram-negative soil bacterium
Flavobacterium heparinum (a.k.a. Pedobacter heparinus) is an excellent example of this
process, having also proven to be a particularly rich biological source for the isolation
and molecular cloning of several GAG degrading enzymes (15, 16). Like the lysosomal
pathway, many of the flavobacterial enzymes possess a high degree of substrate
specificity.
Understanding sulfatase enzymology becomes important on several levels. On
one level, these enzymes play a critical functional role in the maintenance of the
appropriate steady-state levels of bioactive sugars within a given tissue. Loss of this
homeostasis due to genetic defects (e.g., mucopolysaccharidoses) often has profound
pathological ramifications (17). Sulfated carbohydrates also serve as important structural
epitopes in mediating cell-cell interactions and extracellular signaling pathways. Recent
experimental evidence also points to the regulated expression of endolytic HSGAG
desulfating enzymes and their secretion into the extracellular matrix as a mechanism of
modulating these critical GAG-protein interactions (18, 19). The biological relevance of
the HSGAG sulfatases has been, and continues to be, a major impetus behind many of the
biochemical studies.
The use of HSGAG degrading enzymes as analytical tools is central to unlocking
the structural basis of HSGAG function and their potential use in generating structure-
specific, bioactive glycans for therapeutic applications (20). To do so effectively,
however, not only requires a detailed understanding of the biochemistry of these
enzymes, it also requires their ample availability for in vitro use. Both of these criteria
already have been satisfied in structure- function studies of several HSGAG-related
degrading enzymes such as the heparinase enzymes (21-23), and the 2-O-sulfatase (24) .
In this chapter, the molecular cloning and recombinant expression in E. coli of two
additional F. heparinum sulfohydrolases, namely the glucosamine 6-O-sulfatase and the
N-sulfamidase, are reported. The detailed biochemical characterization of the
recombinant enzymes as it relates to its optimal reaction conditions, the role of divalent
metal ions, and most importantly, a description of their respective substrate specificities
is also presented. From these studies, it is possible to recorstruct in vitro the sequential
HSGAG degradation pathway of F. heparinum and use this obligatory sequence to
demonstrate their effective application in the exo-sequencing of a heparin derived
oligosaccharide.
2.2. Materials and Methods
Reagents
Fluorescent glucopyranoside substrates 4-methyllumbelliferyl-a/1-D-
glucopyranoside (4-MU-a-D-Glc, 4-MU-B-D-Glc) were purchased from EMD
Biosciences, Inc (San Diego, CA). 6-0 and N-sulfated fluorogenic glycopyranoside
derivatives were obtained through Toronto Research Chemicals (Toronto, Canada).
Glucosamine and galactosamine monosaccharides, arylsulfate substrates 4-catechol-
sulfate and 4- methyllumbelliferyl-sulfate were purchased from Sigma Chemical Co. (St.
Louis, MO). Exo-glucosidases were purchased from MP Biomedicals (Irvine, CA).
Materials for genomic library construction and screening were obtained from Stratagene
(La Jolla, CA). PCR enzymes, TOP10 chemically competent cells, and oligonucleotide
primers were obtained from Invitrogen (Carlsbad, CA). Additional molecular cloning
reagents were purchased from New England Biolabs (Beverly, MA) or the manufacturers
listed.
Molecular cloning of Flavobacterial 6-0 sulfatase and N-sulfamidase
Both flavobacterial sulfatase genes were cloned by PCR from a XZAPII
flavobacterial genomic library originally screened using DNA hybridization probes
specific to the 2-O-sulfatase (25). Library construction, hybridization screening, and
phage excision were as described. Two overlapping clones were expanded by
chromosomal walking and restriction mapping using the Lambda DASH II genomic
cloning kit (Stratagene) for the ligation of size fractionated genomic DNA (generated by
a partial Sau3A I digestion). 2-0- sulfatase positive clones from an amplified library
were plaque purified through three successive rounds and the DNA purified from a high
titer lysate using standard techniques (26). For DNA sequencing, recombinant phage
DNA was subcloned into pBluescript SK+/-. The coding sequences of two putative
sulfatase genes (described throughout this chapter as ORF B and ORF C) were identified
by the canonical PFAM (27) sulfatase family identifier (CXPXRXXXXS/TG) and
subsequently PCR amplified using the following primer sets: 1) for ORF B (6-0-
sulfatase), 5' GAA TTC ATA TGG GTA AAT TGA AAT TAA TTT TA 3' (forward)
and 5' GGA TCC TCG AGT TAT AAA GCT TCA GTT GGA TTC GT 3' (reverse); 2)
for ORF C (N-sulfamidase), 5' TCT AGA CAT ATG AAA TTT AAC AAA TTG AAA
TAT TTC 3' (forward) and 5' GGA TCC TCG AGT TAC TTC AAA TAA TTG TAA
CTG GAA T 3' (reverse). Amplified genes were subcloned into the T7-based bacterial
expression vector pET28a (Novagen) as an Nde 1-Xho 1 cassette (restriction sites
underlined). Cloning as such allowed these genes to be expressed as an NH2-terminal 6X
His fusion with an intervening thrombin cleavage site for facile removal of this tag
following protein purification.
Bacterial expression and protein purification
Recombinant protein expression in the E. coli strain BL21 (DE3) and one-step affinity
purification by Nickel chelation chromatography were as described for the 2-O-sulfatase
(25). The prediction of NH 2-terminal signal sequences and putative cleavage sites for the
two respective proteins was made by the Von Hejne computational method (28).
Engineering and expression of these truncated proteins (minus signal sequences) was as
described above for the full- length genes with the exception of substituting the 5' primers
which were used in the original PCR amplification step. These internal primers included
5' TCT AGA CAT ATG TCT TGC CAG CAG CCT AAA C 3' (for ORF B) and 5' TCT
AGA CAT ATG TCC TGC ACT TCG CCG GAA 3' (for ORF C), with Nde 1 site
underlined. As such, the ORF B gene sequence begins at Met 18. (Figure 2.1) Likewise,
the ORF C gene sequence begins at Ser 21 (Figure 2.2). Removal of the 6X His tag was
achieved by site-specific protease cleavage using the thrombin cleavage capture kit
(Novagen). Proteolysis conditions were generally as described for other recombinantly
expressed flavobacterial heparin degrading enzymes. Following concentraton of the
enzymes by ultrafiltration, cleaved proteins were dialyzed against 4 liters of 50 mM Tris,
pH 7.5 and 0.1 M NaC1, 4oC, overnight using a 3 mL slide-a-lyzer cassette with a 10,000
molecular weight cutoff (MWCO) (Pierce Chemical, Rockland IL).
Final protein concentrations were determined colorimetrically using the Bradford
Assay (Bio-Rad) and confirmed by UV absorption spectroscopy using theoretical molar
extinction coefficients (E280) of 94,730 M- (61,572 Da) and 86,340 (53,193 Da) for the
NH2-terminally truncated ORF B (6-O-sulfatase) and ORF C (N-sulfamidase),
respectively. These values were calculated for thrombin-cleaved proteins lacking a 6X
His purification tag. Enzymes were stored at 40C at a concentration of -10 mg/mL. Full
enzyme activity was retained for several months under these conditions.
Arylsulfatase Assay
Arylsulfatase activity was measured independently using two chromogenic
substrates, 4-catechol-sulfate and 4-methylumbelliferyl-sulfate (4-MUS). The catechol
substrate assay was
conducted generally as described (29). Briefly, 10 mM substrate was incubated with -30
pM recombinant enzyme overnight (12-15 hours) at 370C in a 100 pL reaction which
included 50 mM MES pH 7.0 and + 2 mM CaCh. Reactions were quenched by the
addition of 5 [tL 5M NaOH and colorimetric activity determined spectroscopically at 515
nm. Fluorimetric arylsulfatase assay us ing 4-MUS was as described (30) with some
modifications. Reaction conditions included 10 pM enzyme, 2 mM 4-MUS, 50 mM
sodium acetate, pH 6.0, and 5 mM CaCl in a 20 gL reaction volume. Enzyme
incubation temperature was 300C. Activity was measured as a function of time ranging
from 3 to 24 hours; the reactions were quenched by the addition of 200pL 0.5 M Na2CO 3,
pH 10.7. Detection of fluorescent methylumbelliferone was measured at this alkaline pH
using a SpectraMax microtiter plate reader (Molecular Dynamics) set at excitation and
emission wavelengths of 360 and 440 nm, respectively. Fluorescence intensity was
corrected against background (minus enzyme control). In both assays, 0.5 units of
arylsulfatase from Aerobacter aerogenes (Sigma) were used as a positive control.
Pilot 6-0 sulfatase and N-sulfamidase Assays
Initial assessment of substrate specificity and pH optima was made using a
capillary electrophoresis-based assay for the detection of desulfated products.
Preliminary enzyme activity was measured against the following series of fluorescently
derivatized, monosulfated gluco and galactopyranosides: 4MU-GlcNAc,6s, 4MU-GlcNs,
4MU-GalNAc,6S, and 4MU-Gals. Standard reactions included 1 mM substrate, 1-10
pM enzyme, 50 mM sodium acetate, pH 5.5-6.5, and 5 mM CaCh in a 20 pL reaction
volume. For pilot experiments, exhaustive reactions involved overnight incubations at
300C. Enzyme was inactivated by heat denaturation at 950C for 10 minutes, followed by
a 10-fold dilution into water. Reaction products were resolved by capillary
electrophoresis using a 25 cm long, 75 gm i.d. fused silica capillary (Agilent
Technologies). Electrophoresis was carried out under negative polarity by applying a
voltage of -15 kV (-1.2 W) for 10 minutes. Substrate desulfation was measured as a
percentage of substrate depletion relative to a minus enzyme control as monitored by the
loss of UV absorbance at 315 nm detected at approximately 4 minutes. A standard
capillary electrophoresis buffer included 50 mM Tris and 10 jiM dextran sulfate (average
MW of 10,000 Da) adjusted to pH 2.0 with phosphoric acid.
The effect of pH was likewise measured by capillary electrophoresis using the
following three sets of buffers with overlapping pH ranging from 4.5 to 8.0: 50 mM
sodium citrate at 4.5, 5.0, and 5.5; 50 mM MES at 5.5, 6.0, 6.5 and 7.0; and 50 mM
MOPS at 6.5, 7.0, 7.5, and 8.0. Reactions included 1 pM enzyme, 2 mM 4MU
GlcNAc,6S (for 6-O-sulfatase) or 4MU-GlcNS (for N-sulfamidase), 50 mM buffer, and 5
mM CaCh in a 20 gpL reaction volume. Assay was initiated by the addition of 2 pl of a
10X enzyme stock to 18 pL of preheated reaction mixture. Reactions were carried out at
300C for either 30 minutes (N-sulfamidase assay) or 60 minutes (6-0 sulfatase assay) and
quenched by heat and dilution as described above.
The ability of both enzymes to desulfate unsaturated heparin and chondroitin
disaccharides was assessed essentially as described for CE based compositional analyses
of enzymatically generated glycosaminoglycan di and tetrasaccharides (31). For these
studies, the following disaccharide substrates were tested: AUGlcNAc,6S; AU2SGlcNAc,6S;
AUGlcNs; AUGlcNs.6s; AU2sGlcNs,6s; and AUGalNAc,6S Reactions included 500 pM
substrate, 10 pM enzyme, 50 mM sodium acetate, pH 6.5 and +/- 2 mM CaCh in a 20 iL
reaction volume.
Coupled enzyme assay for the determination of biochemical reaction conditions and
steady-state kinetics
Indirect measurement of enzyme activity was also made using a fluorimetrically-
based plate assay in which the prerequisite desulfation of the appropriate glucopyranoside
1-4 methlybelliferone substrate by either the 6-O-sulfatase or N-sulfamidase was
coupled to the glucosidase- mediated hydrolysis of the stereo-specific 1--4 glycosidic
linkage between the pyranose ring and the adjoining fluorophore. Release of the free
fluorophore (4MU) was monitored spectroscopically as described above for the
arylsulfatase assay using 4-MU sulfate. The two sulfatase assays differed in the choice of
substrate in accordance to their specificity as well as the glucosidase added during the
second, rate-limiting step. For the 6-O-sulfatase, the hydrolysis of the substrate 4MU-13-
D-GlcNAc,6S at the 6-OH position was coupled to P3-glucosidase purified from sweet
almonds (MP Biomedicals, Catalog No. 195197). Likewise, N-sulfamidase hydrolysis of
4MU-a-D-GlcNs at the 2-amino position was coupled to c-glucosidase (MP Biomedicals,
Catalog No. 153487). In both cases, the efficacy of the coupled assay was contingent on
the intrinsically poor ability either glucosidase possesses for hydrolyzing the glycosidic
bond when the adjoining glucosamine is modified by a sulfate. The presumption of the
first (sulfatase) activity being the rate-limiting step was established experimentally.
Reaction conditions were optimized to satisfy three related criteria: 1) linear readout of
fluorescent signal which is directly proportional to sulfatase activity; 2) quantitative
release of 4MU by glucosidase activity under every biochemical condition examined and;
3) negligible fluorescent quenching of the free chromophore.
For the 6-O-sulfatase/B-glucosidase assay, the standard reaction conditions
included 2 gM recombinant enzyme, 50 mM sodium acetate buffer, pH 5.5, and 5 mM
CaCl2 in a 20 p1 reaction volume. 4MU-GlcNAc,6S substrate concentration was varied
from 0.1-2 mM. 2 gtL of enzyme was added to each well of a microtiter plate (prechilled
on ice), plate gently vortexed, and contents of each well spun down for 1 minute at 500 X
g, 4oC. The assay was initiated by transferring the 96 well plate to a heating block
prequilibrated at 300C. Sulfatase incubation (first enzyme) was carried out at 300 C for 20
minutes, after which enzyme activity was inactivated by heat denaturation (950C, 10
minutes). In the second enzyme (glucosidase) step, the microtiter plate was once again
chilled on ice. 40 units of 3-glucosidase was added to each well, the plate mixed by
gentle vortexing, spun down at 500 rcf for 1 minute at 40C and transferred to a heating
block prequilibrated at 370 C. Incubation proceeded for 60 minutes prior to being
quenched with 200 pL 0.5 M Na2CO 3, pH 10.7. Reactions were transferred to a black 96
well, flat-bottom FIA-plate and fluorescence measured as described above for the
detection of free 4MU. Fluorescent signal was adjusted to background (minus sulfatase
control). For 8-glucosidase, this background hydrolysis was somewhat dependent on
initial 4MU-GlcNAc,6s concentration, but typically was less than 10%. Molar conversion
of product was extrapolated from a standard curve generated from varying concentratiom
of 4MU from 0- 300 gLM.
Coupled N-sulfamidase assay was generally described for the 6-O-sulfatase, but
with the following modifications: 4MU-GlcNs as substrate, 50 mM sodium acetate at pH
6.0 (instead of 5.5), and 1 pM enzyme. For the second enzyme step, 5 units of a-
glucosidase were added. Enzyme incubation was carried out for 22 hours at 370 C. The
obvious difference in enzyme efficacies between a-glucosidase versus 3-glucosidase is
reflected in the substantially longer incubation times required for the a-glucosidase to
quantitatively hydrolyze the glycosidic al-4 linkage between the fluorophore and the
desulfated glucosamine. All other reaction conditions were as described for the coupled
6-O-sulfatase/B-glucosidase assay.
Michaelis-Menten kinetics were extrapolated from Vo vs. substrate concentration
plots fit by non-linear regression to pseudo-first order kinetics. Data represent the
average of three experiments. Substrate concentration was varied from 0.1 to 2 mM
4MU-GlcNAc,6S (for 6-O-sulfatase kinetics) or 4MU-GlcNs (for N-sulfamidase kinetics).
Additional conditions included the presence of 0, 0.5 mM, or 5 mM CaCh or 1 mM
EDTA under otherwise standard conditions described.
Compositional analyses of sulfatase treated heparin
20 gg heparin was preincubated with 10 gM 6-0 sulfatase or N-sulfamidase for 8
hours at 300C in a 20 giL reaction which included 25 mM sodium acetate, pH 7.0 and 2
mM calcium acetate, pH 7.0. Following this preincubation, enzymes were inactivated by
heat denaturation at 950C for 10 minutes and heparin exhaustively digested overnight at
370 C by the addition of 2 pLL of a concentrated enzyme cocktail containing heparinase I
and III. Subsequent CE-based compositional analyses of heparinase-derived
disaccharides were completed as described (22).
Sequential degradation of heparin oligosaccharide by flavobacterial exo-enzymes
The purified pentasulfated tetrasaccharide AU2sHNs,6SIHNS,6S was a kind gift of
Dr. I. Capila (Momenta Pharmaceuticals, Inc). Enzyme sequence was as follows: 2-0-
sulfatase-A4,5 glycuronidase46-0-sulfatase->N-sulfamidase. After each step, the
enzyme was heat inactivated and 20 pL aliquots removed prior to the addition of the next
enzyme in the sequence. Initial reaction conditions included 20 mM Tris, pH 7.2 and 60
nanomoles of tetrasaccharide in a 120 pL reaction volume. All enzyme reactions were
carried out at 300C. Enzyme specific conditions included the following: 1) 2-0-
sulfatase, 1 gM enzyme, 6 hours; 2) A4,5 glycuronidase, 1 gM enzyme, 6 hours; 3) 6-0-
sulfatase, 5 gM enzyme, 5 mM CaCQ, 12-15 hours; 4) N-sulfamidase, same conditions as
for 6-O-sulfatase. Molecular masses of enzyme products were determined by MALDI
mass spectrometry using established methods (32).
CE-LIF for the detection of sequentially degraded oligosaccharides
The APTS derivitization protocol was adapted from Chen et al. (33) Briefly, 2 gl
of 100 mM 9-aminopyrene-1,4,6-trisulfonate (APTS) in 25% acetic acid (v/v) was mixed
with 10 pl of IM sodium cyanoborohydride in tetrohydrofuran and 1 gmol of saccharide.
The reaction mixture was incubated at 750C for 2 hr. and was diluted 1:100 prior to CE
analysis. CE-LIF was performed on a Beckman Coulter ProteomeLab PA 800 with 488
nm argon LIF module. Samples were loaded onto a N-CHO capillary (50 pm I.D. x 65
cm total length) using 0.5 psi of pressure at the anode for 20 sec. Electrophoretic
separations were performed using a 20 kV potential in a 100 mM sodium borate, pH 10.2
buffer for 15 min at 250C. Fluorescence emission spectra were collected using a 520 nm
narrow band filter.
ESI-mass spectrometry of sulfated glucosamine monosaccharides
Electrospray ionization mass spectrometry was performed in the negative ion
mode using an Agilent 1100 Series VL LC/MSD Trap. For simplicity, the samples were
prepared by adding MeOH directly to the enzymatic reaction mixtures without
purification, and were directly injected into the source of the mass spectrometer using a
syringe pump at a rate of -8pl/min. The SPS function of the software (LC/MSD Trap
Software 4.1 Build 143, MSD Trap Control Version 5.0 Build 65) was used to tune the
instrument, with the target mass set to the mass of the substrate, the sample stability set to
50%, and the drive level set to 100%. Data was acquired over the scan range of 100-
2200 m/z by accumulating 30,000 ions per scan. Capillary voltage was set to 3000V.
Nitrogen was used as the drying gas while helium was used as the nebulizing gas, with
flow rates of 5 and 15 liters/min, respectively. In each case a minimum of ten spectra
were averaged.
For the initial substrate specificity experiments on unlabeled monosaccharides,
reactions were carried out with 2.5 mM substrate, 2.5 mM CaCJ2, excess enzyme, and
37.5 mM Tris Buffer at pH 7.5 at 37 'C overnight. For the experiments determining the
obligatory order of action of the enzymes, reactions were carried out with 100 gM
substrate, 2 mM CaCQ, 5 pM enzyme, and various buffers at 37 'C overnight. Samples
were diluted 1:10 in MeOH prior to analysis in the ESI, and the carrier solvent was
H20:MeOH (1:10, v/v). For the time course experiments showing desulfation of
different unlabeled monosaccharides, reactions were carried out with 2.5 mM substrate, 5
mM CaC 2, 1pM enzyme, and 50 mM acetate buffer at pH 5.5 for the 6-O-Sulfatase and
pH 6.0 for the N-Sulfamidase at 37 'C. Reactions were quenched by diluting the samples
1:4 in MeOH. The carrier solvent was H20:MeOH (1:4, v/v). In these experiments,
4MU-GlcNS was added prior to injection as an internal standard to monitor ionization
efficiency and mass accuracy within the source and trap.
2.3. Results
2.3.1. Molecular Cloning and recombinant expression of
Flavobacterium Heparinum sulfatase genes
The two sulfatase genes described in this chapter were first identified through the
screening of a genomic library with hybridization probes directed toward the
flavobacterial 2-O-sulfatase (25). Two overlapping phagemid clones identified during
this process were expanded by chromosomal walking and restriction mapping. Sequence
analyses of this genomic region revealed two sizeable open reading frames of 1647 and
1524 base pairs (described hereafter as ORF B and ORF C, respectively). The two gene
sequences putatively encode proteins of 545 (Figure 2.1) and 500 (Figure 2.2) amino
acids in length (starting at the initiating Met). Neither sequence possessed an obvious
Shine-Delgarno ribosomal binding site within 10 nucleotides of the initiating ATG
codon. A closer examination of their individual sequences at the protein level noted
several important features. Both flavobacterial ORFs possess an N-terminal hydrophobic
signal peptide and corresponding cleavage site sequence predicted by the Von Heijne
method for gram-negative bacteria (28). Both genes encode basic protein sequences of
comparable amino acid composition (by mol percent). Of the two proteins, the ORF B
gene product possesses a slightly higher theoretical pI (8.6 vs. 8.0) relative to ORF C.
Both gene products also possess a canonical sulfatase domain as described by the Protein
Family (PFAM) identifier PF 000884 (see discussion).
Both putative sulfatase genes were robustly expressed in E. coli as soluble
enzymes. To achieve satisfactory expression levels, however, we were compelled to first
1 - ATACTAAAAATGGGTAAATTGAAATTAATTTTACCGGTTTTGTTTGCCGGTGCCACCTTA - 60
(1)- I L K M G K L K L I L P V L F A G A4 T L -(17)
61 - ATGTCTTGCCAGCAGCCTAAACCTGCTGAAAGTGCCAAAAGGCCCAATATTGTGTTCATC - 120
(18)- M S C Q Q P K P A E S A K R P N I V F I -(37)
121 - ATGACAGATGACCATACCATTCAGGCCATAAGCGCTTATGGCAGCAAATTGGTAAAAACG - 180
(38)- M T D D H T I Q A I S A Y G S K L V K T -(57)
181 - CCCAACCTGGACAGAATTGCCAACGAGGGTATGTTGTTTAACAACTGTTTTGTAACCAAT - 240
(58)- P N L D R I A N E G M L F N N C F V T N -(77)
241 - GCAGTTTGCGGGCCATCCAGGGCTACTATCCTGACCGGAAAATATAGCCACCTGAATGGT - 300
(78)- A V C G P S R A T I L T K Y S H L N G -(97)
301 - TTAACAGACAATTCAAAGGTATTTGACAGTACTCAGGTTATTTATCCGCAGTTGTTAAAG - 360
(98)- L T D N S K V F D S T Q V I Y P Q L L K -(117)
361 - AAAGCAGGGTACCAGACCGCAATGATTGGCAAGTGGCACCTGGGCTCAACACCAATGGGC - 420
(118)- K A G Y Q T A M I G K W H L G S T P M G -(137)
421 - TTTGACTATTACAGTATTTTGCCCAACCAGGGACAATATTATCAGCCTGAATTTATAGAA - 480
(138)- F D Y Y S I L P N Q G Q Y Y Q P E F I E -(157)
481 - AACGGGCATCTGGTTAAAGAAAAAGGATATGTAACAGACCTCATCACCGATAAGGCCATC - 540
(158)- N G H L V K E K G Y V T D L I T D K A I -(177)
541 - GGCTTCCTTGAAAAAAGGGACCATGATAAACCCTTTCTGATGATTTACCAGCACAAAGCA - 600
(178)- G F L E K R D H D K P F L M I Y Q H K A -(197)
601 - CCGCACCGCAACTGGTTGCCGGCACCAAGACACCTGGGGATGTTTGACGATACGGTTTTT - 660
(198)- P H R N W L P A P R H L G M F D D T V F -(217)
661 - CCTGAACCTGCCAATTTACTGGATGATTTTAAGGGCAGGGGCAGGGCAGCAAAGGAGCAG - 720
(218)- P E P A N L L D D F K G R G R A A K E Q -(237)
721 - CTGATGAACATTTCTACCGATATGTGGCCTGCATGGGACCTTAAAATGCTTTCTACAGCC - 780
(238)- L M N I S T D M W P A W D L K M L S T A -(257)
781 - CAGCTTGATTCTATGGCGAAACTACCTGTTTCCCCTAAGTTTAAAGATGCCAAGGGTGAT - 840
(258)- Q L D S M A K L P V S P K F K D A K G D -(277)
841 - GATTATCAACAGGCCAATGATCCTTCACTGGATAAAGCCCGTTTTTTTGAAGTGTACAAC - 900
(278)- D Y Q Q A N D P S L D K A R F F E V Y N -(297)
901 - CGCATGACAGATGCTGAAAAGGTACAATGGAGAAAAGTATATGACAAACGCGTAGCCGAA - 960
(298)- R M T D A E K V Q W R K V Y D K R V A E -(317)
961 - TTTAAAAGGCTGAACCCGAAAGGGGCCGACCTGGTGCGATGGAAATACCAGCAGTATATG - 1020
(318)- F K R L N P K G A D L V R W K Y Q Q Y M -(337)
1021 - CGCGATTATCTGGCCTGCGTGGTTTCGGTAGATGAAAATGTAGGCAGGCTGATGGATTAC - 1080
(338)- R D Y L A C VV S V D E N V G R L M D Y -(357)
1081 - CTGAAAAAGATAGGGGAGCTGGACAATACCATTATTGTCTATACTTCCGATCAGGGCTTT - 1140
(358)- L K K I G E L D N T I I V Y T S D Q G F -(377)
1141 - TATTTGGGTGAGCATGGGTATTTCGACAAACGTTTTATGTACGATGAATCTTTCCGTACA - 1200
(378)- Y L G E H G Y F D K R F M Y D E S F R T -(397)
1201 - CCTTTAATGGTGAGGTATCCGCCTTCGGTTAAAGCCGGTTCAGTAAGTAATGCCTTTGCC - 1260
(398)- P L M V R Y P P S V K A G S V S N A F A -(417)
1261 - ATGAACCTCGATTTTGCACCAACTTTACTGGATTATGCAGGGGTAAAAATACCAGCCGAT - 1320
(418)- M N L D F A P T L L D Y A G V K I P A D -(437)
1321 - ATGCAGGGCCTGTCGTTACGTCCGGTATTGGATAACGCAGGAAAATCGCCGGAAAACTGG - 1380
(438)- M Q G L S L R P V L D N A G K S P E N W -(457)
1381 - CGCAAGGCTGTATATTATCATTATTATGAATTTCCAAGCTGGCACATGGTTAAAAGGCAC - 1440
(458)- R K A V Y Y H Y Y E F P S W H M V K R H -(477)
1441 - TATGGCATCAGAACGGAGCGCTATAAACTGATCCATTTTTACAATGACATTGATGAATGG - 1500
(478)- Y G I R T E R Y K L I H F Y N D I D E W -(497)
1501 - GAATTATACGATATGCAGAAAGATCCGCATGAGATGCAAAACCTGTATAACGATAAGGCC - 1560
(498)- E L Y D M Q K D P H E M Q N L Y N D K A -(517)
1561 - TATGAGCCGATTATTAAAGACCTGAAAGTGCAAATGAAAAAGCTGCAGGTACAATATAAA - 1620
(518)- Y E P I I K D L K V Q M K K L Q V Q Y K -(537)
1621 - GATACGAATCCAACTGAAGCTTTATAA - 1647
(538)- D T N P T E A L stop (545)
Figure 2.1 - Flavobacterial 6-0-sulfatase (ORF B) coding sequence.
The gene sequence described as ORF B encodes a polypeptide with 548 amino acids (545 amino
acids starting at the initiating methionine). Translated protein sequence is highlighted in bold.
Numbering of amino acids is noted in parentheses and begins with initiating Met (position noted
above corresponding ATG codon). PFAM sulfatase motif CXPXRXXXXTS/TG is boxed.
Predicted signal sequence is over scored with peptide cleavage site represented by an arrow.
Vicinal glutamines (Q) are shaded in gray. Hind III restriction site is doubled underscored.
1 - AGCTTTATAAAATTGATAAAGATGAAATTTAACAAATTGAAATATTTCCCTGCAGCACTT - 60
(1)- S F I K L I K M K F N K L K Y F P A A L -(13)
61 - TCAATGGTGCTGATATGGGCTTCCTGCACTTCGCCGGAAAAAAAAACGGATCGTCCGAAT - 120
(14)- S M V L I W A 'S C T S P E K K T D R P N -(33)
121 - ATCCTGATGATCATGTCCGATAACCAATCCTGGAACCACGTAGGGAGCTATGGTGATCAA - 180
(34)- I L M I M S D N Q S W N H V G S Y G D Q -(53)
181 - ACGGTACGCACGCCCAATATGGACCGGATTGCGAAAGAAGGGGTACGTTTTACCAATGCT - 240
(54)- T V R T P N M D R I A K E G V R F T N A -(73)
241 - TTTTGCAGTTCACCTTCCTGTACGCCCGCAAGGGCTGGAATGCTGACCGGACAGGATATA - 300
(74)- F C S S P S C T P A R A G M L T q Q D I -(93)
301 - TGGAGGTTAGAAGATGGGGGCAATTTATGGGGTGTTTTACCGGTTAAATATAAAGTATAT 
- 360
(94)- W R L E D G G N L W G V L P V K Y K V Y -(113)
361 - CCGGATTTGCTGGAAGAAGCTGGCTATGCCATAGGTTTTCAGGGAAAAGGCTGGGGCCCG - 420
(114)- P D L L E E A G Y A I G F Q G K G W G P -(133)
421 - GGAAGCTTTGAGGCCAATAAACGCCCAAGAAATCCTGCAGGGAATGAGTTTAAAAGTTTT - 480
(134)- G S F E A N K R P R N P A G N E F K S F -(153)
481 - GGCGCATTTTTAAAAGATAAAAAAGAAGGTCCCTGGTGTTATTGGATCAGTAGTCATGAA - 540
(154)- G A F L K D K K E G P W C Y W I S S H E -(173)
541 - CCTCACCGTCCTTATGTGGAAGGTTCCGGCGAAAAGCTGGTATCGATCCAAATAAAGTA - 600
(174)- P H R P Y V E G S G E K A G I D P N K V -(193)
601 - AAAGTTCCTGCCTATTTGCCAGATCATATCAGTATAAGAAAAGACATTGCAGATTACTAC - 660
(194)- K V P A Y L P D H I S I R K D I A D Y Y -(213)
661 - GCTGCGGTTGAAACCTTTGATCGTGAACTGGGCGAGGCCCTTGACCAGTTGAAAGCAAGT - 720
(214)- A A V E T F D R E L G E A L D Q L K A S -(233)
721 - GGTGAGCTGGACAATACGGTAATTGTGGTATGCAGTGACAACGGCTGGCAAATGCCGCGT 
- 780
(234)- G E L D N T V I V V C S D N G W Q M P R -(253)
781 - GGACTGGCCAACTTGTACGATTTTGGTACACATGTGCCCCTGATCATTTCATGGCCAGGT 
- 840
(254)- G L A N L Y D F G T H V P L I I S W P G -(273)
841 - AAGTTTAAACAGGATGTAGTTGCCGATAACCTGGTCACTGAATGACCTTGCCCCAACA 
- 900
(274)- K F K Q D V V A D N L V T L N D L A P T -(293)
901 - TTCTTACAACTGGGTAAGGTACCTGTACCGGCCGATATGACGGGTAAAAGTTTATTGCCC 
- 960
(294)- F L Q L G K V P V P A D M T G K S L L P -(313)
961 - ATTGTTGAGGCAGGTAAAAAAGATGAAAAACCCCGGGATTATGTAGTACTGGGAAGAGAG 
- 1020
(314)- I V E A G K K D E K P R D Y V V L G R E -(333)
1021 - CGTCATGCATTCGTTCGTCGGCATGGCCTTGGCTATCCTGGCAGGGCAATTCGTACTAAA 
- 1080
(334)- R H A F V R R H G L G Y P G R A I R T K -(353)
1081 - GATTATCTTTACATTAAAAATTATGAACCAAATAGATGGCCGGCAGGTGATCCGCCGTTT 
- 1140
(354)- D Y L Y I K N Y E P N R W P A G D P P F -(373)
1141 - TATGGAGACATTGATCCCTACATGTTCAACTGGCCGGGTGAAACCAAATATTACCTGATA - 1200
(374)- Y G D I D P Y M F N W P G E T K Y Y L I -(393)
1201 - GAACATAAAGATGATCCGAAAGTAAAGTCTTTCTTTGAACTGGGAATGGGCAAACGTCCG - 1260
(394)- E H K D D P K V K S F F E L G M G K R P -(413)
1261 - GCAGAAGAATTATTTGATATCAATAAAGATCCGGATGAATTACACAATCTGGCAGCACTT - 1320
(414)- A E E L F D I N K D P D E L H N L A A L -(433)
1321 - CCTGAATATCAAAAAATAAAACAGGAGCTTGTTGCTAAATTGCGTAATTATTTGGTAGCA - 1380
(434)- P E Y Q K I K Q E L V A K L R N Y L V A -(453)
1381 - ACGAAAGATCCGAGAGAAACTAATGGTAATATACAGATCTGGGATACTGCTGCTTATTTT - 1440
(454)- T K D P R E T N G N I Q I W D T A A Y F -(473)
1441 - AGTGAAATAGATAAAACGCCAAAACCAAGTAAAGAGATGCAAAAGCGTTTTAAATTAGAT - 1500
(474)- S E I D K T P K P S K E M Q K R F K L D -(493)
1501 - TCCAGTTACAATTATTTGAAGTAA - 1524
(494)- S S Y N Y L K stop (500)
Figure 2.2 - Flavobacterial N-sulfamidase (ORF C) coding sequence.
The gene sequence described as ORF C encodes a polypeptide with 507 amino acids (500 amino
acids starting at the initiating methionine). See Figure 2.1 legend for details.genetically engineer
the removal of the amino terminal signal sequences of both proteins. Exclusion of this domain,
however, had little deleterious effect on each enzyme's specific activity. At the same time,
replacement of this NH2-terminal peptide with a histidine (6X His) tag facilitated purification of
the recombinant proteins in essentially a single chromatographic step (to greater than 80%
purity) (data not shown). Subsequent thrombin cleavage of the histidine tag was carried out as
described in experimental procedures. These ANH 2-terminal truncations (lacking both the native
signal sequence and NH 2-6X His tag) were used in all subsequent biochemical characterizations
of the two sulfatases. The apparent molecular weights of the two recombinant proteins based on
SDS-PAGE were consistent with their theoretical molecular weights calculated from their
respective amino acid compositions (ORF B, 61,572 Da; ORF C, 53,193 Da).
2.3.2. Biochemical characterization of recombinant HSGAG
sulfatases: preliminary determination of monosaccharide
substrate specificity
As a first step in the biochemical characterization of these enzymes, we examined
the possibility of both these enzymes (as well as the previously characterized 2-0-
sulfatase) functioning as generic arylsulfatases. All three enzyme activities were tested
against 4-catechol sulfate and 4MU-sulfate, two different aromatic sulfate esters
commonly used as substrates to make this assessment. Of the three enzymes, only the 2-
O-sulfatase exhibited an appreciable level of hydrolytic activity relative to a known
arylsulfatase from Aerobacter aerogenes which served as a positive control (data not
shown). At the same time, the ORF B sulfatase did partly hydrolyze the 4-MU sulfate at
a discernible rate, which was at least 3-fold greater than that measured for the ORF C
protein, which exhibited only negligible activity.
To further test our prediction that these two sulfatases act on carbohydrates, in
particular, heparin and and heparan sulfate, we used a modified substrate whereby the
sulfated hexosamine was linked 1-4 (a or 03) to methylbelliferone (4MU). The presence
of this chromophore allowed us to directly monitor desulfation of the monosaccharide by
capillary electrophoresis. Four monosulfated substrates were tested, all of which were
commercially available. These included the two "heparin" monosaccharides 4MU-
GlcNAc.6S and 4MU-GlcNs in addition to the 6-O-sulfated galactose sugars 4MU-Gal6 s and
4MU-GalNAc,6s (corresponding to the monsaccharide constituents of keratan sulfate and
chondroitin/dermatan sulfate, respectively). In this analysis, the ORFB sulfatase was
specific for the 6-O-sulfated glucosamine (Figure 2.3A). The ORF C gene product could
only hydrolyze the glucosamine sulfated at the 2-amino position (data not shown). The
recombinantly expressed ORF B gene product did not act upon either of the two 6-0-
sulfated galactose sugars.
We further investigated the substrate specificities of the two flavobacteria-derived
sulfatases by examining the influence of various substitutions at the 2N, 3-OH, and 6-OH
positions of the glucosamine. In these experiments, desulfationof non-derivatized
monosaccharide substrates was detected and quantified by electrospray ionization (ESI)
mass spectrometry. In this analysis, the 6-O-sulfatase required a substituted amine
(acetate or sulfate) at the 2-amino position. A comparative kinetic analysis of the two
corresponding substrates (GlcNAc,6S vs. GlcNS,6S) indicated only a modest preference
of the enzyme for the monosulfated substrate (see Figure 2.3B). Reciprocally related to
this observation (Figure 2.4), we found the N-sulfamidase activity at the 2-amino
position was absolutely abolished when a second sulfate at the 6-O-sulfate was also
present. Both hydrolases were completely inhibited by the presence of a 3-O-sulfate
(data not shown).
2.3.3. Optimization of in vitro reaction condition
Having identified suitable chromogenic substrates for each recombinant sulfatase,
we also used these substrates to further develop a fluorescence-based plate assay as the
means to define the optimal in vitro reaction conditions for each sulfatase. We
investigated parameters such as ionic strength and the effect of divalent metal ions as
well as steady-state enzyme kinetics. We chose a coupled enzyme assay in which the
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Figure 2.3 - Substrate specificity of recombinant 6-O-sulfatase.
A. The specificity of the 6-O-sulfatase as heparin/heparan desulfating enzyme.
Desulfation of 4MUGals (i), 4MUGaINAc,6S (ii), or 4MUGlcNAc,6s (iii and iv) by the
recombinant 6-O-sulfatase was followed by capillary electrophoresis. Exclusive
desulfation of 4MUGlcNAc,6s by 6-O-sulfatase is evidenced by a singular disappearance of
absorbance at 315 nm in electrophoretagram iii (that normally appears at approximately 4
minutes). Minus enzyme control is shown in iv. Electrophoretagrams are offset for
illustrative purposes. B. Timecourse analyses of recombinant 6-O-sulfatase activity
using three different, 6-O-sulfated monosaccharide substrates (each at 2.5 pM). GICNAc,6S(0), GlcNS,6s (0), 4MUGlcNAc.6S (A). Inset: timecourse out to 30 minutes.
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Figure 2.4 - Obligatory substrate-product relationship of the 6-O-sulfatase and N-
sulfamidase.
Desulfation of the disulfated monosaccharide HNS,6S (GlcNS,6S) by the two enzymes was
followed by electrospray mass spectrometry (ESI-MS). Panel (i), substrate only shown
here as the sodium adduct of a single ion species (M- 1) with molecular mass of 360.8 Da;
ii) desulfation of disulfated monosaccharide by 6-0 sulfatase, resulting in the
monosulfated product (258.1 Da); iii) inability of N-sulfamidase to hydrolyze the original
disulfated monosaccharide (compare with i); iv) Co-treatment of the disulfated substrate
with both enzymes showing the disappearance of all sulfated monosaccharides and
demonstrating a prerequisite 6-O-desulfation by the 6-O-sulfatase prior to sulfate
hydrolysis at the 2-amino position by the N-sulfamidase. Internal standard (458.1 Da)
used to monitor ionization efficiency and mass calibration is noted by an asterisk.
recombinant sulfatase served as the primary (product limiting) enzyme and either a or (-
glucosidase served as the secondary enzyme. Use of this second enzyme permitted the
indirect detection of relative sulfatase activity by means of the stoichiometric release of
free 4MU which served as the fluorescent signal. This coupled assay for both enzymes
was validated in control experiments demonstrating only modest hydrolysis of the
1-4MU glycosidic linkage of the sulfated glucosamine (6-0 or NS) by either
glucosidase (data not shown).
Both the 6-O-sulfatase and the N-sulfamidase were sensitive to increasing ionic
strength as measured by the addition of NaCl (Figure 2.5A). For both enzymes, 50%
inhibition was observed at approximately 200 mM NaCl with less than 20% activity
remaining at 1 M NaCl relative to the zero NaCl control. Both enzymes exhibited
slightly acidic pH optima (between 5.5 and 6.5) (Figure 2.5B and D). Of the two
enzymes, the N-sulfamidase was active over a broader range, especially above pH 7.0.
Neither enzyme was active below pH 4.5. The enzymes showed higher activity in acetate
buffer when compared to sulfonate buffers such as MES and MOPS when examined over
this same pH range. However, only the 6-O-sulfatase was inhibited by the addition of
sulfate or phosphate (Figure 2.5B). Of the two anions, phosphate was clearly a more
effective inhibitor, with 50% inhibition of 6-O-sulfatase activity observed at
approximately 2 mM P0 42 compared with approximately 20 mM S0 42 .
2.3.4. Role of divalent metal ions in enzyme catalysis
Both sulfohydrolase activities were activated by the presence of calcium in a
concentration-dependent manner albeit to clearly differing extents (Figure 2.6). This
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Figure 2.5 - Sulfatase reaction conditions.
A. Inhibition by NaC1. Results are normalized to 0 NaCl added (which is shown as
100%). 6-O-sulfatase (0); N-sulfamidase (0). B. Inhibition by sulfate (0) or
phosphate (0). Results for 6-O-sulfatase are represented by a solid line; results for N-
sulfamidase by a dashed line. Results are normalized to 0 sulfate or phosphate added.
Note the log scale for inhibitor concentration, [I]. C and D. pH profile of sulfatase
activity for 6-0 sulfatase and N-sulfamidase, respectively. Relative activities (%
desulfation) were measured over a pH range of 4-8, using three buffers: sodium acetate
(0), MES (0), and MOPS (A).
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divalent metal ion effect was especially pronounced for the N-sulfamidase which
we show here to require calcium for activity (Figure 2.6B). In comparison, the 6-0-
sulfatase, although activated 2-3 fold by the presence of calcium, was somewhat active
even in the presence of 1mM EDTA (Figure 2.6A). Interestingly, the divalent metal
activation for both enzymes was specific to calcium; inclusion of Mg+2 or Mn+ 2 had only
negligible effects. To further examine this metal selectivity, we measured the potential
for enzyme inhibition in the presence of the calcium specific chelator, EGTA. As
expected, EGTA inhibited calcium-dependent N-sulfamidase activity (at 5 mM Ca 2+) in a
concentration-dependent manner, with 50% inhibition occurring at approximately 3 mM
EGTA (data not shown). In contrast, EGTA had no appreciable effect on 6-O-sulfatase
specific activity when measured under the same conditions.
In an attempt to determine the mechanism by which calcium exerts its effect on
the two HSGAG sulfatases, we followed-up these metal ion experiments by next
measuring the effect of calcium on enzyme steady-state kinetics (Figure 2.6C and D).
Consistent with our previous results, the initial rates of both enzymes were affected by
calcium in a concentration dependent fashion. For the 6-O-sulfatase, this was largely
manifested as kcat effect (I'able 2.7). For the N-sulfamidase, the effect of calcium was
predictably more pronounced, with both kinetic parameters being affected in a generally
proportional fashion.
2.3.5. Oligosaccharide substrate
The experiments described so far have focused on the use of sulfated hexosamines
as model substrates. These experiments do not address the possibility of one or both of
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Figure 2.6 - Effect of divalent metals on sulfatase activities.
A. and B. Calcium specific activation of 6-O-sulfatase activity and inhibition by EDTA
(A). Calcium-specific requirement for N-sulfamidase activity and inhibition by EDTA
(B). In both cases, the divalent metal effect was not observed when calcium was replaced
by either Mg+2 or Mn+2 (at either 1 mM or 5 mM concentrations) Open bars (no divalent
metals added); black bars (1 mM EDTA added); light gray bars (1 mM divalent metal);
stippled gray bars (5 mM divalent metal). C and D. Effect of calcium on steady-state
kinetics. Enzyme kinetics were measured for the 6-0- sulfatase (C) and N-sulfamidase
(D) as described under materials and methods at varying concentrations of Ca ÷2 or in the
presence of 1 mM EDTA. Substrate saturation plots were fitted to pseudo first-order
Michaelis-Menten kinetics by non- linear regression analyses. 0.5 mM Ca+2 (9), 1 mM
Ca+2 (0), 5 mM Ca+2 (M), 1 mM EDTA (A). For clarification, the EDTA result
(showing a lack of activity) is omitted in Figure 2.8D.
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Table 2.7. - Steady statekinetic parameters using 4MU monosaccharide substrates
these enzymes acting on heparin or heparan sulfate derived oligosaccharides. In nature,
these HSGAG oligosaccharides could possess either an uronic acid (even number of
saccharide units) or hexosamine (odd number oligosaccharide) at their non-reducing
ends. In the former case, the uronic acid would likely be unsaturated due to the preceding
action of heparin lyases which cleave the GAG chain through a f3-eliminative catalytic
mechanism. To address this important issue, both enzymes were initially tested against a
panel of unsaturated heparin disaccharides. These included AU+2SHNAc,6S and
AU+2SHNS,6s for the 6-O-sulfatase and AU±2sHNs+6s for the N-sulfamidase. For these
experiments, standard reaction conditions were chosen as defined in the monosaccharide
studies. None of the unsaturated disaccharides were desulfated by either enzyme (data
not shown). The inability of these enzymes to do so was confirmed in a related
experiment in which all possible heparin disaccharides were first generated by pre-
treating heparin with heparinase I and III prior to adding the sulfatases to the same
reaction tube. The converse experiment was also conducted in which unfractionated
heparin was preincubated with either sulfatase for an extended period of time (8 hours)
followed by the addition of heparinase I and III. In this sequence, sulfatase pretreatment
had no effect on the compositional profile of the heparinase-derived cleavage products.
While the above-mentioned experiments categorize both the 6-O-sulfatase and the
N-sulfamidase as obligatorily exolytic enzymes, they do not rule out the possibility of
these two sulfatases acting on the non-reducing end of saturated, odd- numbered
oligosaccharides. We addressed this possibility using a combination of two structurally-
related sulfated trisaccharides IHNS,6SIHNS,6S and HNS,6SI2sHNs,6s. Each of these
trisaccharides was generated from the corresponding tetrasaccharides
AU2SHNs,6ssI+2SHNS,6s by the tandem use of the 2-O-sulfatase and the A4,5 glycuronidase
prior to the addition of either the 6-O-sulfatase or N-sulfamidase. Desulfation was
followed by MALDI-MS (Figure 2.8). In this experiment, the 6-0 sulfatase was able to
singularly desulfate both trisaccharides (Figure 2.8C); The N-sulfamidase, however,
was not able to do so (Figure 2.8D), presumably because of the presence of the
interfering 6-O-sulfate.
The results presented for the exolytic desulfation of oligosaccharides at the non-
reducing end are generally consistent with the substrate specificity data pertaining to
desulfation of monosaccharide substrates. At the same time, these data cannot rule out
the possibility of the N-sulfamidase being absolutely refractory to oligosaccharides,
perhaps as a result of the adjoining structure(s) present at the reducing end. To resolve
this question, a modified approach was taken using both a different saccharide substrate
(HNsIHNSIHNs) as well as the means to detect the desulfated products. In this experiment,
the trisulfated pentasaccharide was first generated by A4,5 glycuronidase treatment of the
purified hexasaccharide AUHNSIHNsIHNs. Glycuronidase treatment was followed by
incubation with the sulfamidase. All of the saccharides (untreated, A4,5 alone, A4,5
followed by N-sulfamidase) were fluorescently labeled at their reducing end through
reductive amination. End labeling of the sugars permitted their detection by laser-
induced fluorescence (LIF) following resolution of the products by capillary
electrophoresis (Figure 2.9). At each step in the experiment, saccharide peak assignment
was inferred by observing discrete electrophoretic shifts in peak elution times as a
function of exo-enzyme treatment. For example, conversion of the unsaturated
hexasaccharide to a saturated pentasaccharide by glycuronidase-catalyzed uronic acid
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Figure 2.9 - Sequential degradation of an HSGAG hexasaccharide.
As in Figure 2.8, the use of the flavobacterial exo-enzymes for sequentially degrading an
HSGAG oligosaccharide is presented. In this experiment, the ability of the N-
sulfamidase to desulfate the non-reducing end of an oligosaccharide is also demonstrated.
The structurally-defined, heparin derived hexasaccharide AUHNsIHNsIHNs was treated
with A4,5 glycuronidase alone or with A4,5 glycuronidase followed by the N-
sulfamidase. Resultant oligosaccharide products were fluorescently labeled at the
reducing end with APTS by reductive amination as described in the Materials and
Methods. Oligosaccharides were resolved by capillary electrophoresis and detected by
laser-induced fluorescence (CE-LIF). The N-desulfated pentasaccharide HNH2IHNSIHNs is
observed as a unique peak appearing at approximately 7.6 minutes (peak Z).
cleavage is consistent with the disappearance of peak X and the concomitant appearance
of peak Y. Likewise, the N-desulfated pentasaccharide appears as a unique peak eluting
at 7.6 minutes. From this analysis, it appears that the N-sulfamidase does desulfate
certain oligosaccharides in a predictably exDlytic fashion.
2.4. Discussion
Previously cited work in our laboratory has lead to the molecular cloning, and
biochemical characterization of several heparin degrading enzymes derived from the
gram negative soil bacterium Flavobacterium heparinum (Pedobacter heparinus). While
earlier work described the enzymology of the heparin lyases (21, 34-36), more recent
work has focused on down-stream enzymes such as a an unsaturated glucuronyl
hydrolase (A4,5 glycuronidase) and at least three sulfatases (present work included). By
their very nature, these latter enzymes provide an attractive subject of study and
application given 1) their substrate specificity 2) their relevance to multiple biological
processes including the more recently described HSGAG 6-0 endosulfatase (18) and 3) a
solid biochemical foundation of their structure- function relationships that includes
several protein structures (37, 38) and a detailed understanding of their common catalytic
mechanism (39). On a more applied side, these enzymes logically present themselves as
potentially useful "tool-kit" of enzymes for the structural characterization of heparin and
heparan sulfate.
In this chapter, we extend this knowledge base through the cloning of two
additional sulfatase genes from the F. heparinum genome. A BLASTP sequence
homology search of the two flavobacterial genes against the protein database
unambiguously identified both gene products as members of a large sulfatase family.
Both protein sequences possess the signature PFAM sulfatase motif
C/SXPXRXXXXSITG as well as the highly conserved sequence LTG (at the +9 through
+11 positions relative to this motif). As is the case for most (if not all) other sulfatases
that comprise this large enzyme family, this sulfatase domain is located in the N-terminal
region of the encoded polypeptide. The three flavobacterial sulfatases that we have now
cloned (i.e, the 2-O-sulfatase, ORF B and ORF C gene products) share only a limited
overall homobgy to one another. While the latter two flavobacterial enzymes reported
here are structurally distinct from each other at this level, they do exhibit notable
sequence similarity to other select (mostly bacterial) sulfatases, however. In particular,
ORF B shows a strong sequence homology (greater than 50%) to the mucin-desulfating
sulfatase encoded by the enteric bacterium Prevotella strain RS2 (MdsA gene) (Figure
2.10). In addition to mucin, this particular enzyme is specific for free N-
acetylglucosamine-6-O-sulfate (40). The two respective genes encode for proteins of
comparable molecular weight; they also exhibit strong homology throughout their
respective sequences (and not merely biased toward the N-terminal sulfatase domain).
The only substantive difference in their primary structure essentially involves a 31 amino
acid hydrophilic insertion present in the flavobacterial sulfatase which is lacking in the
Prevotella enzyme. In a similar vein, ORF C shows considerable homology to several
putative sulfohydrolases annotated in the Pirelulla sp. Genome (41). The best sequence
alignment is with a predicted heparan N-sulfamidase with which the flavobacterial ORFC
gene product shares approximately 40% compositional identity and nearly 60%
Figure 2.10 - ORFB multiple sequence alignment and putative functional assignment as
a carbohydrate 6-O-desulfating enzyme.
Cloned flavobacterial gene sequence corresponding to ORF B encodes a protein which is
a member of a large sulfatase gene family identified by the PFAM sulfatase consensus
sequence CXPXRXXXXS/TG. Shown in this representative alignment are the primary
amino acid sequences of two bacterial enzymes to which the flavobacterial sequence
exhibited the strongest homology: Bacteroides (abbr. Bacter.) and Prevotella sp. (abbr.
Prev.) The sequence of the human galactosamine-6-0-sulfatase (Gal-6) is also shown for
comparison. The putative functional assignment of the flavobacterial enzyme as a GAG
6-O-sulfatase is based on the functionality of the two bacterial enzymes (especially the
Prevotella sp. mucin desulfating enzyme which specifically hydrolyzes the N-
acetylglucosamine 6-O-sulfate). Sequence alignment was generated using CLUSTALW.
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Figure 2.11 - ORFC multiple sequence alignment and putative functional assignment as
a heparan/heparin N-sulfamidase
Cloned flavobacterial gene sequence corresponding to ORF C likewise encodes a protein
which is a member of a large sulfatase gene family. As was the case for the 6-0-
sulfatase, the functional assignment of the flavobacterial enzyme as a GAG N-
sulfamidase is inferred from the putative functionality of the two bacterial enzymes to
which it shows the strongest sequence homology. Pirellula sp. (abbr. Pirell.) and
Bacteroides (abbr. Bacter.). Also included in this alignment is the primary amino acid
sequence of the human lysosomal enzyme, heparin-N-sulfamidase.
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conserved amino acid substitutions distributed throughout most of the protein (Figure
2.11).
It is evident from these sequence alignments that both putative sulfatases possess
a cysteine-specific active site. It is at this conserved cysteine (and not serine) that the
critical co- or post-translational oxidation to an L-C-a formylglycine (FGly) presumably
occurs (42, 43). A prediction in favor of this covalent modification taking place when
these two enzymes are recombinantly expressed in E. coli would be very much consistent
with the functional expression of other cys-based sulfatases in the same heterologous
system (39). Such evidence includes our results for the previously cloned 2-O-sulfatase
in which we both physically identify FGly formation at a corresponding cysteine as well
as demonstrate its critical function in enzyme catalysis.
Beyond their predicted function as inferred from structural homology to other
known sulfatases, we set out to empirically confirm this putative function, first by
examining the ability of these enzymes to act as so-called "arylsulfatases", and second
(and more importantly) to act within the context of HSGAG degradation. To the first
point, our results failed to unequivocally ascribe to either enzyme a "generic" sulfatase
activity based exclusively on a commonly employed arylsulfatase assay. The fact that the
ORF B (and especially) ORF C encoded enzymes are both poor arylsulfatases, however,
does not preclude them from acting on sulfated carbohydrates. In reality, many sulfatases
(including those which desulfate heparin/heparan sulfate) fail to be classified as so-called
"arylsulfatases" on the basis of this rather non-specific biochemical screen. At the same
time, our results using more structurally directed monosaccharide substrates have
unequivocally confirmed that we had indeed cloned two additional glycosaminoglycan
sulfatases, namely the heparan N-acetylglucosamine-6-O-sulfatase and the heparan N-
sulfamidase. These results do so by demonstrating the exclusivity of the two recombinant
enzymes in terms of the singular position of the sulfate that is hydrolyzed. Moreover,
these experiments go beyond this basic description and expound upon important
structural determinants of enzyme specificity. In particular, the results presented identify
the critical spatial orientation of the C4 hydroxyl as an additional structural determinant
of substrate specificity, thus making the two flavobacterial sulfatases uniquely
heparin/heparan sulfate degrading enzymes. The HSGAG specificity of this enzyme
points to the likely existence of a unique flavobacterial gene (or set of genes) encoding
for the 6-O-desulfation of galactose/galactosamine. By analogy, distinct enzymes for
desulfating these galacto-sugars do exist in the CS/DS and KS specific lysosomal
degradation pathways of higher eukaryotes. At the same time, there have been no reports
(that we are aware of) describing the purification of either galactose or GalNac-6-
desulfating activity directly from F. heparinum.
The standard sulfatase assay described in this chapter typically used singly
sulfated, fluorogenic monosaccharides as substrates. The rationale for using these
substrates was based largely on pragmatic factors relating to assay development such as
sensitivity of detection as well as their commercial availability. In retrospect, these
fluorogenic substrates were invaluable in initially assigning enzyme function as well as
defining the optimal in vitro reaction conditions by which to study their enzymology. At
the same time, we were interested ultimately in the potential use of these enzymes to
desulfate heparin/heparan sulfate oligosaccharides in accordance with their defined
substrate specificities. Central to this application is the question of the endolytic vs.
exolytic potential of the two enzymes. By definition, the former mode of action would
predict their ability to hydrolyze internally located sulfates within either a disaccharide or
oligosaccharide chain. Our results argue against any endolytic potential as neither
enzyme was able to desulfate any of the unsaturated heparin/heparan disaccharides.
Moreover, pre-treatment of unfractionated heparin with either enzyme failed to
demonstrate loss of sulfates as assessed by compositional analysis following heparinase
cleavage of the pre-treated polysaccharide (data not shown).
On the other hand, an exolytic mode of action would necessarily require these
enzymes to sequentially follow A4,5 glycuronidase hydrolysis of terminal uronic acids if,
in fact, they are to act on the non-reducing end of these saccharides. The data presented
here confirm this prediction, i.e., by demonstrating the ability of both enzymes to
hydrolyze the non-reducing end of heparin-derived oligosaccharides, albeit with certain
restrictions. From the perspective of enzyme-substrate interactions, this reality places a
critical structural constraint on the non-reducing end of the saccharide, namely a
requirement of direct access to a sulfated hexosamine which is not hindered by the
presence of an intervening uronate. It also imposes an apparent polarity to substrate
binding within the enzyme active site. It is possible, however, that such a constraint is
not absolutely imposed by the presence of the uronic acid per se (i.e., by virtue of being
joined 144 to the sulfated hexosamine) but, more precisely, to the presence of the
unsaturated bond at the C4 and C5 positions within this uronic acid. As we have pointed
out in our modeling of the 2-O-sulfatase active site, this chemical bond does impose a
conformation of the sugar ring, which, in turn, restricts the relative orientation of the
planar C5 carboxylate. Excluding this possibility will require first generating low
molecular weight oligosaccharides generated by chemical methods (such as nitrous acid
cleavage) rather than through the action of the heparin lyases.
Using this and previous studies, we have been able to reconstruct the F.
heparinum HSGAG degradation pathway in vitro through a biochemical description of
the respective substrate specificities for each of each of the cloned enzymes. As such, we
able also to place the activity of these two enzymes in a sequential context related to the
F. heparinum HSGAG degradation pathway as it presumably exists in vivo-i.e., a
degradation pathway that begins with the heparin lyases (heparinases) and continues
exolytically in the following order: 2-O-sulfatase4-?4,5-glycuronidase46-0-
sulfatase4N-sulfamidase. Interestingly, we still have to assign within this sequence the
functional position of the 3-O-sulfatase activity reported in the literature (44, 45). Based
on the results presented in this chapter, it appears that both the 6-O-sulfatase and the N-
sulfamidase act downstream from the 3-O-sulfatase activity.
Other questions related to the concerted activity of these enzymes in vivo also
remain. Chief among them is the question of what precise form the substrates for these
end-of-the-line sulfatases actually take. Is it reasonable to assume, for example, the
"natural" substrate for the 6-O-sulfatase and/or the N-sulfamidase are actually
monosaccharides? This assumption is at least consistent with the sequentially exolytic
nature of the flavobacterial HSGAG degrading pathway that we have described. It is also
in line with the HSGAG structure-activity relationships and the possibilities concerning
active site architecture implied from these relationships. We cannot ignore the ability of
both these last two enzymes to desulfate fluorescently derivatized sugars in which the
chromophore is linked 4- 1 (ao or 3) to the adjoining hexosamine. Ultimately, the ability
of both these enzymes to act on longer oligosaccharides in a manner predicted by their
substrate specificities is of great practical value toward the use of these enzymes as
discrete analytical tools for elucidating HSGAG fine structure.
In addition to describing the critical substrate specifity for each sulfohydrolase,
we have also defined important biochemical parameters related to their optimal use in
vitro. These include pH and the role of divalent cations, namely calcium. In regard to
pH, the slightly acidic pH optima demonstrated for both of these enzymes is consistent
with our previous observations for the pH optima of the 2-O-sulfatase (25) and A4,5
glycuronidase (22). Taken collectively, this profile also generally distinguishes the
flavobacterial HSGAG degrading enzymes from their lysosomal counterparts, which, by
virtue of their subcellular localization are most active at pH 4.5.
The precise structure-activity relationship which can be derived from our pH
titration of the 6-0- and N-sulfamidase activity must ultimately await further structure-
function studies. However, there are potential inferences relating to enzyme catalysis that
can be made, especially in light of existing crystal structures of other members of this
enzyme family which share a relatively conserved active site and a common enzyme
mechanism for sulfate hydrolysis (37, 46). Histidine, for example, is one such likely
candidate for participating in enzyme catalysis. At least two catalytic roles have been
proposed for separate histidines based on these crystallographic studies. The first role is
stabilizing the Oy2 oxygen of the hydrated formylglycine through hydrogen bonding,
while also possibly acting as a proton acceptor. A second histidine stabilizes the sulfate
itself, likewise through hydrogen bond contacts with one of the terminal oxygen atoms.
Local sequence alignments between each of the flavobacterial sulfatases and the three
structurally defined sulfatases (human arylsulfatase A (47, 48) and B (37) and the
sulfatase from P. aeriginosa (38)) suggest histidine 129 for the 6-O-sulfatase as least one
of the homologous active site residues serving in this capacity (Figure 2.12). At the
same time, we are unable to predict the corresponding histidine in the N-sulfamidase
primary sequence.
In addition to histidine, other residues which line this consensus active site
include at least three additional basic residues, which appear to form a binding pocket of
positive ions. Two of these positively charged residues interact electrostatically with the
negatively charged oxyanions of the sulfate; a third appears to interact with the hydrated
formylglycine via a hydrogen bond. This topology is as one would expect given the
anionic character of the substrate which is to be hydrolyzed. Our preliminary attempts to
identify potential homologous positions in the primary sequences of the two
flavobacterially derived enzymes suggest a few possibilities (again, see Figure 2.12),
e.g., Arg-83, Lys-127, Arg-206, Lys-386 and possibly Lys-503 (6-0 sulfatase); Arg-83,
Lys-128 and possibly Lys-175 (N-sulfamidase) We are currently in the process of
examining these potential structure-function relationships through site-directed
mutagenesis and molecular modeling.
If a catalytic role for calcium is supported by the kinetic data, it is likewise
supported by the consensus structure of the enzyme active site (compiled from the
various crystallographic studies cited above). In this snapshot, a divalent metal ion
coordinates with at least one sulfate oxygen of the substrate while also coordinating with
the carboxylates of four highly conserved acid residues surrounding the modified
cysteine (FGly). Presumably, this coordination would promote catalysis by properly
Figure 2.11 - Structure-oriented multiple sequence alignment of cloned flavobacterial
sulfatases.
Sequence alignment of ORF B (6-0-sulfatase) and ORF C (N-sulfamidase) with the
primary sequences of three sulfatases for which a detailed crystallographic protein
structure is available: bacterial arylsulfatase from Pseudomonas aeruginosa (PARSA),
human arylsulfatase A (Human ARS A), and human arylsulfatase B (Human ARS B),
which is actually an N-acetylgalactosamine-4-sulfatase. Select residues known to
comprise the enzyme active site are boxed. Position of the catalytic cysteine
modification is noted by an asterisk.
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orienting the sulfate ester/amide bond for hydrolysis. Based on this homology, likely
candidates include Asp-39, Asp-40, and Asp-277 (6-O-sulfatase); Asp-39 and Asp-245
(N-sulfamidase).
In reporting together the cloning of both sulfatase genes and an inclusive
description of their enzymology, we run the risk of deemphasizing an obvious functional
distinction. N-sulfated hexosamines are in fact unique to heparin and heparan sulfate. It
follows that the catalytic mechanism of sulfamide hydrolysis must also be somewhat
unique from that of the sulfate ester. This distinction holds true, even when one
considers the ubiquitous involvement of a formylglycine in enzyme catalysis. It is
perhaps this unique chemistry that explains why the N-sulfamidase, unlike the 6-0-
sulfatase, was largely uninhibited by sulfate or phosphate ions. It may also explain other
empirical distinctions observed for the two enzymes such as the absolute requirement for
calcium, the inability to hydrolyze sulfated aromatic substrates (arylsulfates), or the
inhibition by the presence of secondary sulfates within the glucosamine. As form follows
function, this distinction naturally plays out at the level of enzyme structure. For the
lysosomal N-sulfamidase, this distinction is evident even at the primary sequence level
(where there is only about 10-25% identity to O-sulfatases). This limited sequence
homology generally holds true when making the same comparison between the
flavobacterial enzymes.
We also point out that even when one compares the heparan sulfamidase between
divergent organisms such as flavobacterium and mammals, discrete structural differences
are likely given the reversed order within the degradation sequence in which the two
enzymes act--In the lysosomal pathway, the N-sulfamidase is a relatively early enzyme
that precedes the 6-0 sulfatase, whereas our results indicate a reverse order for the
flavobacterial enzymes. As such, the lysosomal heparin N-sulfamidase naturally
possesses broader substrate specificity relative to the functional homologue from F.
heparinum. It follows that the relative active site topologies should also differ, especially
as it pertains to additional residues for the lysosomal enzyme that must accommodate
secondary sulfate interactions.
2.5. Conclusion
We previously reported the cloning, characterization, and recombinant expression
in Escherichia coli of the Flavobacterium heparinum (a.k.a. Pedobacter heparinus) 2-0-
sulfatase. We report here the molecular cloning of two additional sulfatases, a 6-0-
sulfatase and an N-sulfamidase from the same microorganism. We also recombinantly
expressed these two enzymes in E.coli in a soluble, active form to confirm their
functionality as HSGAG sulfatases and to determine their respective kinetic and
biochemical properties. The 6-O-sulfatase is strongly activated by calcium and inhibited
by sulfate and phosphate, while the N-sulfamidase requires calcium but is not apparently
inhibited by either sulfate or phosphate. The 6-O-sulfatase was shown to act on either N-
sulfated or N-acetylated 6-O-sulfated glucosamines, while being completely inhibited by
3-O-sulfation or unsubstituted amines on the same pyranose ring. The N-sulfamidase
was shown to act solely on N-sulfated glucosamines, while being completely inhibited by
3-0 or 6-0 sulfation. Both enzymes were completely inactive when a glycosidically
linked uronic acid was present at the non-reducing C4 position. Taken together with the
reported substrate specificities for the previously characterized F. Heparinum 2-0-
sulfatase and unsattrated glucuronyl hydrolase, we are able to now reconstruct in vitro
the defined exolytic sequence for the heparin and heparan sulfate degradation pathway of
F. heparinum and apply these enzymes in tandem toward the exo-sequencing of heparin-
derived oligosaccharides.
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Chapter 3
Phenylboronic Acid Complexation For Sulfation
Analysis
Simple method for the detection of unsulfated
chondroitin units from glycosaminoglycan mixtures
3.1. Introduction
During recent years, glycosaminoglycans (GAGs) of various types have been
discovered to be key players in a vast number of important biological functions that
involve cell- cell signaling such as development, and pathologies such as viral invasion
and cancer metastasis (1-4). These GAG types differ based on their disaccharide building
blocks, linkages, and sulfation patterns. Although it is known that biologically important
protein-GAG interactions are structurally specific (5-8), there is little information
available as to the structure-function relationships for most GAG epitopes. This is
attributed to inherent structural complexity of these polysaccharides and to the limiting
number of available technologies suitable for the analysis of their fine structure. This
chapter deals with a new tool to rapidly analyze sulfate locations in sulfated GAG
oligosaccharides; these sulfate locations are critical to protein-GAG interactions.
The sulfated GAGs can be broken into several categories including chondroitin
sulfate (CS), dermatan sulfate (DS), heparan sulfate (HS), and keratan sulfate (KS).
These GAG classes are defined by their disaccharide units, linkages, and sulfation
patterns. CS is derived from the polymer D-glucuronic acid P-(1--+3)-D-N-acetyl
galactosamine D- (1--+4), and it can be sulfated at the C4 or C6 position of N-acetyl
galactosamine and position C2 of the uronic acid. HS on the other hand is derived from
the polymer D- glucuronic acid-a-(1--*4) D-N-acelty glucosamine-a- (1--+4).
Modifications can include glucuronic acid epimerization to L-iduronic acid, and sulfation
at positions C3, C6, or the amine of the glucosamine, or at position C2 of the uronic acid
(9).
Changes in GAG content and sulfation patterns can be observed during some
disease states, although the cause-and-effect relationship has not been determined. For
example, increasing levels of CS expression have been associated with the progression of
prostate cancer (10). Although the distribution of sulfation within the polymer is not well
understood, it has been proposed that the CS polymer can contain patches of unsulfated
regions that have been associated with many pathophysiological alterations. For example,
increasing levels of unsulfated chondroitin units have been shown to be a hallmark of
osteoarthritis and the progression of human gastric carcinomas (11, 12). This suggests
that unsulfated chondroitin epitopes could be used as potential biomarkers for the disease
diagnosis.
Despite significant advances in the characterization and quantification of GAG
structures, the heterogeneous physical nature of these biomolecules makes the
determination of bioactive sequences complicated (Chapter 1). Detection of specific fine
structures within GAG chains has been mainly limited to laborious sample preparations,
separation and characterization. A popular technique to shortcut labor intensive fine
structure characterization is to obtain the disaccharide composition of a GAG mixture,
which is used as a fingerprint of the oligosaccharide mixture. These disaccharides are
generated from the whole polymer by digestion with GAG lyases (Figure 3.1). Perhaps
the most popular technique for performing this analysis is capillary electrophoresis.
However, using standard CE conditions for glycosaminoglycan detection, sometimes the
unsulfated units are not easily detected (or require long analysis times) due to the much
lower electrophoretic mobility of these units compared to their sulfated counterparts (13,
14). More recently, techniques have been developed using ESI-MS to quantify relative
amounts of chondroitin disaccharides (15-18). But compositional analysis techniques
cannot give information on oligosaccharide structure and the structural context of the
disaccharides. Since protein-GAG interactions have proven to involve multiple
disaccharide units in a sequence dependent manner, this fine structure information is
important.
Therefore, simple and efficient methods that can recognize specific epitopes of
interest in mixtures of GAG components could significantly accelerate the identification
and quantification of these molecular markers. Here, the focus is on molecular
recognition principles using small molecules; in this case, phenylboronic acids (PBAs).
The ability of boronic acids to form reversible ester complexes with polyol compounds
(such as those found in carbohydrates) has been known for over 40 years (19-21).
However, the use of boronic acids in carbohydrate recognition and separation has been
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Figure 3.1 - GAG Disaccharides Generated Using Bacterial Lyases
The set of these twelve disaccharides (8 heparin derived, 4 CS/DS derived) represent the
various hydroxyl stereochemistries that were tested for phenylboronic acid complexation.
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mainly limited to simple carbohydrates such as glucose, fructose, mannose, and others
(22, 23).
Although mass spectrometry techniques (such as MALDI-MS and ESI-MS) can
be used to determine mass information for oligosaccharides, simple MS data cannot
determine the specific arrangement of the sulfate components within large
polysaccharides (24, 25). The ability of boronic acids to form stereospecific cyclic esters
with vicinal or geminal diols to form five or six membered rings make these molecules
suitable aids to access specific carbohydrate structural information when used in
combination with mass spectrometry. Boronic acid compounds have been used
previously to distinguish isobaric simple saccharides by MS (26). Besides this structural
specificity, boronic acids can be useful for MS analysis of carbohydrate mixtures because
of the unusual isotopic abundance found in Boron. The isotopic abundance of '0B (20%)
and 11B (80%) in combination with A+1 isotopes of C and H give an approximately 1:4:1
isotopic abundance for complexes with disaccharides, giving a triplet of peaks with the
highest abundance isotope in the center. This signature allows the easy identification of
boron containing compounds from complicated mass spectra.
The cyclic ester forming reactions occur in standard buffers, so no laborious
labeling reactions are needed. Although these reactions yield covalent bonds, products
and reactants exist in equilibrium, so usually both the reacted and unreacted species are
detectable. The equilibrium can be shifted by altering the amounts of the reactants or by
changing the pH. The acids can be modified either to increase their specificity for a
certain stereochemistry (27) or to increase their ionization efficiencies in the MS.
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Herein, we report the use of commercial boronic acid molecules in combination
with electrospary mass spectrometry (ESI-MS) for the fast identification of unsulfated
chondroitin units. Specifically, this method allows the rapid and specific identification of
unsulfated chodrotin disaccharides from the isobaric unsulfated heparin disaccharide,
within a background mixture of sulfated disaccharides. In the future, these boronic acids
can be rationally designed to increase their specificity for a specific polyol
stereochemistry (28), and therefore a library could theoretically be constructed to identify
other epitopes. This method provides a research tool that, in combination with other
techniques for GAG characterization, should aid in the total characterization of complex
GAG mixtures, especially in the identification of pathologically- relevant unsulfated
chondroitin.
3.2. Materials and Methods
Materials
All chemicals including 3-acetamidophenylboronic acid, 4-acetylphenylboronic
acid, 3-aminophenylboronic acid, 4-carboxyphenylboronic acid, 4-
dimethylaminophenylboronic acid, 3-nitrophenylboronic acid, and all the CS and HA
derived disaccharides were purchased from Sigma-Aldrich (St. Louis, MO). The HS
derived disaccharides AUA2S-GlcNH 26S (IH), AUA-GlcNH 26S (IIH), AUA2S-GlcNH 2
(IIIH), AUA-GlcNH 2 (IVH), AUA2S-GlcNS6S (IS), AUA-GlcNS6S (IIS), AUA2S-
GlcNS (IIIS), AUA-GlcNS (IVS), were purchased from Sigma (St. Louis, MO). The
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HSGAG derived disaccharides AUA2S-GlcNAc6S (IA), AUA-GlcNAc6S (IIA), AUA2S-
GlcNAc (IIIA), AUA-GlcNAc (IVA) were purchased from Calbiochem (La Jolla, CA).
All solvents were of HPLC grade, and were purchased from EMD Chemicals
(Gibbstown, NJ).
ESI-MS
Samples were directly infused at 10 gL/min into the orthogonal electrospray ion
source of an Agilent Technologies LC/MSD Trap SL mass spectrometer (Palo Alto, CA)
using a KD Scientific Syringe Pump model 100 (Holliston, MA). All samples were
sprayed from a 1:1 Acetonitrile:water solution with 10 mM ammonium bicarbonate, pH
8.0. The disaccharides were detected in the positive or negative ion mode (as indicated)
using the following parameters: nebulizer pressure 15 psi, drying gas flow rate 5 L/min,
drying gas temperature 175°C. For initial experiments, the trap settings were set using
the SPS function of the software. For the final positive mode experiments presented here,
the machine was set to capillary voltage 3500 V, trap drive 48.4, skimmer one -40 V,
capillary exit offset 50 V. The scan range used was m/z 100-1000, with a maximum
accumulation time of 300 ms, and an ICC target of 30,000.
Complexation
Fresh PBA stock solutions at mM concentrations were made weekly by dissolving
PBAs in milliQ water with sonication. PBA stock solutions were stored at 40 C. For
experiments, gLM concentrations of PBA were mixed with jiM concentrations of
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saccharide in 20mM ammonium bicarbonate pH 8.0. Prior to direct infusion into the
ESI-MS, these reaction mixtures were diluted 1:1 with acetonitrile. Spike experiments
were done with the mixture of N-sulfated and N-acetylated disaccharides (12 total, 8 HS
and 4 CS).
3.3. Results and Discussion
We screened six PBA molecules for complexation with GAG disaccharides (lyase
derived) in the MS. These PBAs differed by the substituent groups on the phenyl ring.
This panel was selected to change the character of the PBA (pKa, resonance, charge state
at neutral pH, etc.) to investigate which PBA would be best for MS analysis of PBS
cyclic esters. The best PBA was not apparent a priori, because there were competing
phenomena to consider. One had to consider how different substituent groups would
affect both the formation of the cylic ester and the ionization efficiency in the MS
(Figure 3.2). Preliminary experiments in our lab determined that the best two PBAs that
we tested were 4-dimethylamino-phenylboronic acid (DAPBA) for positive mode and 3-
acetamido-phenylboronic acid (NAcPBA) for negative mode MS. The substituted amine
on DAPBA can hold a positive charge even at a slightly basic pH, and was good for the
positive mode in MS. The acetamido group on NAcPBA is generally neutral and may
stabilize a negative charge, making it a more attractive option for the negative mode of
MS.
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Figure 3.2 -Phenylboronic Acid Structures
These simple, commercial, phenylboronic acids were selected for preliminary
complexation studies with GAG derived disaccharides. They were chosen to represent a
range of chemical properties.
Structure Phenylboronic Acid Polarity
UH 3-acetamidophenylboronic acid Neutral
H • OH 
(NAcPBA)
ON 4-acetylphenylboronic acid Neutral
.OH
SUH 3-aminophenylboronic acid Positive
,*'OH
U" 4-carboxyphenylboronic acid Negative
H
u 4-dimethylaminophenylboronic acid Positive(DAPBA)
'OH
\ J " 3-nitrophenylboronic acid Negative
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For the detection of these small saccharides, vme focused on 4-dimethylamino-
phenylboronic acid (DAPBA) and the positive mode of the MS. Since all GAG
disaccharides are acidic molecules (and only few have free amines to counteract this
charge), the formation of the cyclic ester complex with the basic boronic acid adds a new
charge to the GAG unit. This charge can facilitate the ionization capacity for MS analysis
or change the charge state of the complex compared to the free saccharide to aid in
identification Although each internal GAG disaccharide can contain up to four hydroxyl
groups, based on the boronic acid-carbohydrate interaction selectivity we envisioned that
only the C4 and C6 hydroxyls on the galactosamine unit have the proper stereochemistry
to form cyclic esters with the boronic acids. If the C4 or C6 hydroxyls are blocked as in
HSGAGs, where the C4 position is involved in the 1->4 linkages, or in C4 or C6 sulfated
chondroitin sulfate, no cyclic ester can be formed. Therefore 4,6 unsulfated chondroitin
galactosamines in oligosaccharides should be easily identified within a large mixture of
oligosaccharides by simple infusion with boronic acid molecules in the MS.
In order to determine whether unsulfated chondroitin units are able to form cyclic
boronic ester, we first studied the complexation of the COS disaccharide and DAPBA.
Analysis of a mixture of the COS disaccharide and DAPBA by ESI-MS showed the
appearance of a peak with [M+H]j of 509 corresponding to the cyclic boronic ester
between the COS disaccharide and DAPBA (Figure 3.3). The two minor products
corresponding to the intermolecular ionic complex and the dehydrated complex were also
observed in the same mixture. These kinds of adducts and the dehydrated boronic acid is
often observed even in the absence of diol containing molecules. There are also many
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Figure 3.3 - Complexation of DAPBA with COS
(A) The MS1 spectra of 100gM COS. (B) The structure of COS. (C) The MS 1 spectra of 100gM COS with 12.5gM DAPBA. This
spectra shows peaks corresponding to the mass of the DAPBA-COS cyclic ester, the singly dehydrated complex, and the
intermolecular complex. (D) The proposed struxture of the cyclic ester.
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minor unassigned peaks, which were determined to be mostly due to impurities in the
commercial PBA preparation. The main product, however, was the cyclic boronic ester
expected from the reaction of the boronic acid with the disaccharide (identified by mass
and isotopic ratio). Although reaction of the COS disaccharide with different boronic
acids might in theory be more efficient, the reaction product with 4-dimethyamino
boronic acid showed the strongest signal (a function of both reaction and ionization
efficiency) in the conditions used for ESI-MS analysis. These results confirmed that
boronic acids are in fact able to form stable cyclic boronic ester with chondrotin
disaccharides which are suitable for detection by ESI-MS.
One major benefit of this approach is the easy detection of GAG-PBA complexes
by searching the expected isotopic abundance fingerprint. As shown in Figure 3.4,
complexation of the DAPBA with the COS disaccharide is easily characterized by the
isotopic abundance triplet of the complex, since other biological molecules not containing
Boron will not show this triplet We can search the spectra for the signature peaks of a
PBA molecule, and then use the mass of that peak along with the PBA mass and
specificity to inform us as to the nature of that saccharide.
To show the PBA selectivity for COS, we compared the reaction of DAPBA with
the other unsulfated disaccharide, Hep-IVA (Figure 3.5). These disaccharides are
isomers, with the same mass and putative similar ionization efficiency, so complexes of
PBA with either would be indistinguishable in a mixture experiment. They differ in
stereochemistry, however, and the Hep-IVA should preclude easy formation of any cyclic
ester. Both spectra showed new peaks with the boron isotopic abundance triplet.
However, the mass profile of the peaks was different between the two disaccharides.
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Figure 3.4 - The Isotopic Ratio for PBA Complexes
The 1:4:1 isotopic ratio expected of boron containing complexes (as shown by the
theoretical isotopic abundance calculation shown) aids identification of PBA complexes
(as shown by the MS' spectra of the cyclic ester).
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Figure 3.5 - PBA Cyclic Esters Are Specific to COS
(A) The isomeric disaccharides COS and Hep-IVA were compared in complexation
experiments with DAPBA. At equivalent concentrations, COS showed a much larger
abundance of the cyclic ester, while Hep-IVA formed a majority of singly dehydrated
complex. The proposed structures for the three DAPBA-COS complex types observed in
the MS' spectra are shown (B-D).
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While for COS the major product displayed an m/z of 509.0 corresponding to the cyclic
boronic ester, the major product for the reaction with Hep-IVA showed an m/z 527.0
corresponding to a non-specific intermolecular complex.
Furthermore, by using an excess of DAPBA, we were able to quantify COS
disaccharides to low gM concentrations (Figure 3.6). The intensity of m/z 509
(corresponding to cyclic ester) increases linearly with COS concentration, when DAPBA
is in excess. The intensity of m/z 509 remains constant with increasing Hep-IVA
concentration when DAPBA is in excess. This suggests that something besides cyclic
ester is causing this signal in the Hep-IVA+DAPBA spectra. Detection limits of
approximately 1 gM were obtained with this method, making it useful as a
complementary technique to CE. As we envisioned based on the known molecular
recognition of boronic acids for cis 1,2 and cis 1,3 diols, complexation between DAPBA
and C2S was also achieved while no complexation was observed for C4S or C6S. Lower
intensities were observed for the complex between the singly sulfated CS and DAPBA in
comparison to the unsulfated disaccharide. This is expected due to the lower anticipated
ionization efficiency in the positive mode for the complex containing a sulfate group.
The selective detection of the COS disaccharide was also achieved, using this
method, in the presence of all possible heparanase and chondroitinase derived heparin
and chondroitin sulfate-derived disaccharides. To illustrate the selectivity of the reaction,
an equimolar mixture of eight heparin and four chondroitin-derived disaccharides (20 gM
each) was mixed with a small excess (to COS) of DAPBA (25 gM). The disaccharide
mixture was directly injected into the ESI both before and after addition of the DAPBA.
After subtracting the spectra of the individual contributions of the disaccharides and the
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Figure 3.6 - Cyclic Ester Increases Linearly with Increasing COS Concentration
The intensity of the peak corresponding to the cyclic ester increases linearly with
increasing COS when the DAPBA is in excess. The intensity of the same peak remains
constant with increasing Hep-IVA.
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free boronic acid, the major peaks observed in the MS were those corresponding to the
DAPBA and COS complex (Figure 3.7). By slightly increasing the amount of DAPBA,
we were able to achieve a detection limit of approximately 1~pM COS (signal to noise
ratio ~5) out of the 240gM background. This illustrates the possibility of detection of
COS in a mixture of GAGs units without the need for chromatographic or electrophoretic
separation.
3.4. Conclusion
This data shows the proof of principle for using PBAs and MS to identify specific
unsulfated GAGs epitopes. Using only commercial PBAs, we can detect and quantify
small amounts of these GAGs from a mixture. With chemical optimization of the PBAs,
this technique can be improved. Molecules with multiple PBAs can be designed for more
complex and specific stereochemistry. PBAs that form more stable cyclic esters and that
ionize better in the negative mode of the ESI-MS may also be developed, in order to
facilitate identification of sequences in larger sulfated oligosaccharides that are refractory
to positive mode ESI-MS.
Even without further optimization, this technique has the advantage of rapidly
determining which saccharides contain ~lactosamines with unsulfated C4 and C6
hydroxyls. While this technique is useful for CS/DS GAG analysis, this technique may
be extended to label the chemically generated, unnatural GAG epitope 2,5-anhydro-D-
mannitol created by nitrous acid degradation of HSGAGs. The boronic acid may be able
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Figure 3.7 - Detection of COS Out Of A Mixture Using DAPBA
When 25ptM DAPBA is added to a mixture of 12 disaccharides (A), and the background
disaccharide only and DAPBA only spectra are subtracted (B), the major remaining
peaks are PBA complexes. When those remaining are examined in the original MS'
spectra, they exhibit the expected 1:4:1 isotopic ratio.
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to form esters between the new hydroxyl created when the Cl position becomes
exocyclic and the new hydroxl at the C2 position. This technique could be a valuable
way to singly label the end of each nitrous acid degraded saccharide, or as a way to block
this epitope during GAG-protein binding analysis.
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Chapter 4
Tandem Mass Spectrometry for Structure Analysis
Quantification of Isomers from a Mixture of 12
Heparin and Heparan Sulfate Disaccharides Using
Tandem Mass Spectrometry
4.1. Introduction
Heparin/heparan sulfate-like glycosaminoglycans (HSGAGs) have been shown to
interact with a multitude of proteins including proteases, growth factors, chemokines,
adhesion proteins, and pathogenic proteins (1). Through these interactions, HSGAGs
have been implicated in such clinically relevant processes as hemostasis, infection,
development, and cancer progression (2-6). HSGAGs can be found on the cell surface or
in the extracellular matrix, linked to heparan sulfate proteoglycans (4), and can regulate
such a wide variety of cell processes because of their information-rich nature (7).
HSGAGs are composed of a disaccharide repeat unit of either an a-L-iduronic or P-D-
glucuronic acid 1--4 linked to a glucosamine. The nitrogen of the glucosamine unit may
be N-sulfated, N-acetylated, or N-unsubstituted. Additional modification of this basic
unit can include sulfation of the uronic acid at the C2 position, and sulfation of the
glucosamine at the C6 or rarely at the C3 position.
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As the known functions of HSGAGs are increasing, the potential clinical
applications are also growing. Heparin has become the most commonly used
anticoagulant drug since its discovery almost a century ago (8). Due to its clinical
importance, the specific pentassacharide sequence of heparin that interacts with the
protein antithrombin III (ATIII) has been determined (9, 10). Although no heparan
sulfate based drugs are currently in the clinic, several clinically important sequences have
been determined (6, 11). However, techniques available to characterize and sequence
HSGAG oligosaccharides are limited. Therefore, with few notable exceptions, the
specific HSGAG structures that cause its many biological functions are unknown. Much
of the characterization that has occurred has been limited to compositional analysis of the
disaccharides present in a HSGAG sample. Recently, it has been shown that the
disaccharides containing unsubstituted amines, which are much more prevalent in
heparan sulfate than in highly sulfated heparin, play an important role in inflammation
and herpes virus entry into cells (6, 12, 13).
Analytical techniques are constantly in development to aid in HSGAG
compositional analysis and structural characterization. HSGAG molecules are up to 100
disaccharide units in length, and the method primarily used to look at these full length
molecules is NMR, which can provide information about the composition of the mixture
(14, 15). Since NMR requires milligram amounts of material, more sensitive techniques
are used to gain information about specific HSGAG sequences. These techniques
commonly involve depolymerization of the HSGAG with heparin lyases or nitrous acid,
followed by separation and detection. These techniques can give the disaccharide
composition of a sample, which is useful for fingerprinting and characterization.
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Separation techniques have included high-performance liquid chromatography (HPLC)
(16-19), and capillary electrophoresis (CE) (20-23), using detection techniques such as
UV absorbance and fluorescent detection after chemical labeling. While these techniques
allow quantification of the disaccharide composition of HS samples, these coupled
separation and detection techniques require long separation times and the availability of
standards to identify each peak.
Mass spectrometry (MS) has traditionally been used in HSGAG research to
provide information about the HSGAG structures in a sample, but not the relative
quantities of these structures. Sulfated GAGs have been analyzed directly with such MS
techniques as fast atom bombardment (FAB) (24-27), electrospray ionization (ESI) (28-
32), and liquid secondary desporption/ionizationMS (33). Sulfated GAGs have also
been analyzed in non-covalent complexes with a basic peptide in MALDI MS (34-38).
ESI-MS has been coupled with separation techniques such as HPLC (HPLC-MS) (39-41)
and CE (CE-MS) (42), These techniques have used integration of chromatograms or
electropherograms to attempt quantification.
Prior to this work, a combination of ESI-MS and MS n had been used to directly
quantify picomole amounts of the eight disaccharides most commonly generated by
heparin lyase digestion of heparin, without separation (43). It had also been shown that
MSn can be used for the analysis of chondroitin sulfate isomers (CS) (30, 31). These
techniques rely on quantifying the fragmentation patterns of isomeric saccharides, are
rapid, and require picomole sample amounts. A technique was needed that can directly
quantify all twelve disaccharides formed by heparin lyase digestion of heparin and
heparan sulfate to provide the biologically relevant amounts of N-unsubstituted
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disaccharides in a sample. Knowledge of the fragmentation patterns of all twelve of
these disaccharides (44), in combination with quantitative techniques to identify these
structures, may eventually be used to enable direct MS n sequencing of longer HSGAG
polymers, which is complicated by the fragmentation processes that compete with
glycosidic bond cleavages (45).
Our study provides methods for quantifying ratios of HSGAG disaccharides in
mixtures, which may be applicable to any isomeric mixture, while providing information
useful for future MSn based sequencing of HSGAG oligosaccharies. In our study, we use
MSn to identify and quantify relative amounts of heparinase generated isomeric HSGAG
disaccharides from within mixtures. Out of the twelve total disaccharides, eight
disaccharides (including three of the four N-unsubstituted disaccharides) are isomeric
with at least one other disaccharide species, and these isomers fall into three groups.
Each isomeric group required its own quantification method. In one of these methods, a
stepwise and linked analysis across multiple stages of MSn allows quantification of three
isomers. In the second and third methods, the MS2 spectrum is used to quantify two or
three isomers simultaneously. The quantification of the fragmentation patterns of
additional heparin/heparan sulfate (HS) building blocks may eventually be used to build a
paradigm for gaining sequence information from longer heparin/HS polymers via
collision induced dissociation (CID), while these general schema may be applied to the
quantification of other types of structural isomers using MSn. Methods such as these,
which would enable rapid analysis of small amounts of HSGAGs, will be critical in
enabling elucidation of the structure function relationships of HSGAG protein
interactions.
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4.2. Materials and Methods
Materials
The HSGAG derived disaccharides AUA2S-GlcNH 26S (IH), AUA-GlcNH 26S
(IIH), AUA2S-GlcNH 2 (IIIH), AUA-GlcNH 2 (IVH), AUA2S-GlcNS6S (IS), AUA-
GlcNS6S (IIS), AUA2S-GlcNS (IIIS), AUA-GlcNS (IVS) as well as ammonium
hydroxide, were purchased from Sigma (St. Louis, MO). The HSGAG derived
disaccharides AUA2S-GlcNAc6S (IA), AUA-GlcNAc6S (IIA), AUA2S-GlcNAc (IIIA),
AUA-GlcNAc (IVA) were purchased from Calbiochem (La Jolla, CA). All solvents were
of HPLC grade, and were purchased from EMD Chemicals (Gibbstown, NJ). Propionic
anhydride was purchased from TCI America (Portland, OR).
Synthesis of Disaccharide IP
The disaccharide IP was synthesized by propionylating the free amine of
disaccharide IH. Briefly, 1 mg of disaccharide IH was suspended in 75 gL of saturated
NaHCO 3. While on ice, 2 pgL of similarly ice cold propionic anhydride was added to the
disaccharide. After one hour, the reaction was quenched with acetic acid. The reaction
mixture was frozen and lyophilized, and then dialyzed against water using 100 MWCO
cellulose ester membrane from Spectrum Labs (Rancho Dominguez, CA). The IP
disaccharide was purified using a Sphereclone Strong Anion Exchange HPLC column
from Phenomenex (Torrance, CA).
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Mass Spectrometry
Samples were directly infused at 10 iL/min into the orthogonal electrospray ion
source of an Agilent Technologies LC/MSD Trap SL mass spectrometer (Palo Alto, CA)
using a KD Scientific Syringe Pump model 100 (Holliston, MA). All samples were
sprayed from a 1:1 MeOH/H 20 solution with 10 mM NH4OH. The disaccharides were
detected in the negative ion mode using the following parameters: capillary voltage 3800
V, nebulizer pressure 15 psi, drying gas flow rate 5 L/min, drying gas temperature 200'C,
trap drive 30.9, skimmer one -20 V, capillary exit offset -50 V. The scan range used was
m/z 100-600, with a maximum accumulation time of 150 ms, and an ICC target of
30,000. The isolation width for all MS 2 experiments was 1 m/z, while the isolation width
for the MS3 experiments was 2 m/z. Fragmentation amplitudes varied, and are listed in
the figure caption for each fragmentation spectra.
4.3. Results and Discussion
Heparin/HS can be depolymerized into at least twelve unsaturated disaccharide
building blocks using the bacterial lyases heparinase I, II, and III from Flavobacterium
heparinum. These disaccharides are generated via a 1-elimination mechanism, leaving a
uronic acid with a double bond between the C4 and C5 positions 1->4 linked to a
glucosamine (Figure 4.1) (46). Although the set of twelve enzymatically generated
disaccharides do not represent all the native building blocks that have been found in
heparin, the prevalence of these twelve disaccharides generated by enzymatic digestion of
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Figure 4.1 - HSGAG Disaccharides
The chemical structures of the twelve disaccharides formed by heparinase I, II, and III
digestion of heparin/heparan sulfate are described by the pairwise combination of a
roman numeral and a non-italicized letter from the table (ex. IS =- AUA2S-GlcNS6S).
Propionyl groups designated by the italicized "P" can be added chemically to generate
synthetic standards.
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a sample has been used as a compositional fingerprint of heparin/HS. The most notable
building blocks excluded from these analyses are disaccharides containing 3-O-sulfated
glucosamines that inhibit heparinase enzymes and are involved in the anticoagulant
activity of heparin (47, 48). Traditional methods such as CE and HPLC have been used
to quantify these digestions, and a more sensitive and rapid method to quantify the eight
disaccharides in the "S" and "A" series using ESI-MS n has been developed (43). This
method relies upon the reproducible and quantifiable pattern of collision induced
dissociation of the isomeric disaccharides within that mixture.
In our study, a method for quantifying relative ratios of all eight of the isomeric
disaccharides from the set of twelve total disaccharides is suggested. This method hinges
upon the consistent and quantifiable fragmentation patterns of the isomers. There are
three sets of isomers: one set consists of the three monosulfated isomers IVS, IIH, and
IIIH; the second set consists of the disulfated isomers IIS, IIIS, and IH; the third set
consists of the monosulfated and acetylated isomers IIA and IIIA. Each set of isomers
necessitates a different method of quantification. One method has been previously
published and allows quantification of the two isomers IIA and IIIA using the MS 2
spectra (43). We demonstrate two new methods to quantify triplets of isomers. Our new
methods include a quantification scheme that determines the relative amounts of three
isomers using MS2 and MS3 scans in tandem, and a quantification scheme that
simultaneously determines relative amounts of three isomers using MS 2. While
competition for electrospray ionization prevented the absolute quantification of all twelve
disaccharides from one mixture using one internal standard, we demonstrate the absolute
quantification of one isomeric disaccharide from with the mixture.
126
4.3.1. MS 1 and MSn Characterization of Standards
It has been shown that these twelve unsaturated disaccharides can be detected in
ESI-MS without loss of sulfate in the negative mode using ammonium hydroxide to
reduce sodium adducts (43, 44). After first infusing all disaccharides separately, all
twelve disaccharides were detected in a single mixture, with the most abundant ions
being those with the same charge state as the number of sulfates on the disaccharide
(Figure 4.2). Within these twelve disaccharides only four, IA, IVA, IS, and IVH, are
distinguishable by their mass to charge ratios in MS1 . The eight other disaccharides form
three sets of isomers that cannot be distinguished in MS' via their mass to charge ratios
alone.
We fragmented all eight isomeric disaccharides, and chose diagnostic ions
capable of distinguishing a disaccharide from its structural isomers. The fragmentation
spectra and diagnostic ions chosen are pictured in Figure 4.3. Many of the fragments
observed had previously been identified (44). Each isomeric disaccharide has a distinct,
reproducible, and quantifiable fragmentation pattern in MSn . The unique patterns, similar
to those previously observed, suggested that we could imitate some aspects of the
quantification scheme previously used for the isomer pairs in the "S" and "A" series for
the isomer pairs and triplets that we observed.
4.3.2. MS n Quantification of Isomers
While the addition of the "H" series disaccharides to the "S" and "A" series
creates one new set of three monosulfated isomers at m/z 416.1, and adds a third
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Figure 4.2 - MS' of HSGAG Disaccharides
MS' of an equimolar (100 gM total concentration) mixture of the twelve disaccharides
formed by heparinase I, II, and III digestion of heparin/heparan sulfate.
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Figure 4.3 - MS" of Isomeric HSGAG Disaccharides
MS" spectra of the eight isomeric heparin/heparan sulfate disaccharides. Ions with known
structures are labeled. For all diagnostic ions, the mass is noted and the structure of the ion is
drawn if available. (I) MS 2 spectra (m/z 458.1->) of the two monosulfated, N-acetylated isomeric
disaccharides: (a) MS2 of IIA; (b) MS 2 of IIIA. (II) MS2 spectra (m/z 416.1-->) of the
monosulfated, N-unsubstituted or N-sulfated isomeric disaccharides: (c) MS 2 of IIH; (d) MS 2 of
IIIH; (e) MS2 of IVS. (III) MS 2 spectra (m/z 247.7->) and MS 3 spectra (m/z 247.7->356.8-->) of
the disulfated, N-unsubstituted isomeric disaccharides: (f) MS 2 of IH; (f) MS 2 of IIS; (g) MS 2 of
IIIS; (h) MS3 of IIS; (i) MS3 of IIIS.
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disulfated isomer at m/z 247.7, no new disaccharides are added to the set of monosulfated
and acetylated isomers at m/z 458.1. A method for quantifying the isomeric pair of singly
sulfated and N-acetylated disaccharides IIA and IIIA using their CID spectra has
previously been described by Saad and Leary (43). Briefly, the method involved first
determining the relative abundance of the diagnostic ions created by fragmenting each
standard individually, under identical fragmentation conditions. These abundances are
used to determine the "percent ion contribution" of each standard to the diagnostic ion.
These values are used in a system of equations, along with two normalizations, to
determine the relative amounts of each isomer in the mixture (Figure 4.4a). This method
was reproduced and simplified (by only analyzing the pure standards singly instead of in
triplicate before each experiment), allowing the accurate and precise quantification of the
ratio IIA and IIIA in mock mixtures (Table 4.1). In order to quantify the isomeric triples,
new methods were created.
The disulfated isomers IIS, IIIS, and IH at m/z 247.7 contain the pair of isomers
IIS and IIIS that are relatively indistinguishable using the major ions in the MS2 spectra.
By fragmenting the major isomeric [0'2A2'-1 ion at m/z 356.8 created from these two
disaccharides in MS 2, two quantifiable diagnostic ions are generated in the MS 3 spectra.
These two diagnostic ions, [0,2A2-H20]-' created from IIS and the [2,4A 2 ]-1 created from
IIIS (Figures 4.3g-j), can be used to quantify the relative ratios of these isomers using the
MS 3 spectra as previously described (43). Since the IH disaccharide does not create any
fragment ions at m/z 356.8, it does not contribute to the MS3 spectra used to quantify the
ratio of IIS and IIIS (Figure 4.3f). Therefore, the method described by Saad and Leary
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Table 4.1 - IIA/IIA Quantification
Results of the quantitative analysis of mock mixtures of the isomeric disaccharides IIA
and IIIA from the MS2 spectra (m/z458.1--). Three individual experiments were
performed for each mixture, and the errors reported are the average ± standard deviation.
After Norm. 2 % Error (n=3)
IIA IIIA IIA IIIA
20.0 80.0 17.7 82.3 2.3 ± 3.7
40.0 60.0 37.9 62.1 2.1 + 5.4
60.0 40.0 57.8 42.2 2.2 ± 4.4
80.0 20.0 78.5 21.5 1.5 ± 3.9
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Actual %
Figure 4.4 - Equations for MS" Quantification
Linear algebra equations used in our method for determining the percentage of isomeric
disaccharides in a mixture. Term definitions are as follows: am,n - The ioncontribution
to ion m from disaccharide n calculated by fragmenting the standard n; x, - The "raw"
percentage of disaccharide n in the mixture, prior to normalization; ym - The contribution
of ion m to the total MSn spectra; (-L )M,, S The ratio of the calculated percentages of IIS
to IIIS from the MS3 quantification (after MS3 normalization). (a) The equations used for
quantification of the ratio of IIA and IIIA from the MS2 spectra (m/z 458.1->). (b) The
equations used for first the quantification of the ratio of IIS to IIIS from the MS3 spectra
(m/z 247.7->356.8--), and then for the quantification of the ratios of IH, IIS, and IIIS
from the MS2 spectra (m/z 247.7-4). (c) The equations used for quantification of the
ratios of IIH, IIIH, and IVS from the MS 2 spectra (m/z 416.1->).
a. IIA/IIIAL a237,IIA a2377, XIIA Y237
a357,/ a357.mA XIIA Y357
b. IH/IIS/IIIS
a297,1IS a297,IIIS XIIS _ 297
a339 IIS a339,IIIS XIIIS Y339
a218,lIH 2181 S 2181IS XIH Y218
a357,IH 357,1IS 357,IIIS XIIS Y357
0 1 -( )MS3 XIIIS 1  0
c. IIH/IIIH/IVS
a138 IIH a138 IIIH a138,IVS XIIH Y138
a237,IIH a237,IIIH a237,IVS XIIIH Y237
a 2 58 ,IIH a 25 8,11IH a 25 8,IVS XIVS Y258
132
may be used to quantify the ratio of IIS and IIIS, but not their relationship to the amount
of IH.
In order to quantify the amount of IH, the results of the MS3 quantification need
to be used to solve a set of equations defined using the MS2 spectra. A linear system of
equations with three equations and three unknowns is used, but these equations only
involve two diagnostic ions. The first two equations are similar to those used in the
IIA/IIIA quantification, and are defined by multiplying the percent ion contribution of
each of the three disaccharides (determined by fragmenting the pure standard) bytheir
unknown raw (pre-normalized) percentages, and summing these products to get the
observed contribution of the relevant diagnostic ion (either m/z 218.0 or 356.8) in the
MS 2 spectra. The third equation is defined using the MS3 results. The third equation
forces the ratio of IIS to IIIS to be the ratio observed in MS3 (Figure 4.4b). This method
was used to analyze a series of mock mixtures of these three isomers, in triplicate, and the
errors and standard deviations are reported in Table 4.2.
The three monosulfated isomers IIH, IIIH, and IVS were quantified using a
method which utilizes the contribution of three diagnostic ions in the MS 2 spectra. This
method is analogous to the method for IIA and IIIA in MS 2, except that instead of two
equations and two unknowns for two diagnostic ions, there are three equations and three
unknowns (the raw relative ratios for the three disaccharides) using three diagnostic ions.
The diagnostic ions that are used are m/z 258.0, 236.9, and 137.9 (Figure 4.3c-e). The
coefficients determining the contribution of each disaccharide to the diagnostic ions are
again determined by fragmenting the standards individually under the same conditions,
and the normalizations are carried out in the same manner as in the two isomer method.
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Table 4.2 - IH/IIS/IIIS Quantification
Results of the quantitative analysis of mock mixtures of the isomeric disaccharides IH,
IIS, and IIIS. Three individual experiments were performed for each mixture, and the
errors reported are the average ± standard deviation. See supplemental table 1 for the
calculations associated with these results.
Actual % % Error (n=3)
IH IIS InS IH IIS mS
50.0 33.3 16.7 3.6 ± 1.0 -2.7 ± 5.9 -0.9 ± 6.4
16.7 50.0 33.3 -0.2 + 2.2 -5.5 + 7.4 5.7 + 8.9
33.3 16.7 50.0 -0.3 + 1.0 -0.7 + 6.1 1.0 + 6.8
75.0 25.0 0.0 3.9 + 3.4 -3.9 + 3.4 0.0 + 0.0
0.0 75.0 25.0 0.1 ± 0.2 2.4 + 4.4 -2.5 ± 4.6
25.0 0.0 75.0 -0.4 + 0.8 0.0 ± 0.0 0.4 ± 0.8
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Using this method, mock mixtures of these three disaccharides were analyzed in
triplicate, with the errors and standard deviations reported in Table 4.3.
Three different methods were used to quantify the relative amounts of isomers in
a mixture. The methods have small, seemingly random errors and small standard
deviations demonstrating their accuracy and precision. These methods suggest that up to
n isomers can be distinguished from an MS n spectra as long as there are n diagnostic ions
in that fragmentation spectra. These diagnostic ions do not need to be unique to each
isomer, but the percent contributions of these diagnostic ions to the total spectra needs to
be significantly different between each isomer. These methods also suggest that these
quantifications can be linked across different MS n spectra so that if there are not ernugh
diagnostic ions in one MS n spectra to quantify all the isomers, product ions can continue
to be fragmented until an additional MSn spectra can be used to quantify the relative
ratios of a subset of the isomers. This information can then be used as a constraint to
quantify the remaining isomers using previous MS n spectra that did not have enough
constraints.
4.3.3. Absolute Quantification of an Isomer from a Mixture
Ideally, a single internal standard and the MS' spectra could be used in a
quantitative analysis of the absolute amounts of the disaccharides in the mixture. A
synthetic disaccharide IP, which is similar to the disaccharide IA except the amine is
propylated instead of acetylated, was used as a single internal standard. This
disaccharide ionizes with a mass to charge ratio of 275.7, unique from the native
disaccharides. Disaccharide IP was previously used to quantify the amount of the norn-
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Table 4.3 - IIH/IIII/IVS Quantification
Results of the quantitative analysis of mock mixtures of the isomeric disaccharides IIH,
IIIH, and IVS. Three individual experiments were performed for each mixture, and the
errors reported are the average ± standard deviation. See supplemental Table 2 for the
calculations associated with these results.
Actual % % Error (n=3)
IIH IIIH IVS IIH IIIH IVS
50.0 33.3 16.7 4.4 + 3.0 -3.0 + 2.8 -1.4 + 0.4
16.7 50.0 33.3 -1.5 + 0.8 1.8 + 2.9 -0.3 + 2.2
33.3 16.7 50.0 1.0 + 2.5 0.4 + 0.5 -1.4 + 2.6
75.0 25.0 0.0 5.3 + 1.8 -5.4 + 1.8 0.1 + 0.1
0.0 75.0 25.0 0.0 + 0.0 -0.6 + 4.4 0.6 + 4.4
25.0 0.0 75.0 2.3 ± 2.4 0.0 + 0.0 -2.3 ± 2.4
isomeric disaccharides in a mixture of eight heparin disaccharides from the "A" and "S"
series (43). The method involved calculating a response factor of each disaccharide to a
constant concentration of the internal standard in MS1. We used the same internal
standard, and demonstrated that each individual disaccharide has a linear response to the
internal standard in the desired dynamic range (Table 4.4).
Unfortunately, competition for electrospray ionization within the complex
mixture of twelve disaccharides alters the response factors of the individual
disaccharides. Depending on the composition of the mixture, the response factor for a
disaccharide fluctuates enough to prevent accurate quantification. This effect is
demonstrated by showing the different linear responses of the disaccharide IH to the
internal standard IP within six different background mixtures of the other eleven
disaccharides (Figure 4.5). This effect may also explain discrepancies seen when
comparing quantification of biological samples using the previously published MS n
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FIGURE 4.5 - Linear Ionization in Constant Background
Competition for electrospray ionization affects the response of a disaccharide to the
internal standard. Experiments were conducted with different background mixtures of 11
disaccharides, and the internal standard IP at a constant total concentration of 150 RiM,
while the twelfth disaccharide (IH) was titrated at various concentrations. Each data set
and linear fit is normalized by the intercept to correct for the signal given by the isomers
of 1H. Each fit had a regression coefficient >0.98. The linear fit for mixture 3 is
indicated by a dashed line to distinguish it from the linear fit for mixture 2, since they are
almost co-linear. The response to the internal standard (the slope of each line) varies by
over 100% depending on the background mixture of disaccharides, preventing accurate
quantification using this single standard from an unknown mixture in MS1 .
.5S
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Background Mixture (Concentrations in pM)
Disaccharide 1 2 3 4 5 6
IS 35 5 15 15 30 45
IIS 25 10 15 5 20 20
IIIS 15 10 15 25 10 20
IVS 10 5 20 10 10 15
IIH 10 20 15 5 5 5
IIIH 10 20 15 10 10 5
IVH 10 20 15 10 10 10
IA 10 20 10 20 15 10
IIA 10 15 10 15 15 5
IIIA 10 10 5 20 10 10
IVA 5 15 15 15 15 5
method for eight disaccharides to literature values, since the biological samples contained
all twelve disaccharides.
In order to calculate the absolute concentration of a single isomeric disaccharide
in a mock mixture, we calculated the response of IH to IP within a constant background
mixture of the other eleven disaccharides, and altered the IH concentration as the only
unknown. In this way, we were able to get an accurate response factor to use in a
complete quantitative analysis of the absolute amount of disaccharide IH within the
mixture. In order to extend this method to the absolute quantification of all
disaccharides simultaneously, it may be possible to use multiple internal standards more
similar to each type of disaccharide.
Table 4.4 - The linearity of the ESI-MS process for single disaccharides.
The ratio of the intensity of the disaccharide to the intensity of 50 gM IP was measured at
disaccharide concentrations of 6.25pM, 12.5 gLM, 25 jiM, 50 jtM, and 100 pLM.
Slope
R2  I(IPD M
IH 0.9ý 4.53E-03
IIH 0.94 1.76E-01
IIIH 0.9 1.82E-01
IVH 0.9 1.10E-01
IS 0.9 4.02E-03
IIS 0.9 6.31E-03
IIIS 0.9 4.11E-03
IVS 0.9 8.02E-03
IA 0.9c 4.75E-03
IIA 0.9 1.22E-02
IIIA 0.9 3.36E-02
IVA 0.97 2.12E-01
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To obtain the absolute amount of IH in the mixture, we first determined the ratio
of IH to IIS and IIIS using our method outlined in the previous section. We then used the
calculated response factor for IH to determine the absolute concentration of IH in the
mixture (Table 4.5). The method calculates the relative ratios of IH to IIS and IIIS
within a few percent error and standard deviation. The overall accuracy and precision of
our absolute quantification using MS3 , MS2 , and then MS' is demonstrated by the final
small errors and standard deviations.
4.4. Conclusions
Heparin and heparan sulfate have been shown to interact with many biologically
important proteins, but the necessary tools to discover the specific GAG sequences that
affect these interactions are not available. We have demonstrated a method to quickly,
accurately, and precisely determine the relative ratios of the isomeric disaccharides in a
mixture using MSn. After the completion of this work, a competing method to quantify
these same disaccharides was published (49). The method uses the same general
methodology, but different ions and equations and was performed using different
equipment. While the authors claimed that their method is superior due to the ability to
quantify mixtures with single standard curves, early experiments using our equipment has
been unable to reproduce their experiments. Perhaps the differences in MS equipment
between the two groups (Agilent Ion Trap versus Thermo Finnegan LCQ) cause the
differences in results. Finally, it is important to note that the methods developed here for
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Table 4.5 - Quantification of IH from Mock Mixture
Results of absolute quantification of IH from within mock mixtures using three stages of MS".
The average of the errors of the ten different experiments is reported.
22.5 52.4 25.1
27.2 43.9 28.9
24.4 48.6 27.0
34.7 48.9 16.5
36.7 42.0 21.3
43.4 35.0 21.6
50.5 33.2 16.3
50.6 31.4 17.9
52.2 28.8 19.0
53.6 28.2 18.2
4.7
0.1
2.9
8.2
6.2
-0.6
2.5
2.3
0.7
-0.7
% Error
IIS
-6.9
1.6
-3.2
-13.2
-6.3
0.8
-3.8
-2.0
0.6
1.2
inIS
2.2
-1.7
0.3
5.0
0.1
-0.2
1.3
-0.3
-1.3
-0.6
10.1 -4.9 165
13.7 -1.3 165
23.2 8.2 165
29.6 -0.4 180
30.3 0.3 180
23.2 -6.8 180
42.0 2.0 190
45.8 5.8 190
41.3 1.3 190
42.5 2.5 190
I Avg. 0.7
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MS3
Actual % Calculated % Error
Sample IIS IIIS IIS HIS IIS IIIS
1 62.5 37.5 67.6 32.4 -5.1 5.1
2 62.5 37.5 60.2 39.8 2.3 -2.3
3 62.5 37.5 64.3 35.7 -1.8 1.8
4 62.5 37.5 73.5 26.5 -11.0 11.0
5 62.5 37.5 66.4 33.6 -3.9 3.9
6 62.5 37.5 61.8 38.2 0.7 -0.7
7 62.5 37.5 67.0 33.0 -4.5 4.5
8 62.5 37.5 63.7 36.3 -1.2 1.2
9 62.5 37.5 60.3 39.7 2.2 -2.2
10 62.5 37.5 60.7 39.3 1.8 -1.8
Actual % Calculated
H IIS IS IH IuIS ins IH
MS2 M S1 (background 150 pM total)
Sample
1
2
3
4
5
6
7
8
9
10
27.3 45.5
27.3 45.5
27.3 45.5
42.9 35.7
42.9 35.7
42.9 35.7
52.9 29.4
52.9 29.4
52.9 29.4
52.9 29.4
[a (pM) Total
Actual Calc. Diff. M % Error
27.3
27.3
27.3
21.4
21.4
21.4
17.6
17.6
17.6
17.6
-3.0
-0.8
5.0
-0.2
0.2
-3.8
1.0
3.1
0.7
1.3
0.3
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isomer quantification could be applied in theory to any isomers with reproducible but
distinct fragmentation patterns.
MS n has proven invaluable in the sequencing of peptides, but the complex
fragmentation patterns of saccharides has hindered the use of MSn to sequence GAGs.
The reproducible and quantifiable fragmentation of the isomeric disaccharides shown in
this chapter can be used as a stepping-stone toward complete structural characterization
of heparin and heparan sulfate oligosaccharides in MS n. While competition for
electrospray ionization within the complex mixture prevented the simultaneous
quantification of the absolute amounts of all twelve disaccharides using a single internal
standard, the methods presented herein may be used with better standards in the future
such as heavy stable isotope-labeled standards to enable total compositional analysis
using ESI-MS and MSn alone. After completion of this work, a method was published
that allowed sequencing of limited, short HSGAG oligosaccharides using this
information and these principles (50). However, the method was limited by several
factors, including not being able to address 3-O-sulfate containing saccharides, the
differences between glucuronic and iduronic acid containing saccharides, and requiring
compositional analysis (and therefore pure) samples of the oligosaccharides. Therefore,
there is still a need for development in this area. We are pursuing this work by
generating oligosaccharide standards with defined structures including 3-O-sulfates and
uronic acid epimerizations in order to determine fragmentation differences to identify
these important structures.
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4.6. Supplemental Tables
Sample data from computations from the two novel methods for quantifying
the isomeric disaccharides I H, I IS, and II IS and II H, II IH and IVS.
Supplemental Table 1 - Computations for quantification of the ratios of the isomeric disaccharides IH, IIS, and IIIS in mock
mixtures
Experiment 1
MS3
%TIC for ions Raw % after Norm. 1 after Norm. 2 Actual % % Error
Sample m/z 338.8 m/z 296.8 IIS IIIS S IIIS S ms IIS ms IIS HiS
1 55.6 5.5 91.7 20.6 140.3 58.2 70.7 29.3 66.7 33.3 4.0 -4.0
2 44.3 5.8 72.2 21.9 110.5 61.9 64.1 35.9 60.0 40.0 4.1 -4.1
3 30.4 13.7 44.2 51.9 67.7 146.6 31.6 68.4 25.0 75.0 6.6 -6.6
4 58.1 0.0 98.9 0.0 151.3 0.0 100.0 0.0 100.0 0.0 0.0 0.0
5 55.5 3.5 92.6 13.1 141.7 37.0 79.3 20.7 75.0 25.0 4.3 -4.3
6 8.3 27.6 -1.1 104.1 0.0 294.5 0.0 100.0 0.0 100.0 0.0 0.0
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MS 2
%TIC for ions Raw % after Norm. 1 after Norm. 2 Actual % % Error
Sample m/z 356.8 m/z 218.0 IH US HIS IH IS s IH US HIS IH IIS HIS 1H IIS HIS
1 8.0 51.1 80.4 17.2 7.1 127.5 74.8 31.0 54.7 32.1 13.3 50.0 33.3 16.7 4.7 -1.3 -3.4
2 21.2 24.1 36.7 40.5 22.7 58.2 176.0 98.6 17.5 52.9 29.6 16.7 50.0 33.3 0.8 2.9 -3.7
3 18.3 40.5 63.3 14.9 32.2 100.4 64.6 140.0 32.9 21.2 45.9 33.3 16.7 50.0 -0.4 4.5 -4.1
4 2.4 61.3 96.9 8.4 0.0 153.7 36.4 0.0 80.9 19.1 0.0 75.0 25.0 0.0 5.9 -5.9 0.0
5 30.9 1.5 -0.2 78.8 20.6 0.0 342.8 89.5 0.0 79.3 20.7 0.0 75.0 25.0 0.0 4.3 -4.3
6 23.8 31.4 49.0 0.0 54.0 77.8 0.0 234.9 24.9 0.0 75.1 25.0 0.0 75.0 -0.1 0.0 0.1
Ex 
eriment 
?
MS 2
%TIC for ions Raw % after Norm. 1 after Norm. 2 Actual % % Error
Sample m/z 356.8 m/z 218.0 IH IIS IIIS IH IIS mS IH US mS I IIS mS 1H IIS mIS
1 9.7 48.5 73.1 13.6 12.9 132.0 60.7 57.7 52.7 24.2 23.1 50.0 33.3 16.7 2.7 -9.1 6.4
2 26.2 19.1 28.0 31.7 38.5 50.6 141.9 172.3 13.9 38.9 47.2 16.7 50.0 33.3 -2.8 -11.1 13.9
3 20.3 37.4 56.3 6.6 41.6 101.6 29.4 186.3 32.0 9.3 58.7 33.3 16.7 50.0 -1.3 -7.4 8.7
4 3.6 57.7 86.4 11.6 0.0 156.0 51.9 0.0 75.0 25.0 0.0 75.0 25.0 0.0 0.0 0.0 0.0
5 34.0 0.9 -0.5 74.1 28.5 -0.9 331.7 127.5 0.0 72.4 27.8 0.0 75.0 25.0 0.0 -2.6 2.8
6 25.3 31.6 47.6 0.0 57.1 86.0 0.0 255.7 25.2 0.0 74.8 25.0 0.0 75.0 0.2 0.0 -0.2
Experiment 3
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MS3
%TIC for ions Raw % after Norm. 1 after Norm. 2 Actual % % Error
Sample m/z 338.8 m/z 296.8 IIS IIIS IIS IIIS IIS IIIS uS IIS IIS mS
1 40.6 3.0 75.7 12.2 116.3 68.5 62.9 37.1 66.7 33.3 -3.7 3.7
2 46.8 4.4 86.6 17.8 133.1 100.1 57.1 42.9 60.0 40.0 -2.9 2.9
3 30.1 13.1 49.6 53.3 76.3 299.6 20.3 79.7 25.0 75.0 -4.7 4.7
4 52.1 0.0 99.3 0.0 152.6 0.0 100.0 0.0 100.0 0.0 0.0 0.0
5 55.6 1.7 105.0 6.8 161.3 38.4 80.8 19.2 75.0 25.0 5.8 -5.8
6 3.5 21.0 -5.6 85.8 -8.7 482.0 -1.8 101.8 0.0 100.0 -1.8 1.8
MS--- -
MS 3
%TIC for ions Raw % after Norm. 1 after Norm. 2 Actual % % Error
Sample m/z 338.8 m/z 296.8 IS IIIS IIS HIS IIS IS HS IS IIS IIS
1 42.5 3.8 73.3 14.6 111.1 34.1 76.5 23.5 66.7 33.3 9.8 -9.8
2 38.4 10.1 61.5 38.4 93.2 89.7 50.9 49.1 60.0 40.0 -9.1 9.1
3 1.6 1.0 2.1 3.7 3.1 8.7 26.5 73.5 25.0 75.0 1.5 -1.5
4 52.5 0.0 94.0 0.0 142.5 0.0 100.0 0.0 100.0 0.0 0.0 0.0
5 49.9 3.5 86.8 13.3 131.6 31.2 80.8 19.2 75.0 25.0 5.8 -5.8
6 10.7 23.8 2.0 90.6 0.0 211.9 0.0 100.0 0.0 100.0 0.0 0.0
MS 2
%TIC for ions Raw % after Norm. 1 after Norm. 2 Actual % % Error
Sample m/z 356.8 m/z 218.0 M1 IIS HIS IH IIS IS M IIS HIS IH US IS 1H IIS ms
1.0 8.7 52.0 79.6 19.2 5.9 129.1 86.4 26.5 53.3 35.7 11.0 50.0 33.3 16.7 3.3 2.4 -5.7
2.0 23.4 24.9 37.7 31.5 30.4 61.1 141.9 136.7 18.0 41.8 40.2 16.7 50.0 33.3 1.3 -8.2 6.9
3.0 18.0 40.4 61.8 11.4 31.7 100.2 51.3 142.6 34.1 17.5 48.5 33.3 16.7 50.0 0.7 0.8 -1.5
4.0 2.5 58.9 90.5 7.7 0.0 146.6 34.5 0.0 81.0 19.0 0.0 75.0 25.0 0.0 6.0 -6.0 0.0
5.0 31.8 1.5 1.1 77.8 18.5 1.8 350.3 83.1 0.4 80.5 19.1 0.0 75.0 25.0 0.4 5.5 -5.9
6.0 25.6 31.4 47.9 0.0 55.8 77.7 0.0 251.4 23.6 0.0 76.4 25.0 0.0 75.0 -1.4 0.0 1.4
Supplemental Table 2 - Computations for quantification of the ratios of the isomeric disaccharides IIH, IIIH, and IVS in
mock mixtures
Experiment 1
%TIC for ions Raw % after Norm. 1
Sample m/z 137.9 m/z 258 m/z 236.9 1IH IIIH IVS 11I IIIH IVS
1 1.1 9.1 1.4 63.6 27.8 2.7 122.1 68.0 35.2
2 3.2 4.1 3.2 24.4 65.0 7.9 46.7 158.9 102.0
3 5.6 8.7 1.3 59.4 25.2 14.0 114.0 61.5 180.4
4 0.1 10.4 0.7 74.7 14.6 0.0 143.3 35.7 0.2
5 2.9 0.9 4.4 -0.1 89.8 7.0 0.0 219.6 91.0
6 13.2 11.5 0.1 78.9 -1.0 33.3 151.4 0.0 430.8
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After Norm. 2 Actual % % Error
IM IUH IVS 11H IIIH IVS IH IHI IVS
54.2 30.2 15.6 50.0 33.3 16.7 4.2 -3.2 -1.0
15.2 51.6 33.2 16.7 50.0 33.3 -1.5 1.6 -0.2
32.0 17.3 50.7 33.3 16.7 50.0 -1.3 0.6 0.7
80.0 19.9 0.1 75.0 25.0 0.0 5.0 -5.1 0.1
0.0 70.7 29.3 0.0 75.0 25.0 0.0 -4.3 4.3
26.0 0.0 74.0 25.0 0.0 75.0 1.0 0.0 -1.0
Experiment 2
%TIC for ions Raw % after Norm. 1
Sample m/z 137.9 M/z 258 m/z 236.9 IH IIIH IVS IIH IIH IVS
1 0.6 6.4 0.8 88.4 29.3 1.4 118.3 56.8 30.7
2 1.9 2.9 2.3 35.1 92.6 4.5 46.9 179.4 100.8
3 3.4 8.1 1.0 110.9 35.9 8.1 148.3 69.5 182.8
4 0.0 5.5 0.4 76.9 14.4 0.0 102.9 27.9 0.0
5 1.7 0.6 4.2 -2.2 175.9 4.0 0.0 340.9 89.2
6 8.1 10.5 0.1 142.9 -2.5 19.7 191.2 0.0 443.4
after Norm. 2 Actual % % Error
IIH IIIH VS IH IIH IVS IIH IIIH IVS
57.5 27.6 14.9 50.0 33.3 16.7 7.5 -5.7 -1.7
14.3 54.8 30.8 16.7 50.0 33.3 -2.3 4.8 -2.5
37.0 17.4 45.6 33.3 16.7 50.0 3.7 0.7 -4.4
78.7 21.3 0.0 75.0 25.0 0.0 3.7 -3.7 0.0
0.0 79.3 20.7 0.0 75.0 25.0 0.0 4.3 -4.3
30.1 0.0 69.9 25.0 0.0 75.0 5.1 0.0 -5.1
Experiment 3
%TIC for ions Raw % after Norm. 1
Sample m/z 137.9 M/z 258 m/z 236.9 IIH IIIH IVS IH IIIH IVS
1 1.9 9.3 1.6 61.7 26.8 4.3 113.3 72.8 33.5
2 6.0 4.8 3.4 27.0 56.3 14.1 49.5 152.9 109.8
3 8.5 9.0 1.2 58.0 19.0 19.9 106.4 51.5 155.0
4 0.1 12.2 0.7 82.7 12.0 0.0 151.9 32.7 0.3
5 4.8 0.9 5.4 -1.7 87.8 11.2 0.0 238.3 86.9
6 17.4 9.5 0.0 60.4 0.0 40.8 110.8 0.0 317.7
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after Norm. 2 Actual % % Error
II IIIH IVS IH IIIH IVS IH 1 IIIH IVS
51.6 33.2 15.3 50.0 33.3 16.7 1.6 -0.2 -1.4
15.9 49.0 35.2 16.7 50.0 33.3 -0.8 -1.0 1.8
34.0 16.5 49.5 33.3 16.7 50.0 0.7 -0.2 -0.5
82.2 17.7 0.1 75.0 25.0 0.0 7.2 -7.3 0.1
0.0 73.3 26.7 0.0 75.0 25.0 0.0 -1.7 1.7
25.9 0.0 74.1 25.0 0.0 75.0 0.9 0.0 -0.9
Part III
Tools for Glycosaminoglycan Epitope Analysis
There is a lack of epitope mapping tools to quantify or identify functionally
relevant GAG sequences from mixtures. Epitope data, or data on the binding footprint of
a protein partner-analogous to domain identification in proteins-can shortcut the need
for laborious sequencing of oligosaccharides and directly give a readout of the amount of
functional sugar present. By taking advantage of specific protein binding, one may also
circumvent the need to purify oligosaccharides to homogeneity, and may instead be able
to get epitope information directly from GAG chains contained in mixtures. These tools
could enable high throughput analysis and fingerprinting of GAG mixtures. Those
capabilities would, in turn, facilitate searches for biomarkers, GAG diagnostics,
manufacturing quality control, and the monitoring of GAG biosynthesis in experimental
models.
Part two is divided into three chapters, each containing a novel tool or set of tools
aimed at providing methods to quantify specific epitopes within small amounts of
unlabeled GAGs. The first chapter in this section deals with the application of a
microfluidic silicon field effect sensor to the detection and analysis of HSGAGs. This
device operates by detecting changes in surface potential upon binding of charged
analytes. The sensor is useful either for quantifying the total amount of heparin in a
sample via its interaction with protamine, or for quantifying the clinically active
anticoagulant heparin epitope in a sample via its interaction with AT-III. The second
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chapter in this section deals with the application of a suspended microchannel resonator
to the detection and analysis of HSGAGs. This device operates by detecting the change
in effective mass of a resonating cantilever that contains a fluid filled channel, allowing
the detection of HSGAGs binding to receptors immobilized on the cantilever's inner
surface. The chapter continues on to discuss comparisons between the FET and SMR
detection of HSGAGs. The third and final chapter in this section deals with attempts to
use directed evolution to generate anti-heparinoid single chain variable fragments for use
as analytical tools and potential clinical treatments.
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Chapter 5
Silicon Field Effect Sensor for HSGAG Detection
Monitoring of Heparin and Its Low Molecular Weight
Analogs by Silicon Field Effect
5.1. Introduction
The lack of good analytical tools for heparin analysis means there are poor
clinical diagnostics for these molecules, including heparin based anticoagulants. The
complications associated with regulating blood coagulation present major health concerns
that can be managed by careful administration and monitoring of anticoagulant drugs (1,
2). In a clinical setting, it is critical to maintain anticoagulant le~Is that are sufficient to
prevent thrombosis yet low enough to avoid bleeding risks. Heparin has been used as a
major anticoagulant, and it is second to insulin as a natural therapeutic agent (3). Heparin
is a linear glycosaminoglycan consisting of uronic acid-(1? 4)-D-glucosamine repeating
disaccharide subunits containing variable substitution with N-sulfate, O-sulfate and N-
acetyl groups (4). The biological activities of heparin result from sequence-specific
interactions with proteins, most importantly with antithrombin III (AT-III), a serine
protease inhibitor that mediates heparin's anticoagulant activity (5-7). Heparin, heparan
sulfate (HS), and other structurally similar glycosaminoglycans (GAGs) have been
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implicated in various other biological processes including embryonic development,
cancer metastasis, and viral pathogenesis (8-10).
Despite its widespread use, the native, unfractionated heparin has many limitations,
such as interpatient variablility, non-specific protein binding, unstable pharmacokinetics,
and potential side-effects such as hemorrhage and heparin-induced thrombocytopenia
(11). The variability of heparin arises from its complex molecular structure, intrinsic
polydisperity (Mw ranges from 3 to 30 KDa) and heterogeneity of samples (only one in
three molecules contains the active AT-III-binding site) (12). Clinical use of heparin
remains high because it is the only anticoagulant drug that can be effectively controlled
and neutralized by an antidote, namely the cationic protein protamine (13).
Low-molecular-weight heparins (LMWHs), i.e. chemically or enzymatically
modified heparin molecules with reduced chain length, have been designed as a class of
heparin-based drugs with improved bioavailability, simplified administration, more
predictable dose response and pharmacokinetics, and therefore improved safety (14).
LMWHs such as enoxaparin (Lovenox), which is generated by chemical P-elimination
of heparin, have been used for prophylaxis of deep venous thromboembolysms (DVT),
which occurs in as many as 50% of patients after undergoing elective orthopedic surgical
procedures (15). Compared to heparin, LMWHs have a longer half-life and a lower
incidence of complications.
Fondaparinux (ArixtraI), a synthetic heparin-based drug based on the unique
pentasaccharide AT-III binding domain of heparin, has antithrombotic anti-Xa activity
superior to LMWHs. Fondaparinux is therefore used for the prevention of
thromboembolic events following elective orthopedic surgery and other prophylactic
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indications, as well as the treatment of DVT, pulmonary embolisms, and coronary artery
diseases (16). Although LMWHs and fondaparinux improve upon heparin's therapeutic
limitations, they also have shortcomings. The most important safety concerns are that the
anticoagulant activity of LMWHs and fondaparinux cannot be effectively neutralized
(17), and that their blood levels cannot be effectively monitored by current point-of-care
clinical methods. Without the ability to monitor and control their blood level, LMWHs
are unsuitable for certain critical and unmet clinical needs. For example, patients with
acute coronary syndrome taking a LMWH are at high risk of bleeding complications in
the case of an urgent surgical intervention (18).
Standard clinical procedures for monitoring anticoagulant activity of heparin are
based on measuring the activated clotting time (ACT) or activated partial thromboplastin
time (APTT) (1, 19). Although widely used, these tests often fail to provide the actual
heparin level because the clotting time can be affected by additional factors commonly
encountered during surgery, such as hypothermia or hemodilution, as well as abnormal
levels of clotting factors (1, 20, 21). It has been demonstrated that careful patient-
specific assessment of heparin levels would reduce the occurrence of anticoagulation
complications (20, 22). Standard colorimetric assays of heparin levels based on the anti-
Xa or other activities are available, but they require laboratory settings and elaborate
sample handling.
There have been extensive efforts to develop new devices suitable for routine
measurement of heparin levels in clinical settings (1, 23). Various approaches such as
quartz crystal microbalance, surface plasmon resonance, ion-sensitive field-effect
transistor, and membrane-based ion-selective electrode involve either protamine or
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synthetic cationic polymers as heparin probes, and they are either based on surface
affinity capture or on an automated heparin titration (23-34). Such methods have had
variable success in fully achieving the required objectives: selectivity, sensitivity,
robustness and reusability. Moreover, because the heparin capture is based on activity-
independent electrostatic binding, these measurements are of limited utility since they can
only determine total rather than clinically active heparin (12).
Here we use electronic field-effect sensors based on the electrolyte- insulator-
silicon (EIS, or field effect transistor FET) structure (35, 36) to directly monitor the
binding of heparin by detecting its intrinsic negative charge. EIS structures enable a
simple and highly sensitive measurement of surface potential at the electrolyte- insulator
interface (37, 38), and they have been previously used to measure pH and the adsorption
of highly charged molecules such as DNA (39, 40). To address the need for LMWH
monitoring, we demonstrate that a protamine- functionalized EIS can measure the
concentration of enoxaparin and that an AT-III functionalized EIS can selectively detect
the physiologically active pentasaccharide domain in unfractionated heparin and in
fondaparinux. To validate the potential for clinical applications, we demonstrate the
correlation to a standard assay of heparin's anti-Xa activity.
5.2. Materials and Methods
Device Design and Packaging
Devices were fabricated at the MIT Microsystems Technology Laboratory. Field
sensitive regions (50x50 gm or 80x80 pm) were defined by p-type doping and
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electrically isolated by the n-type substrate. Metal contact pads were connected to the
field-sensitive regions by heavily doped p-type traces. The n-type and heavily doped p-
type regions were passivated with 0.8 gm of silicon nitride deposited by low pressure
chemical vapor deposition The silicon nitride was removed over the field sensitive
region and native silicon oxide was used as the gate oxide. Reference electrodes were
defined by evaporating 10 nm of chromium and 1 pm of gold or platinum directly on the
heavily doped p-type trace. Devices were encapsulated by either glass or PDMS
microfluidic channels using previously developed procedures (40, 41). The silicon oxide
above the field-sensitive region was regenerated by a 30 second etch with buffered oxide
etching solution (ammonium fluoride: hydrogen fluoride 7:1 v/v) and a thorough rinse
with water. The device was then allowed to equilibrate overnight until the baseline signal
was stable and long-range drift was insignificant. Although each channel contains two
field-sensitive regions only one region was used.
Surface Chemistry
Protamine was physisorbed to the sensor surface by flowing a 20 pM solution of
protamine in 10% phosphate-buffered saline (PBS) for 10 minutes, followed by rinsing
with the buffer. A control sensor was prepared in separate flow channel by the same
procedure except that bovine serum albumin (BSA) was used in place of protamine. The
layer-by-layer deposition of protamine and heparin was examined using Sentech SE400
ellipsometer, with the assumed refractive index of organic film of 1.5. The experiments
were done by the alternating 5-min exposure of a crm2 piece of silicon wafer to a 20 pM
protamine solution and 1 U/ml heparin solution, separated by a buffer rinse. AT-III was
156
covalently attached to the sensor surface by the following procedure: "Piranha"cleaned
devices were rinsed with ethanol, incubated with a 1% (v/v) ethanolic solution of
propyltrimethoxysilane aldehyde for 20 minutes, rinsed with ethanol, incubated in an
oven for 30 minutes at 80 °C, and rinsed with water. The active sensor was treated with a
1.0 mg/ml solution of avidin in 100 mM phosphate buffer pH 8.0 containing 50 mM
NaCNBH3 for 3 h Upon rinsing with buffer, the unreacted aldehyde groups were
quenched by a similar treatment using 0.5 M ethanolamine instead of avidin The device
was then treated with a 1.0 mg/ml solution of biotinylated AT-III for 6 h, rinsed three
times with buffer and allowed to equilibrate. The control sensor was covalently
passivated by BSA using the same procedure.
Instrumentation
The surface potential of the field sensitive region was determined by applying an
AC signal (50 mV sine wave at 4 kHz) to the reference electrode and measuring the
resulting current through the EIS structure with a current preamp (Keithley Model 428)
and a lock-in amplifier. The p-type field sensitive region was biased into partial
depletion in order to maximize sensitivity to changes in surface potential. The n-type
substrate was biased to 1 V. Capacitance-voltage curves of the EIS structure were
acquired in order to determine the optimal p-type bias point (42). The surface potential
resolution was -10 gV in a 1 Hz bandwidth and the linear range was -100 mV. The
solution was electrically grounded using a pair of Ag/AgC1 wires as reference electrodes
incorporated in the microfluidic setup. The data was acquired with LabView software at
16-bit accuracy with a sampling rate of 5-10 Hz All signals for the active and control
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sensor were calibrated to the applied 2.5 mV change in p-type bias potential, and the
resulting normalized signals were subtracted. The readout of the baseline shift from the
differertial measurement was chosen at a consistent point of time when the signal
reached steady state after the injection of the analyte sample. The data were processed
using SigmaPlot software.
Chemicals
All chemicals were purchased from Sigma-Aldrich unless nrted otherwise.
Porcine heparin (activity 180 U/mg) was purchased from Celsus.
Trimethoxypropylsilane aldehyde was from United Chemical Technologies.
Fondaparinux (activity 700 U/mg, Organon, Inc.) and enoxaparin (activity 100 U/mg,
Aventis Pharmaceuticals Inc.) were from a local pharmacy, and human antithrombin III
was from Bayer Corporation Biotinylated AT-III was prepared using a previously
established method (43). The reagents for the Coatest Heparin anti-Xa chromogenic
assay were from Diapharma Group, Inc. Serum samples were filtered through a 0.2 pm
membrane and diluted to 10% (v/v) with distilled water. The running buffer was a 3.0
mM phosphate-citrate buffer containing 7.0 mM NaCl pH 7.0 (total ionic strength 10.0
mM) for AT-III sensor measurements and 10% PBS for protamine sensor measurements.
Anti-Xa Assay
The Chromogenix Coatest Heparin assay was performed as instructed by the
product insert for a semi- micro cuvette, except one quarter of the instructed volumes was
used to adapt the assay for a 96 well plate format Plates were read on a SpectraMax 96
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well plate spectrophotometer (Molecular Devices). Absorbances were compared to a
linearly fit standard curve as instructed.
Isolation and Quantification of Cell Surface Heparan Sulfate
Human umbilical vein endothelial cells (HUVECs) were grown to confluency on
500 cm2 tissue culture plates. Briefly, cells were washed twice with PBS and then
incubated with trypsin with EDTA (Gibco) for 25 minutes at 37 'C. The supernatant and
cells were separated by centrifugation at 2000 rcf The supernatant was boiled to
inactivate the trypsin and destroy RNA, and then syringe filtered through a 0.45 gm
membrane. The supernatant was then concentrated and buffer exchanged using a
centricon centrifugal concentrator (MWCO 3k) as directed. DNAse was then added to
digest DNA. The GAG solution was then loaded onto a DEAE anion exchange column.
Buffers for the column were 4 M urea, 3.25 mM CHAPS, 50mM sodium acetate, 10 mM
EDTA at pH 6.0. The wash buffer contained 200 mM NaCl and the elution buffer
contained 2 M NaCl Following elution of the HSGAGs, samples were buffer exchanged
into water and concentrated using the centricon centrifugal filters.
Experimental Setup
For all measurements, solutions were introduced to the device with a constant-
flow fluid delivery system involving an in-line degasser, an HPLC pump, and a
refrigerated autosampler at 4 'C. The analyte exposure times were controlled by
adjusting the flow rate (usually 2.0 - 10.0 il/min) and the injection volume of the analyte
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(usually 5.0-40.0 il). A valve upstream from the device was used for switching between
flowing different solution over the sensors during differential sensor modifications, and
simultaneously flowing identical solutions to both sensors during the measurements.
Before and after each analyte injection, the sensor was rinsed thoroughly using "running"
buffer identical to that of the analyte solution After each measurement, the surface of
the active sensor was regenerated by 10 minute incubation with 20 .pM protamine
solution for the case of protamine sensor and with 2.0 M NaCl solution for the AT-III
sensor.
5.3. Results and Discussion
5.3.1. Operation of Silicon Field-Effect Detection
Figure 5.1a shows an optical micrograph of two EIS structures with 50x50 jim 2
sensing surfaces in a single microfluidic channel Twenty sensors (two in each channel
for redundancy) were fabricated on a single chip and were subsequently encapsulated
with either poly(dimethylsiloxane) (PDMS) or glass microchannels. Glass microchannels
were more robust to stringent cleaning procedures, and they eliminated defects and
tediousness associated with hand packaging individual devices with PDMS slabs. A
cross-section of the structures (Figure 5.1b) illustrates the use of silicon implantation
(dotted green) for establishing electrical connections to each sensor and their reference
electrode. The surface potential of the insulator-electrolyte interface is determined by
measuring the capacitance between the implanted silicon and the reference electrode (35,
36, 39).
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Figure 5.1. - Field Effect Sensor
a) Optical micrograph showing an array of parallel anodically bonded glass microfluidic
channels, each containing two 50x50 gm field-effect sensors and a gold signal electrode.
Differential measurements involved two channels, one for the active sensor and another
for the control sensor; b) Schematic illustration of device operation showing the depleted
region (dotted area) in p-doped Si (black) under the sensor oxide surface (gray). Highly
doped buried conductive traces (dotted area) connect the signal electrode ard the sensors
to their respective gold traces away from the channels. Heparin (yellow) binds to the
surface of the sensor containing the protamine receptor (red) whereas this binding is
absent for the control sensor passivated by BSA (blue);
a)
b)
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Specific detection of biomolecules requires prior sensor surface functionalization
with receptors that exhibit high specificity towards the target analyte. In order to reduce
unwanted interference from bulk properties of the solution (e.g ionic strength and pH)
and, to some extent, the interference from nonspecific binding, we measure the difference
in surface potential between two sensors in adjacent channels. The active sensor is
modified with a heparin receptor, protamine or AT-III, and the control sensor is
passivated with BSA.
5.3.2. Protamine Based Sensing of Total Concentration of
Heparin, Enoxaparin, and Cell Surface Heparan Sulfate
Total heparin concentration is measured by modifying the active sensor with
protamine, a cationic protein used as a high affinity (Kd<10 -7 M) (44) heparin antagonist
Figure 5.2a shows the absolute and the differential surface potential response of
protamine sensor to a 0.3 U/ml heparin solution and the subsequent recovery of the
protamine surface. During the injection the active and control sensor respond to surface
adsorption as well as to the slight difference between ionic strength and pH of the sample
and the running buffer. The resulting differential response, however, eliminates the bulk
effects, and the signal primarily represents heparin binding to the active sensor. Arrows
(from left to right) indicate the injection of heparin solution, buffer, a 20.0 gM protamine
solution, and the final buffer rinse. The increased baseline upon injection of heparin
solution, expected from its negative charge (39), gradually decreases during the buffer
rinse, which suggests a slow dissociation of sensor-bound heparin in the non-equilibrium
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Figure 5.2. - Protamine Functionalized Sensor for HMWH Heparin Sensing
a) The response to a 0.3 U/ml heparin solution in 10% PBS of the active sensor (red) and
the control sensor (blue). The differential response (green) reveals the surface potential
change caused by heparin binding by eliminating bulk solution effects. The arrows from
left to right correspond to the injection of heparin solution, rinse with running buffer,
injection of protamine solution, and the second buffer rinse. The spikes at 6 and 67 min
corresponds to externally applied positive and negative 2.5 mV calibration signal; b)
Dose-response curve for heparin in 10% PBS from a protamine functionalized sensor; c)
Clinically relevant range of the dose response curves from the protamine sensor for
heparin in 10% human serum. Each data point is an average of two measurements ± one
standard deviations.
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conditions of the flow-through setup. The transient baseline change during protamine
injection over the active sensor originates from the variations in ionic strength and pH
between the 20 gM protamine solution and the running buffer.
The baseline recovery to the original level prior to heparin injection is consistent
with the surface deposition of a fresh protamine layer on top of the existing heparin layer.
Such layer-by- layer assembly of protamine and heparin, commonly observed with
alternating electrostatic adsorption of oppositely charged polyelectrolytes (45), was
confirmed by ellipsometry. The first deposition of a protamine-heparin pair layer yielded
a 0.8-0.3 nm thick film, whereas ten deposition cycles produced a film with thickness of
7.4±0.6 nm, consistent with the expected ten protamine-heparin layers. Importantly, as in
our previous studies involving DNA and polylysine multilayers (39, 40), the deposition
of multiple layers does not decay signal amplitude over multiple measurements,
suggesting that the overcompensated surface charge at the top layer is effectively
propagated to the sensor surface. The regeneration of the sensor surface and the recovery
of the initial baseline allows for multiple measurements on the same device, a feature
necessary for clinical applications.
To evaluate the performance of the protamine sensor, we obtained the dose-
response curve for heparin in buffer (Figure 5.2b). The data were successfully fitted to a
Langmuir isotherm with Kd = 44 nM (0.12 U/ml), with the sensitive region ranging over
two orders of magnitude, from approximately 0.01 to 1 U/ml. Heparin doses given to
patients are typically in the range of 2-8 U/ml during bypass surgery, and an order of
magnitude lower for post-surgical therapy (1). The protamine sensor is therefore capable
of detecting heparin at and below clinically relevant concentrations, and the most
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sensitive range of the dose-response curve could be matched to a desired range by an
appropriate sample dilution.
To demonstrate the clinical utility of the protamine sensor, we analyzed samples
of diluted human serum spiked with known heparin concentrations. The resulting
calibration curve, shown in Figure 5.2c, corresponds to the range of 0.5 U/ml to 20 U/ml
for the original undiluted serum. The observed decreased sensitivity (detection limit of
0.05 U/ml in 10% serum) compared to the buffer samples can be attributed to partial
heparin neutralization by serum proteins such as platelet factor 4 (20), as well as to
surface fouling by interfering molecular species present in the serum sample.
Importantly, the device response remained linear in the clinically relevant range,
providing simple device calibration and easy readout and data interpretation.
There is a growing view that monitoring LMWH is necessary in certain clinical
cases, although the demand for laboratory monitoring of LMWH is not as frequent as for
heparin since the interpatient variability in dosage requirements is much lower. The
guidelines of the College of American Pathologists recommends laboratory monitoring in
pediatric patients and suggests laboratory monitoring in patients with renal insufficiency,
those receiving prolonged therapy including pregnancy, those at high risk of bleeding or
thrombotic recurrence, and patients with obesity or low body weight (20). The current
inability to monitor LMWH levels particularly limits its usage in catheterization
laboratory, and a simple and rapid point-of-care monitoring system would therefore
improve the safety and efficacy of LMWH administration (18).
Figure 5.3 shows the dose-response curves of enoxaparin binding to the
protamine sensor. As with unfractionated heparin, the sensitive region of the dose-
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response curve, successfully fitted to a Langmuir isotherm with Kd = 150nM (0.06 U/ml),
includes the clinically relevant concentrations. Although protamine is not effective at
completely neutralizing the activity of LMWHs in vivo (it neutralizes the anti-
thrombin activity but not the anti-Xa activity) (46), the interaction is sufficient to detect
enoxaparin using the protamine sensor. The somewhat lower signal amplitude compared
to heparin can be attributed to less overall negative charge introduced to the surface of
the relatively shorter polysaccharide chains.
To demonstrate the utility of this device for laboratory analysis of bioactive
GAGs, and to validate its advantage as a low sample consumption assay, we used the
sensor to quantify cell surface heparan sulfate (HS). Cell surface HSGAG
peptidoglycans were isolated, and compositional analysis was performed using capillary
electrophorisis to confirm their purity. The concentration of the purified HSGAGs was
determined via monitoring the UV absorbance of a heparinase digestion of the sample,
and comparing it to a standard curve. Then, a dose response standard curve (104', 10-',
5.5*10 -3 , 10-2, 5.5*10-2, 101 U/ml) for the protamine sensor responding to commercial
HS was generated, and a Langmuir isotherm was fit to the data. Diluted cell surface HS
was then injected and the signal was compared to the standard curve for quantification
The result of the digest quantification was 0.80 mg/ml, while the result of the sensor
quantification was 0.75 mg/ml, and the differences between the two answers was not
statistically significant.
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Figure 5.3. - Protamine Functionalized Sensor for LMWH Sensing
Dose response curves of the protamine sensor for enoxaparin in 10% PBS. Each data
point is showed as the average of two measurements ± one standard deviations.
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5.3.3. AT- I Il Based Sensing of Active Heparin and
Fondaparinux
The highly specific interaction between AT-III and heparin involves clinically
active pentasaccharide domains, which are randomly distributed along the heparin chains,
and a single binding site on the AT-III surface (16). The preparation of the AT-III-based
sensor (Figure 5.4a) involves covalent immobilization of avidin via aldehyde- modified
silane, followed by the capture of biotinylated AT-III. Because the heparin-binding site
was protected during the biotinylation process (43), the immobilized AT-III remains
active and properly oriented away from the surface.
The dose response curve for heparin from the AT-III sensor (Figure 5.4b) was
fitted to a Langmuir isotherm with a Kd of 180 nM (0.49 U/ml), which is about 2.5 to 5
times higher than the reported values in solution (47, 48). To evaluate the selectivity of
the AT-III sensor for heparin, we measured its response to a negatively charged
glycosaminoglycan, chondroitin sulfate, which is structurally related to heparin but
known not to interact with AT-III (Figure 5.4b). As expected, the response is negligible
and consistent with the expected low binding affinity, thus confirming the selectivity of
the AT-III sensor.
Next, we tested the capability of the AT-III sensor to selectively detect
fondaparinux, a synthetic drug based on the AT-III-binding pentasaccharide domain of
heparin. The sensitive region of the dose-response curve (Figure 5.5) includes the
clinically relevant range of concentrations. The data were successfully fit to a Langmuir
isotherm with a Kd of 200 nM (0.24U/ml), a value 8 times higher than that obtained for
fondaparinux binding to AT-III in solution. (16, 49) The amplitude of the sensor response
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Figure 5.4. - A T-III Functionalized Sensor for Sensing HMWH
a) Procedure for immobilizing AT-III to the sensor surface; b) Dose-response curve for
the AT-III sensor with heparin (?) and with chondroitin sulfate (?), a carbohydrate that is
structurally related to heparin but known not to interact with AT-III. Chondroitin sulfate
data points are connected with a dashed line and heparin data points (showed as the
average of two measurements + one standard deviations) are fit with a Langmuir
isotherm (solid line).
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Figure 5.5. - A T-Ill Functionalized Sensor for Pentasaccharide Sensing
Dose-response curve of the AT-III-sensor for heparin-based pentasaccharide drug
fondaparinux (?) and 6-0 desulfated fondaparinux (?), which is known to exhibit low
binding affinity for AT-III. Data points for fondaparinux are fit with a Langmuir
isotherm (solid line), and those for and 6-0 desulfated fondaparinux are connected with a
dashed line.
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of 2.3 mV is lower than that of unfractionated heparin, presumably due to less overall
surface charge per molecule that is introduced upon fondaparinux binding.
To further investigate the selectivity of the AT-III sensor to the active sequence of
heparin, we also analyzed a pentasaccharide with a single 6-0 sulfate moiety removed
from the non-reducing end of the fondaparinux, a modification that renders the
pentasaccharide completely inactive (43). Unlike with fondaparinux, there was
negligible response from the inactive pentasaccharide, confirming the expected
selectivity of the AT-III sensor. Such sequence-specific detection demonstrates that this
sensor could be used to study interactions of heparin, HS, and other GAGs with proteins
(such as cytokines or growth factors), as well as for sequence-specific quantification of
scarce HSGAG samples.
5.3.4. Comparison of the Field-Effect Sensor to the Anti-Xa
Assay
As a validation for clinical use, we compared our measurements with an assay of
heparin's anti-Xa activity (Coatest), a standard method for clinical assessment of heparin
levels. Although ACT and APTT remain the dominant tests for monitoring
anticoagulation, it is widely known that they may poorly correlate to the actual heparin
level due to the lack of specificity arnd interference of other factors (20, 21). Enzymatic
assays such as this anti-Xa assay (which has a reported correlation coefficient of 20.90
with the APTT), are more accurate in reporting heparin levels, but they are complex,
reagent-intense, and they require laboratory settings, which makes them impractical for
routine near-patient testing. Moreover, the anti-Xa assay relies on unstable reagents, is
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sensitive to the presence of other molecules that can affect stability of chromogenic
substrate and activity of Xa, and is sensitive to Xa levels in test plasma.
To compare the performance of the protamine sensor to that of the anti-Xa assay
and to the actual heparin concentrations, we obtained a standard curve for each method
using 0.1, 0.3, 0.5, 0.7 and 0.9 U/ml solutions of heparin, and we used them to determine
five "unknown" concentrations in this range by both methods. Because the sensitivity of
the protamine sensor exceeds the range of anti-Xa assay (broadly 0.1-1.0 U/ml) by an
order of magnitude, the samples were adequately diluted. Figure 5.6 shows a good
correlation (correlation coefficient r = 0.97) between the two methods. Importantly, the
comparison of the standard deviations and the divergence from the expected values show
that field-effect sensor exhibited both better precision and accuracy compared to the anti-
Xa assay, while consuming only nanogram sample quantities.
5.4. Conclusion
We have demonstrated the potential of the field-effect sensor to detect and
quantify clinically relevant concentrations of heparin, its low molecular weight analogs,
and cell surface heparan sulfate. In order to meet this potential in the clinical setting,
certain obstacles common to many types of electronic sensors and medical devices may
need to be overcome. First, the sensors often require long initial equilibration time. We
have found that careful cleaning of the sensor surface and differential detection improves
performance but does not completely eliminate these effects. Second, we occasionally
observe device-to-device variations in both the amplitude of the signal and the sensitivity
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Figure 5.6. - Comparison to anti-Xa Assay
Linear correlation (2 = 0.97) between the values for different heparin concentrations in
10% PBS obtained by field-effect measurements and by the colorimetric anti-Xa assay
(?). The values were obtained using a five-point standard curve in the range of 0.1 to 0.9
U/ml. The actual values (?) were 0.1, 0.3, 0.45, 0.6, and 0.75 U/ml. The samples were
diluted 10 times in the case of field-effect measurements. The horizontal error bars
represent the standard deviation from three distinct anti-Xa assays and the vertical error
bars represent the standard deviation from two field-effect measurements.
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for heparin binding. Third, although the sensor is capable of detecting heparin in plasma
samples (data not shown), the device exhibited a gradual decrease in sensitivity over
successive sample runs, presumably due to non-specific deposition of plasma
components in the sensor channel, a frequent problem of plasma-contacting medical
devices. We anticipate the majority of these issues could be addressed by improving the
quality of the sensor surface through pre-grown oxide layers during the fabrication
process and more rigorous procedures for surface preparation and regeneration.
In its present state, this device is useful for the analysis of heparin, HS and other
similar GAGs in the laboratory setting. The sensitivity and low volume sample
requirements allow total or specific heparin quantification using nanogram quantities of
material, with the ability to recover most of the analyzed sample. In contrast, the current
standard methods for non-activity based quantification of GAGs, such as the m-
hydroxydiphenyl method, consume micrograms of material and are highly affected by the
presence of other glycosaminoglycans (GAGs), neutral carbohydrates, or proteins.(50,
51) The specificity of the AT-III based sensing suggests the possibility of immobilizing
other heparin binding proteins to the surface of the device and quantifying other epitopes
within a diverse HSGAG population. When corrbined, these two capabilities of sensitive
and specific detection have the potential to allow novel studies of heparin binding
epitopes from scarce preparations of cell surface HSGAGs.
In summary, we have demonstrated the capability of silicon field-effect sensors to
measure clinically relevant concentrations of heparin, the LMWH enoxaparin, and the
synthetic pentasaccharide drug fondaparinux. We obtained dose-response curves and
achieved detection limits that are sufficient for clinically-relevant concentrations, and we
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demonstrate good correlation to a standard laboratory-based anti-Xa assay of heparin
activity. We envision that the ability to make direct and routine measurements of
heparin, LMWHs, and heparin based drugs such as fondaparinux could increase the
safety and efficacy of these drugs in the clinical setting. Moreover, in the research
laboratory, the quantitation of absolute amounts and specific active sequences of
HSGAGs could enable in-depth investigations of their interactions with other
biomolecules.
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Chapter 6
Comparison of Suspended Microchannel
Resonator to Silicon Field Effect for HSGAG
Detection
6.1. Introduction
Heparin and heparan sulfate glycosaminoglycans (HSGAGs) are known to affect
many important biological activities including coagulation, development, cell-cell
signaling, viral pathogensis, and cancer metastasis (1-5). These linear sulfated
polysaccharides mediate these biological functions through sequence specific interactions
with dozens if not hundreds of proteins, more of which are being discovered every day.
However, the current analytical tools available to the laboratory scientist are not
sufficient to tackle the quantification of these relevant epitopes. The available techniques
are too time, labor, and/or material consuming to be applied to regular analysis or to
tissue culture samples. Therefore, in the efforts to understand basic biology as well as
engineer and monitor new therapeutics, a robust and modular biosensor capable of
directly quantifying biologically relevant epitopes would be extremely useful.
Many attempts have been made to attempt to address this analytical gap. Due to
the large market, most of these efforts have focused on developing sensors for routine
measurement of total heparin levels in clinical settings (6, 7). Various approaches such as
quartz crystal microbalance, surface plasmon resonance (SPR), ion-sensitive field-effect
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transistor, and membrane-based ion-selective electrode involve either protamine or
synthetic cationic polymers as heparin probes; they are either based on surface affinity
capture or on an automated heparin titration. (7-18). All of these devices, however, are
based on activity-independent electrostatic binding, and are therefore limited to
determining total heparin as opposed to a specific bioactive epitope in heparin (19).
Recently, we developed an electronic field-effect sensor based on the electrolyte-
insulator-silicon (EIS) structure (20, 21) to directly monitor the binding of heparin by
detecting its intrinsic negative charge (22). Because heparin has a high charge density,
the field-effect device has high sensitivity for HSGAGs. We have demonstrated the
potential of the field-effect sensor to detect and quantify clinically relevant
concentrations of heparin, its low molecular weight analogs, and cell surface heparan
sulfate using either protamine or antithrombin III (AT-III) as surface receptors.
However, this laboratory device had limitations common to many types of electronic
sensors and medical devices that prevent its immediate scale-up and adoption.
The EIS sensors (also known as field effect transistors or FET) have an inherent
sensitivity to changes in ionic strength, which alter the conductance in the channels and
screen the charges on the biomolecules from the surface. In addition, the electronic
sensors often require long initial equilibration time, have device-to-device variations in
both the amplitude of the signal and the sensitivity, require off-line surface chemistry for
immobilization of specific heparin binding proteins, and show a gradual decrease in
sensitivity over successive sample runs when detecting heparin from plasma (22). While
there are ways to address these limitations prior to scale-up, we decided to compare other
biosensors to the EIS device for HSGAG detection.
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Many of the limitations of the EIS device are avoided by using the mass sensitive
Suspended Microchannel Resonator (SMR) (23, 24). The SMR detection method is
based on the changing resonant frequency of fluid filled hollow microscale cantilevers;
the resonant frequency change is proportional to the effective mass of the cantilever
(Figure 6.1). This change can be due to changes in density of the solution in the channel,
particles passing through the channel, or molecules binding to the inside of the channel.
Although the resonant frequency decreases when the cantilever becomes heavier, all
figures in this chapter show the -Afrequency so that an increase in the y-axis value
indicates an increase in cantilever mass (to make the graphs more intuitive to read and to
match the orientation of other sensorgrams such as those from SPR).
This highly sensitive device has been shown to be capable of giving kinetic
readouts of protein-protein binding using non-covalent surface chemistry (23). While the
device is mass sensitive as opposed to charge sensitive, it can detect very small changes
in mass, therefore we anticipate that it will be able to detect highly charged but smaller
GAG molecules. Assuming an estimated heparin density 2.2 times greater than water, a
heparin MW of 12kDa, and approximately 1 fg/mHz change in frequency, a 0.1 mHz
change in the frequency of the cantilever would require the binding of only 0.083 fg of
heparin or about 7 zmoles of material (-4200 heparin molecules). Each device is
extremely robust, allowing harsh cleaning and reuse, and a simple automated reversible
surface chemistry for protein immobilization has been developed.
This chapter will discuss our efforts to develop the SMR as a heparin sensor, and a
comparison between the SMR and the FET. We began by using a protamine
functionalized SMR to sense two classes of heparin drugs, high molecular weight heparin
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Figure 6.1 - Suspended Microchannel Resonator (SMR)
(A) There are two bypass channels, one running on either side of the cantilever channel,
allowing quick exchange of solutions. Fluid flows from the higher pressure bypass
through the cantilever to the lower pressure bypass. (B) The resonant frequency of the
cantilver changes with the mass of the cantilever (e.g. with the binding of molecules to
the interior surface of the cantilver).
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(HMWH) and low molecular weight heparin (LMWH), using a continuous flow system,
in comparison to the FET experiments. We then continued on to use an automated stop
flow system to immobilize AT-III to the SMR surface, and perform specific sensing of a
bioactive epitope. The SMR setup proved to be more sensitive than the FET in detecting
heparins. However, the charge based sensing of the FET actually made it more robust
with regards to a better signal to noise ratio when sensing heparins in complex biological
mixtures.
6.2. Materials and Methods
Materials
All chemicals (unless otherwise noted) were purchased from Sigma-Aldrich.
Porcine heparin (activity 180 U/mg) was purchased from Celsus. Enoxaparin (activity
100 U/mg, Aventis Pharmaceuticals Inc.) was from a local pharmacy, and human
antithrombin III was from Bayer Corporation. Biotinylated AT-III was prepared using a
solid state reaction. Briefly, AT-III was bound to a heparin-agarose column to protect the
binding site, and to allow buffer exchange. The bound AT-III was then biotinylated as
directed using the Pierce Chromogenic biotin kit (Pierce). Biotinylated AT-III (bAT-III)
was eluted with 2M sodium chloride, and fractions were analyzed for protein and biotin
content using a nanodrop spectrophotometer. The bAT-III was then concentrated and
desalted using a 10k MWCO microcon centrifugal concentrator as directed. The running
buffer was PBS (CellGro,) diluted to 10% with milliQ water and with 0.01% sodium
azide.
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Device Design and Measurements
Devices were fabricated as described (23). The 200 X 33 X 7 .m (length X width
X thickness) microcantilever containing a 3 X 8 glm (height X width) channel is
suspended in a vacuum cavity (optical micrograph, right). Microfluidic bypass channels
(30 X 100 gm, height X width) are connected to the inlet and the outlet of the suspended
channel, and enable the quick exchange of samples by pressure driven flow. The
frequency response was monitored via an optical lever method, utilizing a 635nm laser
and a position sensitive photodetector (PSD) to track cantilever vibrational amplitude.
The cantilever was driven electrostatically at its dynamic resonant frequency by a phase-
locked closed feedback drive circuit, with a bias voltage of 60 volts. The resonant
frequency was monitored using an Agilent 53131A universal counter, and the data were
collected using Lab View and processed using Matlab and Sigma Plot.
SMR Experimental Setup
For protamine based measurements, protamine solutions were introduced to one
device bypass with a constant-flow fluid delivery system consisting of a syringe pump
(Harvard PHD2000) with 0.22 micron inline filter (Upchurch). The protamine exposure
times were controlled by adjusting the bypass outlet pressure using an automated
switching valve. Heparin and cleaning solutions were introduced using a constant-
pressure flow through an autosampler (Hitachi) and inline filter (Figure 6.2a).
For AT-III based experiments, all experimental and cleaning solutions were
introduced to one device bypass with a constant-pressure flow through a refrigerated
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Figure 6.2 - Schematic of Experimental Setups
(A) Continuous flow protamine based experiment set-up. Solutions generally flow
continuously through the autosampler, across the cantilever, and to waste. Flow can be
switched across the cantilver to functionalize the surface with protamine from the other
cantilever. (B) Stopped flow AT-III based experiment set-up. Solutions generally flow
continuously through the autsampler and to waste, while the cantilver is continuously
flushed with buffer from the other bypass. Flow in the autosampler bypass can be
stopped when a sample plug is centered across the entrance to the cantilever, and forced
through the cantiver at an approximately constant concentration.
Protamine Experiment Fluidics
1.10%PBS, 15psi .
. 3 0.1 mg/mi Protamine
2. Waste, 5psi
10%PBS, 4 uL/min
(syringe pump)
4'. Waste, Opsi
Switch 4 using computer
controlled 6 way valve
1.10%PBS, 15psi
3. 0.1 mg/ml Protamine,-
10%PBS, 4 uL/min
(syringe pump)
2. Waste, 5psi
4. Waste, 15psi
AT-III Experiment Fluidics
1.10%PBS, 2. Waste, 0 psi
Autosampler, 15 psi
3.10%PBS, 20 psi 4. Waste, 0 psi
Switch 2 using computer
controlled solenoid valve
1.10%PBS,
Autosampler, 15 psi
3.10%PBS, 20 psi
2. Waste, 15 psi
4. Waste, 0 psi
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autosampler (Agilent 1100) and inline filter. Solenoid valves were used to actuate the
pressures at the inlets and outlets of each (Figure 6.2b). Before and after each analyte
injection, the sensor was rinsed thoroughly using "running" buffer identical to that of the
analyte solution. After each measurement, the surface of the active sensor was
regenerated by a 2.0 M salt 0.05% acetic acid wash. In the case of protamine sensor the
salt removes heparin and protamine both, while in the case of the AT-III sensor the salt
removes bound heparin from the AT-III while leaving the PLL-PEG-biotin-avidin-
biotinylated-AT-III surface intact.
SMR Surface Chemistry
For protamine physisorption, one bypass was continuously flowing buffer from
the autosampler, while the second bypass was continually flowing protamine solution. In
general, surfaces were functionalized with a 20 pM solution of protamine in 10%
phosphate-buffered saline (PBS) for 10 minutes from one bypass, followed by rinsing
with buffer from the other bypass (Figure 6.2a). Protamine surfaces were regenerated by
a 10 minute wash with 2M sodium chloride, 0.5% acetic acid injected through the
autosampler.
For AT-III functionalization, one bypass was continuously flowing buffer from
the autosampler, while the second bypass was continually flowing a wash buffer (Figure
6.2b). AT-III functionalization was accomplished in three steps: one, electrostatic
adsorption of poly(ethyleneglycol)-biotin grafted poly-L-lysine (PLL-PEG-biotin, 1
mg/ml); two, binding of avidin (0.5 mg/ml); three, attachment of biotinylated AT-III (0.5
mg/ml) to the avidin. The mass increase at each step can be followed in real time.
FET Surface Chemistry and Experimentals
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Thet FET device was operated as described in Milovic et al. (22). Briefly, the
main differences between FET operation and SMR operation are as follows. A valve
upstream from the device was used for switching between flowing different solution over
the sensors during differential sensor modifications, and simultaneously flowing identical
solutions to both sensors during the measurements. All experiments were performed
using continuous flow over the sensors driven volumetrically by an Agilent 1100 HPLC,
although faster flow rates enabled by the high pressure flow reduced diffusion of sample
plugs and resulting concentration variations.
6.3. Results and Discussion
6.3.1. Operation of the Suspended Microchannel Resonator
A schematic of the SMR cantilever and bypass channels is shown in Figure 6.1.
There are two bypass channels, allowing quick exchange of solutions. Fluid flows from
the higher pressure bypass through the cantilever to the lower pressure bypass.
Functionalization of the interior of the cantilever allows specific measurement of target
analytes. Both functionalization schemes that we currently employ take advantage of the
negative surface charge of the native silicon oxide coating the silicon cantilevers. For
protamine experiments, the positive protamine is adsorbed, and for AT-III experiments, a
positive poly-lysine-PEG-biotin layer is adsorbed. In order to reduce long-term drift, the
SMR is temperature controlled via continuous exchanging liquid bath, kept at 250C..
For protamine based experiments, a continuous flow system was used where the
plugs injected from the autosampler continuously flow by the cantilever (Figure 6.2a).
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This means that the cantilever is exposed to a changing concentration profile due to
diffusion and other mixing at the front and back ends of the sample plug. This general
set-up was common to the FET and SMR. In contrast, the SMR AT-III based
experiments used a stop-flow system to expose the cantilever to a constant concentration
profile. Flow through the cantilever was maintained through the wash bypass as the
sample plug was centered in the other bypass. Then, the pressure at both ends of the
sample bypass was raised and equalized, stopping the plug and switching the flow
direction across the cantilever, injecting the center of the plug through the cantilever for
the duration of the experiment at approximately constant concentration (Figure 6.2b).
6.3.2. Protamine Based Sensing of Total Concentration of
Heparin and Enoxaparin
For the detection of total heparin, sensors were functionalized with protamine, a
cationic protein used as a high affmity (Kd<10 -7 M) (25) heparin antagonist. For FET
experiments, these measurements could be taken by alternating protamine and heparin.
Each polyelectrolyte layer that was built in this manner was approximately charge
neutral, allowing for the signal to return to baseline. On the contrary, each multilayer is
directly observable in the SMR (Figure 6.3). One can see that the layers gradually grow
in size and become irregular, necessitating another method for multiple measurements.
The measurement cycle that was developed for protamine based sensing in the
SMR was different than that used in the FET (Figure 6.4). First, the bare silicon was
exposed to a protamine solution, and one could observe a consistent and quick ~2Hz
frequency change as the protamine physisorbed to the surface. Following a short buffer
189
Figure 6.3 - Polyelectrolyte multilayers
30 alternating cycles of protamine solution and heparin injections build multilayers that
are observable in the SMR, due to the increase in mass of the cantilever with each layer,
and the layer size seems to increase. In the FET, each layer is approximately charge
neutral, and each layer returned the surface potential to baseline. Inset is a schematic of
the separation of the protamine solution and the heparin plugs from the autosampler.
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Figure 6.4 - SMR Measurement Cycle - Regeneration
In order to return the SMR signal to baseline following the formation of a protamine-
heparin layer, the surface was regenerated with an acidified salt wash (2M sodium
chloride with 0.5% acetic acid). The plot shows the regeneration cycle, with the signal
corrected for density differences in the solutions (any Afrequency attributable to solution
phase changes in density - observable as instant and equal changes in signal when new
solutions enter and then exit the cantilever - are subtracted). Inset is the uncorrected
data.
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rinse which removed some loosely associated protamine, a heparin plug was injected.
Although a fast association of heparin is observed, kinetic data cannot be extracted from
this sensorgram because the heparin plug is not at constant concentration. In order to
remove the protamine-heparin layer, an acidified salt solution was used. Although this
measurement cycle is longer than the multilayer building cycle in the FET, the ability to
observe the formation of the protamine layers does provide some measure of quality
control. As an interesting aside, this protamine cycle has also be used to repeatedly
measure DNA in a dose dependent manner (data not shown), whereas the more common
poly-lysine-DNA Layers are much harder to remove.
We compared the performance of the SMR protamine-based sensor to the FET by
generating dose response curves to HMWH and LMWH (Lovenox) in buffer. Lovenox is
generated by chemical depolymerization of HMWH, and the primary difference between
the two that interests us is the size difference between the two pools of molecules
(HMWH -~12,000 Da and Lovenox ~4,200 Da average MW). The current inability to
measure LMWH especially limits its utility, particularly in the catheterization laboratory,
since overdose of LMWH cannot be effectively neutralized (26, 27). When the SMR
sensorgrams are overlaid, the dose response and saturation behavior are apparent, as is
the consistency of the protamine layers after cleaning (Figure 6.5). The data in all cases
were successfully fitted to Langmuir isotherms, appropriate for single site equilibrium
binding.
For the HMWH (Figure 6.6) and LMWH (Figure 6.7) experiments, the Kd of the
interactions were well below the clinically relevant range of 0.2-8 U/ml (6). Although
protamine cannot completely neutralize LMWHs in vivo (it neutralizes the anti-thrombin
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Figure 6.5 - Protamine-heparin Dose Response
The drift corrected sensorgrams for protamine-heparin layers over five orders of
magnitude of heparin injections are overlaid. One can see the bulk density change in the
10U/ml heparin sample as it passes through the cantilever, before signal returns to the
saturated binding frequency. Inset is the overlay of the entire set of runs.
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Figure 6.6 - Protamine-HMWH Dose Response Comparison
The FET data is plotted in black, the SMR data is plotted in blue. Both devices are
capable of measuring heparin at concentrations below the clinically relevant window.
The apparent Kd of the interaction in the SMR is lower.
FET: Detection limit <10 -2 U/ml and apparent Kd of 120 mU/mL
SMR: Detection limit <10 -3 U/ml and apparent Kd of 3.4 mU/mL
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Figure 6.7 - Protamine-LMWH Dose Response Comparison
The FET data is plotted in black, the SMR data is plotted in blue. Both devices are
capable of measuring Lovenox at concentrations below the clinically relevant window.
The apparent KI of the interaction in the SMR is lower.
FET: Detection limit <10 -2 U/ml and apparent KI of 62.6 mU/mL 150nM
SMR: Detection limit <10 -3 U/ml and apparent Kd of 4.5 mU/mL 1.67nM
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activity of larger molecules but not the anti-Xa activity that remains with smaller
molecules) (28) the interaction is sufficient to detect enoxaparin using the protamine
sensor. Either the larger molecules are sufficient for detection, or the change from
solution phase to surface interaction allows the protamine coated surface to bind
molecules of heparin that protamine cannot in solution. However, the Kd in both devices
varied between experiments, requiring standard curves be generated prior to each set of
measurements. Notably, the Kd within the same device was similar for HMWH and
LMWH. However, as expected, the saturating signal was less for LMWH than HMWH,
since these molecules are smaller (and therefore are less massive and carry less charge).
Within experiments, the FET showed smaller standard deviations than the SMR, which
would allow more certainty in quantification without repetition. Both devices were also
sensitive over several orders of magnitude, suggesting a good dynamic range for these
assays, which could be matched to the necessary concentrations via dilution.
6.3.3. AT-III Based Sensing of Heparin Anticoagulant Epitope
As a proof of principle for heparin epitope sensing, the protein AT-III was used as
a specific heparin sensor. The highly specific interaction between AT-III and heparin
involves pentasaccharide domains, randomly distributed among the heparin chains, and a
single binding site on the AT-III surface.(5) Biotinylated AT-III (bAT-III) was
manufactured either by solution phase (22) or solid phase labeling of human AT-III; in
either case the AT-III was bound to heparin during the labeling to protect the binding site.
The preparation of the AT-III-based sensor (Figure 6.8a-b) involves immobilization of
bAT-III via avidin to either silane aldehyde (FET) or poly-lysine-PEG-biotin (SMR).
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While the FET covalent avidin immobilization provides the FET sensor with added
stability, the silanization process requires several off-line steps that prevent the
monitoring of the immobilization reaction. The non-covalent SMR surface chemistry not
only can be monitored real-time for quality control purposes, but it can also be cleaned
off via a stringent 50% acetic acid- 50%hydrogen peroxide wash.
The dose response curves for heparin from the AT-III sensor (Figure 6.8c) were
fitted to Langmuir isotherms with Kd values several times greater than the reported values
in solution(29, 30) To evaluate the selectivity of the AT-III sensor for heparin, we
measured its response to another sulfated glycosaminoglycan that is known not to interact
with AT-III, chondroitin sulfate (CS). At CS concentrations equivalent to the heparin
concentrations, neither the FET nor the SMR detected significant CS-protamine binding,
thus confirming the selectivity of the AT-III sensor. Although there is variability in the
Kd when comparing the devices to each other or to literature values, this may be
explained by the differing surface chemistries and bAT-III preparations. While these
methods may not be useful in determining native Kd for protein-GAG interactions, they
are useful to quantify amounts of this significant GAG epitope. The specificity and
sensitivity of this detection demonstrates the utility of this sensor for measuring the
interaction of GAGs with other proteins (such as cytokines or growth factors) from scarce
samples.
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Figure 6.8 - AT-III Based Epitope Sensing
(A) The surface chemistry used to immobilize the biotinlyated AT-III in the SMR. (B)
The surface chemistry used to immobilize the biotinylated AT-III in the FET. (C) The
FET data is plotted in black, the SMR data is plotted in blue. Both devices are capable of
measuring heparin at concentrations below the clinically relevant window. The apparent
Kd of the interaction in the FET is lower.
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6.3.4. Comparison of the FET to the SMR for Sensing from
Mixtures
The inherent differences between the FET and SMR sensors put the FET at an
advantage when sensing heparin out of a mixture. The FET sensor was originally chosen
by us as a heparin sensor because the FET is a charge based sensor, and heparin (and
other sulfated GAGs) have a high charge density (~2-3 negative charges per 500 Da). On
the other hand, proteins and other non-nucleic acid biological molecules generally have
charge densities at least an order of magnitude lower. Therefore, the FET itself shows
some specificity towards detecting heparin over proteins, outside of the specificity of the
receptor immobilized on the FET surface.
To demonstrate this effect, we measured binding to the FET and SMR of heparins
in dilute (10%) plasma (Figure 6.9). In the FET, the surface potential change decreases
when the heparin is measured in dilute plasma compared to buffer. In the SMR, the
frequency change increases when the heparin is measured in dilute plasma compared to
buffer. We hypothesize that the same binding events are occurring in both cases,
however the differing physics of the devices give the differing results. These results
could be explained if in the presence of plasma, there is less heparin binding to protamine
because some protamine binding sites are occupied with non-specific binding of low
charge density plasma elements. The charge-based FET sensor would not detect the
plasma components (decreasing signal) while the SMR sensor would preferentially detect
the larger plasma components (increasing signal). The concept that a charge-based
sensor is more specific for charged analytes goes against the perception that this type of
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sensor is vulnerable to non-specific signals (such as minute changes in pH, ionic strength,
etc.).
Figure 6.9 - Sensing in Plasma Comparison
(A) In the FET, the surface potential change of an enoxaparin-protamine measurement
(red) is larger than the same measurement in plasma (black). We hypothesize that heparin
binding (orange) is less when injected with plasma due to competition for binding sites
with plasma components, but the FET does not detect the non-specific binding of low
charge density plasma elements (green). (B) In the SMR, The ? frequency of a heparin-
protamine measurement (red) is dwarfed by the same measurement in plasma (black).
We again hypothesize that heparin binding (orange) is less when injected with plasma,
but the SMR detects the non-specific binding of massive plasma elements (green).
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6.4. Conclusion
Both the FET and SMR have demonstrated their use as HSGAG sensors. These
devices have high sensitivity and low sample volume requirements, and can therefore
quantify nanogram (FET) or femtogram (SMR) amounts of material. Common
laboratory techniques for HSGAG quantification are orders of magnitude less sensitive
and are interfered with by proteins or other saccharides (31, 32). In addition, both
sensors specifically quantified a biologically relevant GAG epitope by using a HSGAG
binding protein as a receptor, so in the future other proteins may be used to sense other
epitopes, allowing novel studies of GAG biology, or "fingerprinting" of GAG samples.
However, each sensor has its own strengths and weaknesses. The FET can
operate with a quicker, multilayer measurement cycle and provides some specificity
advantages because it is more sensitive to highly charged molecules. The SMR appears
more robust against drift, and changes in ionic strength, and the sensor can be reused ad
infinitum by regeneration after protamine or AT-III measurements. With future work,
perhaps the limitations of one of these devices will be overcome, but for now, neither
device has de facto superiority and the device selected should reflect its strengths and
weaknesses.
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Chapter 7
Directed Evolution of anti-HSGAG scFv
7.1. Introduction
Antibodies are key tools for biologists and clinicians. Normally, these molecules
are evolved in vivo by the mammalian immune system to bind foreign epitopes with high
specificity. Antibodies are used primarily for the detection and quantification of epitopes
(ELISA assays, Immunohistochemistry, etc.) or the neutralization of those epitopes as
treatments (Herceptin, Avastin, etc). Therefore, developing antibodies to GAGs would
be extremely beneficial both for analytical and therapeutic purposes. However, given the
lack of immunogenicity of GAGs (they are virtually identical in structure across species
in mammals), classic monoclonal antibody technology has not been very successful in
generating anti-GAG antibodies. Prior to the use of combinatorial phage display libraries,
only a few antibodies that recognize HSGAG epitopes (and not the core protein) have
been described (1, 2).
This problem was circumvented by the use of phage display technology to select
for antibodies against HS (3-5). Phage display technology was used to generate anti-
heparin single chain variable fragments (scFv) because this technique can generate self-
recognizing antibodies out of a mutagenized combinatorial library (3, 4. The anti-
HSGAG antibodies isolated in this manner had affinities of approximately 100nM.
However, phage display has significant limitations regarding expression bias, artifacts of
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stickiness, artifacts of selection (selecting for non-binding properties such as improved
host survival) and the generation of mutagenized libraries. Yeast display was developed
to directly address these limitations (6, 7) and has to date enabled significant
improvements in affinity and stability that were previously unachievable with phage
display (8, 9).
For the generation of high affinity antibodies, yeast (S. cerevisiae) surface display
provides many advantages over phage display (Figure 7.1). Because yeast, as a
eukaryote, has protein folding and secretory machinery similar to those of mammals,
there is little to no expression bias. Since genetic manipulation is also facile in yeast, it is
possible to generate extremely large and diverse non-immune libraries that can be
propagated without losing diversity (10). By using labeled ligand, magnetic assisted
cytometric sorting (MACS) can be used to rapidly enrich for clones that express binders
(11). This method is limited though, due to a bias for high expression clones. By using
fluorescently labeled ligand, and fluorescently labeled expression tags for the displayed
antibodies, fluorescence activated cytometric sorting (FACS) can subsequently be used to
rapidly isolate rare clones with quantitatively determined binding parameters while
correcting for surface expression levels of antibody (12, 13). The affinity of the
antibodies expressed on these clones can then be rapidly characterized directly on the
surface of the yeast (10) (Figure 7.2).
Antibodies to heparin based compounds would be especially useful since these
compounds are used as anti-coagulant drugs, and billions of dollars of these drugs are
used each year. Heparin primarily mediates its anticoagulant activity through a unique
pentasaccharide sequence that contains a rare 3-O-sulfated glucosamine. Heparin is a
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Figure 7.1 - (Reproduced from (7)) - Yeast Surface Display of scFv
The scFv is expressed from a pCTCON plasmid as a fusion protein with the Aga2p
mating protein, under the control of a GAL1,10 promoter. The yeast strain used for
expression, EBY 100, has a single copy of Agalp in its genome under the control of the
same promoter. When induced with galactose, both proteins are coexpressed and the
Agalp is bound to the cell wall and linked to the Aga2p-scFv fragment via disulfide
bonds. Expression of the scFc can be probed with fluorescently conjugated anti-HA or
anti- c-Myc secondary antibodies, and scFv bound biotin labeled antigen can be probed
with fluorescently conjugated streptavidin or other secondaries. The expression and
activity of the scFv can therefore be characterized by FACS.
Aga2p -
8·i~
Ye v
Yeast cell membrane
206
Figure 7.2 - (Reproduced from (14)) Flow Cytometer Sorting and Characterization of
Yeast Surface Display
(A) Flow cytometer schematic. Extensional shear causes cells to align and flow single-
file through an elliptical laser focal spot. Multicolor fluorescence emissions are
quantified, and emerging aerosol drops can be sorted into different pools based on user-
selected criteria. (B) Representative flow cytometry data for a double-labeled sample of
yeast displaying a scFv. Each dot represents data from a single cell, labeled with a green
fluorescent antibody against the epitope tag, and a red fluorescently labeled antigen.
Although the variability in antigen labeling is large (spanning two orders of magnitude),
normalization by epitope tag labeling allows sort windows to be set on the basis of
normalized binding levels. (C) Quantitative kinetic and equilibrium data obtained by flow
cytometry. Dissociation rates and equilibrium binding constants can be measured with
excellent precision in situ on the surface of the yeast cell, as shown. (6, 7)
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highly sulfated HSGAG produced by the mast cells of the immune system, which is considerably
more homogenous than HSGAGs produced by other cell types, predominantly consisting of a
trisulfated disaccharide repeat unit, (IdoA2s(oa 1 -4)GIcNS,6s)n (~60-90%). In a typical
polysaccharide of heparin, repeats of this trisulfated disaccharide unit are interrupted on occasion
by other minor sequences, including the AT-HI binding pentasaccharide sequence. This
pentasaccharide is present on average in only one-third of all UFH chains and binds with
high affinity to the serine protease inhibitor antithrombin III (ATIII) (15-17) .
Presently, unfractionated heparin (UFH), a heterogeneous mixture of complex
heparin chains, is the drug of choice in acute clinical situations where high doses of wide-
range anticoagulant activity are desired. UFH is the drug of choice due to the availability
of a universal clinical antagonist to neutralize the anticoagulant effects of UFH, name ly
protamine sulfate. Coagulation monitoring is required with UFH treatment, due to its
variable pharmacokinetic profile and the need to keep heparin levels within the
therapeutic window to prevent serious adverse events such as hemorrhage or stroke.
Currently, there is no simple method to directly detect heparins in circulation, let alone determine
the molar amount of the ATIII binding pentasaccharide.
Low molecular weight heparins (LMWHs) are derived from UFH, and have
largely replaced heparin for some clinical indications, notably deep vein thrombosis.
LMWHs are generated using many different techniques, ranging from controlled
chemical and enzymatic depolymerization to size fractionation, all of which lower the
molecular weight and the polydispersity of the resulting molecules compared to UFH
(18-21). The newest heparin-based anticoagulant is the synthetic pentasaccharide Arixtra
(fondaparinux), an improved version of the naturally occurring heparin
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pentasaccharide (22, 23). All of these LMWHs have unique non- natural epitopes based
on the method of their formation (Table 7.3).
Protamine, a mixture of basic proteins, is routinely used to neutralize bleeding
complications associated with UFH treatment. However, protamine may trigger adverse
and sometimes fatal reactions such as cardiotoxicity, systemic hypotension, pulmonary
hypertension and systemic fatal allergic reaction. In addition, LMWHs and especially
Arixtra are not neutralized by protamine, making this antidote inadequate to modulate
anticoagulant levels of these drugs (24). Effective fine tuning of anticoagulant treatment
with UFH or LMWHs requires a superior antidote that possesses a more selective
biological action and a better safety profile than protamine
The spectrum of modern anticoagulants, such as LMWHs and synthetic
pentasaccharide-analogues, successfully addressed some of the limitations of UFH. In turn, these
anti-coagulants have significant drawbacks of their own, especially with regard to anti-coagulant
monitoring and neutralization. Anti-IIa and anti-Xa activity assays are very unreliable for
LMWHs, and not applicable to Arixtra. LMWHs and Arixtra found clinical use as
prophylactics because of the redundancy for coagulation monitoring. IHobwever, the
impossibility of reliable monitoring led to their limited use in coronary and other major
surgical procedures.
The development of a rapid, sensitive assay that can be used for bedside
monitoring of anticoagulant levels and that is broadly applicable to UFH, LMWHs, and
synthetic saccharides would greatly enhance both the use and safety of heparin- like
molecules in the clinical setting. Current clinically approved methods for monitoring the
plasma heparin level including partial thromboplastin time (PTT) correlate poorly with
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Table 7.3 - Key Properties of Heparin Based Anti-coagulants
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UFH Lovenox Fragmin Arixtra
(Enoxaparin) (Dalteparin) (Fondaparinux)
Anti-Xa (IU/ mg) 160 100 150 700
Polydispersity 1.5 1.35 1.4 1
Method of Purification Chemical f3- Nitrous acid Chemical
Generation elimination degradation synthesis
heparin concentration in various clinical situations ard its improved version, the Xa
assay, has not gained widespread acceptance because of its considerably higher cost.
Most importantly, neither one of these assays reliably monitors LMWHs and synthetic
pentasaccharide analogs. The first direct detection assay of heparin in plasma was
recently published (25). This ELISA-based assay uses a three-copy fusion protein of a
hyaluronan-binding domain for the aspecific detection of therapeutic plasma levels of
UFH, but its detection range falls short regarding clinically relevant concentrations of
LMWH. Application of a pentasaccharide sequence-specific antibody with a sufficiently
high affinity in a similar ELISA-based approach will increase the detection specificity
and sensitivity.
We propose to generate specific, high affinity antibodies against heparinoids that
can be used for monitoring and neutralization of heparins. With the selection of a broad
panel of heparin-recognizing human antibodies, we anticipate generating a new set of
tools to analyze heparin-protein interactions. These antibodies may be used in antibody-
based biosensors for direct detection of the bioactive sequences. A direct detection
methodology for heparin drugs will greatly decrease the response time for in-line
determination of the anti-coagulant potential. These antibodies may also be developed as
a neutralizing treatment to reverse anti-coagulation.
The analysis of non-anticoagulant heparin and heparin-protein interactions is
another crucial application of these antibodies. The structural diversity and complicated
biosynthesis of GAGs renders these molecules difficult to study, mainly due to the
limited availability of sequences with physiological and pharmacological significance. By
developing approaches for the isolatbn and direct quantification of protein binding GAG
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epitopes, the in depth analysis of heparin sequences that specifically interact with a given
protein has become feasible, even if such sequences are present in small quantities
(Chapters 1, 5, 6).
This chapter deals with our first work towards generating anti-heparin antibodies
for analytical and therapeutic purposes. We propose to develop a panel of specific, high
affinity, antibodies for heparins through using our ability to generate nanomolar affinity
single chain antibodies (single chain variable fragments, scFv) through a novel display
technology. Following the development of these scFv, we plan on applying our novel
analytical tools to determine the epitopes to which they bind, as well as which antibodies
have anticoagulant activity neutralizing ability.
7.2. Materials and Methods
Yeast surface display:
We used a yeast display library that encompasses the naive human antibody
repertoire (10) to select a panel of scFv antibodies against biotinylated HMW-heparin and
LMW-heparin. Selections against low-micromolar concentrations of biotinylated LMW-
and HMW-heparin were performed through one or two initial rounds of magnetic cell
sorting (MACS): 5-10 copies of the induced library (0.5-1*1010 cells) were washed and
resuspended in 10 ml sterile PBS/ 0.1% BSA containing the biotinylated heparin sample
(UFH, Celsus, Cincinnati, OH, enoxaparin and dalteparin were obtained at a local
pharmacy), incubated at 40 C for 60 minutes, washed with ice-cold PBS/B, resuspended
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and incubated at 40 C for 30 minutes in 10 ml PBS/B containing 500 jl Miltinyi MACS
Streptavidin magnetic beads (Miltinyi Biotech, Auburn, CA). Cells were washed with ice
cold PBS/B, resuspended in 50 ml PBS/B and loaded onto a LS MACS column. The
column was washed with 3x 10ml PBS/B and bound cells were eluted with 7 ml
SD/CAA growth medium. The enriched library was grown and induced for subsequent
rounds of selection. Subsequently, iterative rounds of FACS selection were performed:
-107 cells were washed and resuspended in 0.1 ml sterile PBS/ 0.1% BSA containing the
biotinylated heparin, incubated at 370 C for 60 minutes, washed with ice-cold PBS/B,
resuspended and incubated on ice for 30 minutes in 0.1 ml PBS/B containing
fluorescently conjugated biotin-binders (anti-biotin antibody, Neutravidin, or
Streptavidin; Molecular Probes, Eugene, OR). Cells were washed with ice cold PBS/B,
resuspended in 0.75 ml PBS/B and cells with positive signal for both antibody expression
and heparin binding were selected in a MoFlo cell sorter (Cytomation, Fort Collins, CO).
The sorting window was set to select for the highest fluorescent intensity (0.1-0.5% of the
population). Cells were also analyzed for heparin binding in between FACS sorts using
flow cytometric analysis.
Preparation of heparin hexa- and octasaccharide libraries:
UFH from porcine intestinal mucosa was partially depolymerized by recombinant
heparin lyases from Flavobacterium heparinum (26-28). Separate incomplete digestions
were performed overnight at 370 C in Heparinase I digestion buffer (100 mM MOPS/ 5
mM calcium acetate, pH 7.0) with limited amounts of the individual heparinases I, II, and
III, as well as with combinations of these enzymes. Digests vwre pooled and size
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fractionated over a Bio Gel P6 size exclusion chromatography column, using 100 mM
ammonium carbonate as running buffer. Absorbance of individual fractions was be read
at 232 nm in a SpectraMAX 190 spectrophotometer (Molecular Devices, Sunnyvale,
CA).hexa- and octasaccharide containing fractions were pooled, lyophilized, dissolved in
milliQ water, and stored at -200 C.
Biotinylation of Anticoagulant Drugs Through Uronic Acids
The anticoagulant drugs Fragmin and Lovenox have been biotinylated non-
specifically through the carboxyl groups on the uronic acids. The uronic acids are
activated using the water-soluble carbodiimide EDC (1-Ethyl-3- (3-
dimethlaminopropyl)carbodiimide), making them reactive to amine groups including
hydrazide amino groups. The amount of EDC and Biotin-hydrazide can be controlled in
an attempt to achieve single biotinylation of the chains (29). For Fragmin and Lovenox,
which are mixtures of chains, the number average molecular weight (30) was used to
calculate a mean number of uronic acids in a chain. A binomial distribution was used to
calculate the molar amounts of Biotin- hydrazide to use so that less than 10% of the
biotinylated chains are multiply labeled (these conditions theoretically leave the vast
majority of chains unlabeled). The molar ratio of Biotin-hydrazide to uronic acids was
used to establish the probability of labeling each uronic acid, while the EDC was used in
excess.
The biotinylated chains were purified from the unbiotinylated chains prior to their
use in Ab selections. Since Fragmin and Lovenox are mixtures, separation of singly
labeled chains from other species via HPLC is not practical. Instead, a monomeric avidin
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column (Pierce) was used to purify the biotinylated chains, which were eluted with
excess biotin. Following dialysis and lyophilization, the amount of biotinylated drug that
was recovered was quantified using a microtiter plate assay for uronic acid determination
(31). Since for each chain at least one uronic acid is linked to a biotin and is not detected
by this assay, the final concentration that was calculated using the number average
molecular weight was adjusted accordingly.
Characterization of Soluble Single-chain Antibodies
Soluble production of single-chain antibodies will follow a method previously
described (32). Briefly, the single-chain variable region antibody fragments (scFv) will
be cut from the purified pCTCON based expression plasmids from the desired clones
using restriction enzymes BamHI and XhoI to remove the c-myc epitope tag and then
ligated into the pRS44220 vector cut with the same enzymes. The resulting vectors will
contain the scFv with a c-terminal 6-histidine tag for nickel affinity purification. These
vectors will be transformed into and expressed in the yeast strain YVH10 (33). Soluble
expression can be tested using an immunoblot with an anti-tetra his antibody, and then
expressed on a large scale and purified using nickel affinity (33, 34).
In vitro Anti-Xa and Anti-IIa monitoring
To evaluate the effect of antibodies on the anti-Xa and anti-IIa anticoagulant
activity, materials and methods from Coatest kit (Diapharma, Columbus, OH) were used.
Chromogenic substrate S-2222 will be used to assay the Xa activity. The anti-IIa assay
will be performed using the thrombin-specific chromogenic substrate S-2238.
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7.3. Results and Discussion
7.3.1. Anti-LMWH scFv
My initial studies were aimed at the generation of an antibody panel that
specifically recognizes epitopes in LMWHs and synthetic oligosaccharides. We
endeavored to use the yeast display system for directed evolution of scFv to LMWH
epitopes. I hypothesized that LMWH, being structurally different from native UFH and
containing synthetic epitopes, may be less refractory to scFv generation than UFH. Any
antibodies generated to LMWH specific epitopes could be used as starting points for new
libraries of variable region sequences for eventual affinity maturation to native heparin
epitopes. In addition, it was likely that we would identify scFv to native heparin epitopes
also.
Developing antibodies to GAGs using yeast surface display poses several unique
challenges. The challenges involve antigen selection and labeling. Ideally, a single
homogenously labeled antigen can be used for sequential rounds of positive selection to
select the highest affinity antibodies and for subsequent affinity maturation. If the
antigens are known to be homogeneous and the valency is known, the affinity of the
antibodies can be determined experimentally using binding isotherms on the yeast.
Commercial preparations of GAG drugs, however (with Arixtra being the notable
exception), are heterogeneous mixtures that possibily have multiple epitopes on each
chain, and labeling these preparations can be a challenge.
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A potential complication of selecting antibodies against biotinylated
polysaccharides may be the selection for antibodies that interact with unique or
combination epitopes involving reagents used in the selection procedure. To minimize
the odds of selecting for antibodies that interact with biotin epitopes, singly biotinylated
antigens are preferred. However, the LMWH drugs we are targeting have reducing end-
chemistry refractory to single biotinylation, and therefore are biotinylated on carboxy
groups of the uronic acid, with a predominant stoichiometry of one biotin per GAG chain
(estimated using a binomial distribution for random biotinylation events). Furthermore,
the alternating use, in sequential rounds of selection, of various biotin-binding reagents
(streptavidin, and neutravidin) and conjugated fluorescent labels [R-Phycoerythrin (PE),
Allophycocyanin (APC)] will minimize the risk of selecting antibodies against these
reagents. Furthermore, a dose-response competition by unbiotinylated ligand is an
absolute requirement for selected antibodies to be considered lead candidates for a
subsequent stage of this project. Specificity can also be determined by testing the
antibodies against panels of negatively charged polymers including other GAGs, Dextran,
and DNA.
Direct selections of antibodies against biotinylated Fragmin (dalteparin) and
Lovenox (enoxaparin) were first performed. In these experiments, we aimed to select
antibodies that recognize epitopes specific for these LMW-heparins, notably the
modifications along the polysaccharide chains and on their reducing ends that result from
the employed depolymerization methods. In addition, the native heparin epitopes are also
present, so a panel of antibodies would probably contain antibodies to those epitopes
also. Along with direct selections against biotinylated dalteparin and enoxaparin alone,
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we performed competition selections with unbiotinylated high molecular weight heparin
(HMWH). This way, we anticipated driving the selection towards specific artificial
epitopes in Dalteparin and Enoxaparin that are not shared with heparin (Figure 7.4). In
parallel, collaborators Guido Jenniskens and Wai Lau were performing selections
attempting to generate antibodies against reducing end biotinylated UFH and Arixtra.
The scFv library we began with was the previously generated non immune Feldhaus
library (naive library) as described (10).
I began four different sorting lineages with a single round of MACS sorts. There
were two Lovenox sorting lineages, beginning with one sort against 1 gM biotinylated
Lovenox, and one sort against 1 piM biotinylated Lovenox with competition from 5pM
HMWH. There were two Fragmin sorting lineages, both beginning with one sort against
200 nM Fragmin. Although these sorts are relatively stringent, we were limited by the
amount of biotinylated LMWH available. Also, we wished to bias those picked for any
high affinity binders. Following the MACS sorts, we tested the resulting enriched
libraries for LMWH binders using a flow cytometer, but did not see any dose dependent
binding.
Following the initial MACS enrichment, we continued onward to conduct five
sequential rounds of FACS to enrich each of the four lineages for LMWH binders (Table
7.5). Each sort was conducted with alternating secondary fluorescent detectors of
biotinylated-LMWH binding (neutravidin-PE with streptavidin-APC). After each round,
a flow cytometer was used to analyze the enriched pools for binding to LMWH. After
the second round of FACS sorts (the first FACS sort using streptavidin-PE), streptavidin
binders began to appear in the pools of clones. There were negligible increases in total
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Figure 7.4 - Formation of two Key LMWHs from UFH.
Both Enoxaparin (Lovenox) and Dalteparin (Fragmin) are generated by chemical
depolymerization of UFH. (left) Enoxaparin is generated by 1-elimination after
esterification of the carboxylate groups. As a result of this chemistry, a number of
chemical modifications occur to the heparin backbone, including (1) formation of a A4,5
double bond at the non-reducing end; (2) reaction of the reducing end with a 6-O-SO3-
resulting in 1,6-ring closure, and (3) C-2 epimerization of the reducing end glucosamine
to form mannosamine, among others. (right) Dalteparin is generated through nitrous acid
depolymerization of UFH. As a result of this process, (4) a 2,5-anhydromannitol moiety
is formed at the reducing end of the chain.
Enox SO3a H, SO 3' Hoso -
Enoxaparin \ Dalteparin
H2-0SO3' H0SiYZ O" •SO
H03 H 3 HS3.0_ i
Table 7.5 - Sorting Procedure Aimed at anti-LMWH scFv
Anti-Lovenox Anti-Lovenox Anti-Fragmin Anti-Fragmin
w/ Competion w/ Competition
MACS 1pM Lovenox 1pM Lovenox 200nM 200nM Fragmin
5pM HMWH Fragmin
FACS 4X 500nM 500nM 500nM 500nM Fragmin
Lovenox Lovenox Fragmin 5pM HMWH
5pM HMWH
FACS 5 500nM 500nM 500nM 500nM Fragmin
Clone Selection Lovenox Lovenox Fragmin 5pM HMWH
5pM HMWH
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population binding to LMWH after four sorts, and streptavidin binders were starting to
overwhelm the enriched libraries (despite our efforts to limit streptavidin binders by
sorting with neutravidin secondaries) (Figure 7.6). However, there still could have been
LMWH binding clones in low abundance that could not shift the mean fluorescence of
the entire library when labeled for LMWH binding.
The fifth FACS sort was used to isolate individual clones into 96 well plates, so
that the diversity of the remaining library could be investigated and individual LMWH
binding clones could be sought. Out of 42 individual clones that were screened by flow
cytometry after expansion from the 96 well plates, none bound LMWH to a discernable
degree. While we did not sequence those clones to determine the actual genetic diversity,
it was clear that the libraries had not been significantly enriched for heparin binders, and
therefore would not later yield diverse LMWH binders for subsequent affinity
maturation.
There are several reasons why the first attempt at generating anti-LMWH scFV
could have failed. The first possibility is that there are no scFv in the naive library that
are capable of binding to LMWH with any significant affinity. Due to the unknown
LMWH exposure history of the donors from whom the library was made, and the lack of
immunogenicity of heparin in general, this is quite possible. The second possibility is
that the MACS step failed, and no LMWH binders from the naive library made it to the
FACS stages. This is a possibility because the MACS step was quite stringent. Another
piece of data that suggests the MACS step caused problems was the isolation of
streptavidin binders early in the FACS process. The MACS beads were streptavidin
coated, and therefore anti-streptavidin yeast would preferentially be enriched during this
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Figure 7.6 - Demonstration of Streptavidin Binders
Individual yeast appear in red, multiple yeast at similar intensities generate a heat map
from red (individual) to blue (highest density). (A) The fourth FACS sort of the anti-
Fragmin lineage (F4), using neutravidin-APC as a secondary fluorescent label. Region
"1" contains clones not expressing full length scFv (not labeled by anti-cmyc secondary).
Region "2" contains clones expressing scFv, but not binding to biotinylated Fragmin (not
labeled by fluorescent neutravidin secondary). Clones that are highly labled by both
secondaries would be putative Fragmin binders. (B) A FACS sort against the same
population (F4), using stretavidin-PE as a secondary fluorescent label. The fraction of the
population that increases in fluorescent intensity when the biotinylated Fragmin is labeled
with streptavidin-PE, but not when the biotinylated Fragmin is labeled with neutravidin-
APC, are streptavidin binders.
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step. However, my collaborator Wai Lau saw the emergence of streptavidin binders in
his anti-HMWH search without the use of MACS (see below). The third possibility is
that the FACS steps failed. They could have failed due to several reasons, including poor
quality antigen, too stringent sorting conditions, or even a fast off rate for the initial scFv
that caused the LMWH to fall off the yeast sometime during the incubation with the
secondary, the wash step, or the FACS sort. One method to address this issue is to pre-
incubate the biotinylated heparins with the secondaries.
In preparation for second attempt at finding initial LMWH binding scFv, I
generated higher quality Lovenox-like antigens. The LMWH Lovenox shares the same
non-reducing end epitope (the A4,5 double bond) with heparinase treated heparin. I used
this fact to create Lovenox-like epitopes to target this modification I used heparinase to
cut UFH, size fractionated it using a size exclusion column, and then used biotin-
hydrazide to singly biotinylate the size fractionated lovenox-like oligosaccharides at the
reducing end. In addition, I manufactured a replacement for the MACS beads to try to
avoid isolating streptavidin binders. IHeparin coated agarose beads (with the heparin
attached via its reducing end) were treated with heparinase to create Lovenox-like
epitopes.
I carried out three rounds of selection with these beads, beginning with a naive
library. For these sorts, I washed the library over the beads, and isolated the beads with
the adherent yeast. I then attempted to elute yeast with soluble heparin competitor, and
grew up the eluent and the bead fraction (with yeast that were not competed off)
separately. The eluted fraction should contain yeast with affinity to the epitopes that the
lovenox-like heparin beads and the UFH competitor shared.
222
Following the bead sorts, I began FACS sorts as before. Interestingly enough, the
yeast in these sorts showed much larger forward and side scatter signals than typical yeast
in previous sorts. Under microscopic inspection, these yeast seemed to have larger, dark
nuclei, and also seemed more prone to agglomeration than the yeast in the naive library.
Either something about the scFv they were expressing was causing a physiological
change (cross reactivity perhaps with a cellular component such as DNA), or the yeast
cultures could possibly have been contaminated with some sort of pathogen (although
they were being grown in antibiotic treated media). Flow cytometer analysis of these
enriched libraries after FACS sorts showed signal that seemed to represent heparin
binding; but, after careful analysis, heparins or other negatively charged polymers
seemed to just be enhancing the scattering (and probable agglomeration) of the cells. The
selection of "sticky" yeast could have been predicted, because the column sorts with the
agarose beads should preferentially trap large agglomerations of yeast that do not
propagate well through the bead column during wash steps.
7.3.2. Anti- HMWH scFv
While my efforts to generate scFv against LMWH were making little progress,
my collaborator Wai Lau did manage to generate putative anti- HMWH scFv. Lead single
scFv against heparin were isolated from the naive library. Heparin-bnders were selected
using heparin-agarose Cellthru Big Beads (Sterogene) and FACS. Seven rounds of
selection using heparin-agarose and four rounds of FACS using biotinylated heparin were
performed. To facilitate selection of weak binders, the biotinylated heparin was preloaded
onto streptavidin-fluorescent conjuages prior to labeling of yeast cells (this became
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unnecessary after the second mutagenized library, H2). In the last round of FACS, the
percentage of heparin-binders was about 0.4%. The scFvs isolated from the non-immune
library were engineered for increased affinity using random mutagenesis. Error-prone
PCR was performed using the nucleotide analogues 8-oxo-2'-deoxyguanosine-5'-
triphosphate (8-oxodGTP) and 2-deoxy-P-nucleoside-5'triphosphate (dPTP), which were
purchase from TriLink Biotechnologies. The mutated DNA was transformed into yeast
using homologous recombination to generate the next library (H1) (8, 9, 32, 35).
After 3 rounds of heparin-agarose selection and seven FACS, a significant
population of surface-displayed scFv that bind biotinylated heparin was obtained. This
pool of clones was verified as heparin-binding when the pool showed decreased binding
to biotinylated heparin in the presence of unfractioned heparin competition (Celsus). Six
cycles of random mutagenesis followed by heparin-agarose and FACS selection were
conducted. In each cycle, the stringency of selection, such as temperature and time of
incubation, was increased in order to isolated heparin-binders of higher affinity.
When the affinity maturation reached the 8th round, scFvs that cross-reacted with
streptavidin fluorophore conjugates and heparin began to populate. However, attempts to
remove reagent binders were met with little success. Finally, individual clones were
screened for specificity towards heparin. A set of clones specific towards heparin was
isolated and used to generate subsequent libraries. In addition, FITC-tyramine-heparin
conjugate and biotinylated heparin were used in alternating rounds of FACS in order to
prevent selection of Streptavidin-binders. Despite these attempts, scFvs that possess high
affinity to Streptavidin conjugate re-emerge after a few rounds of FACS. When
Streptavidin-binders appeared, multiple rounds of negative sorting were performed until
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the population was depleted of Streptavidin binders. In the end, a total of six cycles of
mutagnesis-selection was performed. Using flow cytometry, the ensemble of scFv from
the latest library has an affinity onthe order of 100 nM, and several clones are being
solubly expressed for further characterization.
7.4. Conclusions and Future Directions
After exhaustive effort, directed evolution using yeast surface display has
managed to generate a pool of anti-HMWH scFv with nanomolar affinity. These
individual scFv need to be characterized, to determine their specificities and affinities, to
evaluate them for future uses. With some work, these scFv could be useful for
fractionation, chemical analysis, biological research, clinical screening, or clinical
interventions.
The first step is to examine the protein sequence of the heparin-binding scFv to
see if any patterns emerge. Diversity in the variable regions could determine which lead
candidates to move forward with to cover different putative heparin epitopes. Also,
analysis of the sequences would allow the selection of a heparin-binding biased library
for use as a starting point in directed evolution of anti-LMWH scFv.
Each clone needs to be tested not just for sensitivity, but also for specificity.
Since heparin is highly negatively charged (>3 negative charges per disaccharide on
average), the possibility exists that the selected antibodies interact non-specifically with
the high charge density on the linear polysaccharide. To determine the specificity for
heparin, we will test the interaction of the selected antibodies with other GAGs and with
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negatively charged polymers (e.g DNA, CD, DS, dextran, etc.). Also, we can test for the
affinity to various heparin based drugs (enoxaparin, dalteparin, etc.) to look for cross
reactivity with other epitopes.
In order to gauge the actual affinity of the scFv for heparins, I propose
simultaneously using SPR and SMR analysis using solubly expressed and singly
biotinylated scFv. Antibody affinity is regularly determined using a BIAcore 3000
instrument by immobilizing antibodies on the surface of a sensor chip. The antigen will
bind to the antibody from a continuous flow over the chip surface at various
concentrations, and the kon and koff rates can be determined from the sensorgrams. We
plan to match SPR data to SMR data not only to get a more robust estimate of scFv Kd,
but also to validate the SMR method.
Finally, we aim to develop a human antibody-based antidote for the in vivo
reversal of anticoagulant activity of UFH, LMWHs, and synthetic (penta)saccharides. An
antibody that can quickly and specifically reverse the anticoagulant activity of modern
anticoagulants without serious side effects will be a long anticipated drug candidate in the
field of anticoagulant therapy, as well as an important diagnostic tool for monitoring anti-
coagulation Therefore, we will test scFv candidates for their ability to neutralize
anticoagulant activity in commercial heparin anti-Xa and anti-IIa colorimetric assays, on
the way to choosing a panel for humanization into full IgG.
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Part IV
Implications
Chapter 8: Future Directions and Conclusions
8.1. Future directions
8.1.1. Advancing the Analytical Tools
This thesis provides a series of tools and methods to deal with the unique
complexities in GAG analysis. Each tool adds novel and useful capabilities to the GAG
analysis toolbox. However, each of these tools leaves room for improvement both
individually, and in its use in conjunction with the others. Continued development of
these tools is necessary to maximize their usefulness and enable their widespread
adoption.
I presented two novel HSGAG degrading enzymes from F. heparinum which help
determine the location of sulfates with these GAGs. While these two enzymes are useful
for exosequencing HSGAG oligosaccharides, they are limited in their applications. Their
exolytic and obligatory sequential nature can provide useful constraints in sequencing,
but also can be limiting. Detailed site directed mutagenesis and crystallization studies
should be undertaken to elucidate the enzymes' structure- function relationships. With
this understanding, these enzymes may be engineered to work on other substrates, or
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even endolytically, providing more tools for the sequencing toolbox. In addition, the 6-
O-sulfatase has the capability to remove the terminal 6-O-sulfate on the anticoagulant
Arixtra, neutralizing its activity. However, the enzyme is inhibited by the phosphate in
plasma. If the enzyme could be reengineered to remove this inhibition, the enzyme could
be a viable neutralizing treatment for this anticoagulant therapy. Finally, there is one
other novel coding sequence which we discovered in F. heparinum that has putative
GAG sulfatase activity (by sequence homology analysis). However, even after cloning
and recombinantly expressing this enzyme, we were unable to detect any activity against
a panel of sulfated GAG derived substrates. We should continue onward to analyze this
enzyme and determine its activity, since perhaps it could be another useful tool for GAG
microsequencing.
As complements to sulfation locating tools, phenylboronic acids are demonstrated
as specific indicators of unsulfated epitopes. While our preliminary data focused on their
application in the MS to detect unsulfated chondroitin, future work could expand the use
of these molecules. First, PBAs can be investigated for use in chromotagraphy. Since
the reaction of carbohydrates with these molecules is in equilibrium, molecules that bind
should just be retarded in a chromoatographic column, allowing separation without an
elution gradient. This sort of chromatography should therefore lend itself well to
fractionation of saccharides upstream of an ESI-MS, which is sensitive to mobile phase
changes. Molecules containing multiple boronic acids could be designed and
synthesized to complex with different moieties, expanding the epitopes that can be
probed. In addition, the stability of these complexes in tandem MS could be investigated,
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to see if they can be used during fragmentation analysis of larger oligosaccharides in an
attempt to locate the epitopes in question.
Tandem MS in an ESI ion trap device is used as a tool to quantify relative ratios
of HSGAG derived structures. While our work was limited to disaccharides, this work,
along with other recent work, demonstrates the possibility of building to a tandem MS
method for sequencing GAG oligosaccharides (1). But currently, there are no data on the
fragmentation patterns of glucuronic versus iduronic acid or 3-O-sulfate containing
HSGAGs. Our analytical expertise, along with our exolytic enzymes, can be leveraged to
create substrate "ladders" which are created by sequentially removing single
modifications from an oligosaccharide, and pairs of oligosaccharides that differ only by
glucuronic versus iduronic acid epimerization. We can then apply the same rigorous
observation of fragmentation patterns of these substrates to create rules for distinguishing
these important modifications in the tandem MS sequencing of unknown
oligosaccharides.
While sequencing is a versatile tool that can be used to look for specific known
epitopes, we developed a set of tools that can more rapidly and directly quantify bioactive
epitopes without knowing their sequences. Both the microfluidic field effect sensor and
the suspended microchannel resonator improve on the sensitivity of existing methods for
HSGAG quantification by orders of magnitude. In addition, we have modified both
sensors with a protein that can be used to specifically quantify a bioactive epitope without
characterizing the entire GAG molecule. However, in order for these tools to be widely
adopted, the ease of use and scope of these tools to rapidly quantify multiple different
epitopes must be improved. We have begun to address this issue by looking for
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improvements in the surface chemistry for immobilizing our GAG receptor proteins.
Two technologies will be investigated to immobilize proteins on the sensor surface in a
single orientation, preserving the surface activity of the protein. Building on the modular
PLL-PEG-biotin-avidin layer chemistry, we are going to singly biotinylate scFv using
enzymatic biotinylation of an acceptor peptide genetically engineered onto the protein
using the E. coli enzyme BirA (2). To simplify the modification process, we are
investigating the immobilization of FGF-2 by engineering a silicon-oxide binding
peptide, developed by E.M. Krauland in the Belcher laboratory at M.I.T., directly onto
the terminus of the protein. In this manner we can functionalize the sensor surface in a
single step, enabling more rapid and consistent functionalization.
Since obtaining the amounts of functionalized proteins necessary to perform these
experiments is not trivial, we should attempt to generate a panel of anti- GAG scFv with
varying specificities to eliminate the need for the natural GAG binding proteins. We can
use the scFv in immunoprecipitation experiments and determine the scFv specificity by
sequencing the precipitated oligosaccharides. Or, we can characterize the scFv binding
epitope by testing for competition with proteins of interest. After characterizing the anti-
HMWH scFv which we have generated, we can use those lead scFv as the starting points
for new mutagenized libraries to attack new epitopes (such as those in LMWH). We can
also select promising scFv that compete with biologically relevant proteins as candidates
for antibody humanization and clinical use.
It is difficult to prioritize these future projects without considering which
applications are most pressing. While clinical development of diagnostics and
neutralizing treatments is obviously attractive, the goal of contributing to basic science
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should not be bypassed. Now that we have tools that can analyze the minute amount of
material that can be produced in tissue culture, what questions could we answer? One
key question is how do cells change their glycosylation patterns in response to stimuli or
their differentiated state? The answer to this question could aid in understanding the
implications of glycosylation in development, cell-cell signaling, cancer metastasis, and
infection, as well as help in the search for biomarkers.
8.1.2. Mining and Modeling
One of the premises of systems biology is that measurement should be used in
concert with mining, modeling, and manipulation (experimentation) to understand the
complete picture of GAG biology. Moving forward, we plan on mining the literature
and online databases for enough data to generate a preliminary model for HSGAG
biosynthesis. HSGAG biosynthesis involves a sequence of enzymes with various
specificities, acting in a nontemplate based manner, stochastically generating the GAG
chains which are attached to core proteins (Chapter 1). A model that adequately
represents this synthetic system could suggest sensitive nodes where GAG synthesis
could be regulated to change the amount of a bioactive epitope which is generated. Or,
one may use the model to translate changes that are observed experimentally to changes
in the synthetic machinery. These hypothesized changes could be analyzed as potential
endpoints of the regulatory pathway that is modulating the cellular behavior.
Our model will be based on the three main phases of HSGAG biosynthesis: chain
initiation, chain elongation, and chain modification. Chain initiation sets the stage for the
creation of a GAG chain, creating a platform to elongate the chain from a base attached
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to a protein (proteoglycan). Chain elongation adds subunits to the chain to create a
"default" chain. Chain modification, the phase of most interest, then modifies the
elongated chain via reactions carried out by four classes of sulfotransferases and an
epimerase (enzymes). These enzymes recognize specific binding sites on a chain, and
carry out a modification reaction upon them (3, 4).
Preliminary work has generated a framework for such a model. There are several
non-trivial computational challenges to overcome to simulate the creation of GAG
chains. The three phases of GAG chain creation mentioned above need to be represented
in software in a flexible manner to allow study of various conditions. The desired
flexibility in simulation conditions can only be achieved by careful software engineering.
In addition, the algorithms and data structures require special attention. To simulate
chain modification, we need to be able to represent enzymes with varying reaction rates,
recognition sites, and binding affinities. Each of these enzymes will then have multiple
reactions with different binding sites and binding affinities. From this collection of
possible reactions, we need to correctly simulate the order in which they stochastically
take place in solution, and then apply them to a collection of GAG chains. To achieve this
goal, we will build off of the Gillespie algorithm (5), initially developed to simulate
chemical/biochemical systems of reactions efficiently and accurately.
The Gillespie algorithm takes into account enzyme concentrations, product and
reactant concentrations, reaction rates, and stochasticity to calculate the time step (in
simulation time) until the next instance of a particular reaction will occur. With this
calculation, we can order the overall set of reactions. As a reaction causes a change in
concentration of reactants or products, reaction times are updated and reactions are
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resorted. To efficiently calculate product and reactant concentrations, we must be able to
keep track of the number of occurrences and the location of all the binding patterns that
the enzymes in the simulation can recognize. The most conceptually straight-forward
solution to this problem would require vast amounts of computational resources, making
the simulation practically unfeasible. Therefore, we will need to design an efficient
tracking data structure. The Gillespie approach has been used by others to simulate
complicated biological processes, including infection of a bacteria by a T7 bacteriphage
(6), and we believe it is a good choice to implement here.
Once the model is complete, we will need to parameterize the simulation using
known biochemical data, such as the binding affinity of enzymes to different recognition
sites, the reaction rates of the enzymes, etc. These parameters can be acquired through
literature searches and online databases. Unknown parameters will be estimated based on
similarity to similar known proteins. Once we begin simulating the creation of GAG
chains, we need to verify the model by comparing the output to known data to
compositional analysis and gene expression data from tissues, and oligosaccharide
sequences and knockouts. This data will be provided by previous work done in the lab,
and further literature search.
Depending on the rnture of the model predictions, different experimental systems
will be needed to test the model. The aim would be to choose interesting predictions
from the model to test, so we can simultaneously learn about the quality of the model and
answer biological questions. We can then use the results of the experiments to inform the
model, and make new predictions and perform new experiments in an iterative fashion, in
an attempt to answer major open questions in GAG biosynthesis.
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8.1.3. Modeling, Measuring, and Manipulating
In order to probe model predictions, it is best to select well characterized and
controlled experimental systems that can be exactly perturbed. For example, GAG
binding proteins are known to play an important role in the differentiation and
maintenance of hepatocytes and endothelial cells. In both of these experimental models
GAG binding growth factors are known to influence the differentiated state of the cells.
Therefore, we can observe these cell types as they differentiate (e.g. tubularization of
HUVEC cells) or dedifferentiate (primary hepatocytes in culture) and determine how
their GAG profiles change using all the sensitive tools outlined in this thesis. With the
help of the computational model, we can hypothesize as to the proteins regulating these
changes and how these changes will alter the cells' responses to GAG binding growth
factors, such as FGF-2 or heparin binding EGF. We can then test those predictions
experimentally. These experimental models are exceptionally attractive because they are
well characterized, and these culture models are in use by ourselves and collaborators at
MIT (7-10).
8.2. Conclusions
The research tools presented in this thesis were purposefully designed to allow the
use of tissue culture derived material in GAG analysis. These new methods and devices
significantly reduce the amount of sample and sample preparation needed in order to
perform meaningful analysis. Prior to this thesis work, researchers were stymied by the
lack of these sorts of sensitive tools. To this day, crucial questions such as "how do cells
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actively change their GAG profiles to regulate their response to GAG binding growth
factors" have not been satisfactorily answered. These questions are unanswered, in the
first instance, because the tools are not available to perform the experiments necessary to
answer them
The new techniques presented in this thesis can begin to help answer these
questions. Mass spectrometry enabled enzymatic exosequencing, chemical
complexation, and fragmentation can all rapidly provide sequence information on small
amounts of important oligosaccharides. Microfluidic biosensors that detect surface
binding by charge or mass, in concert with protein or novel antibody GAG receptors, can
rapidly profile scarce GAG mixtures.
With future development, these tools and novel anti- GAG antibodies have the
potential to make a noticeable impact. New sensors could become clinical diagnostics.
New antibodies might develop into clinical treatments, blocking the activity of bioactive
GAGs. In concert with new models and experimental systems, some of these techniques
may become fixtures in basic science laboratories investigating the fundamentals of
glycobiology. While individually each tool discussed in this thesis provides a small piece
of the larger puzzle, continued concerted effort to advance and integrate this suite of tools
represents the largest opportunity to make a difference.
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Abbreviation Definition
AU A(4,5)-uronic acid; generated by lyase depolymerization
4MU 4-methylumbelliferyl
Ab Antibody
ACT Activated Clotting Time
APTS 9-aminopyrene-1,4,6-trisulfonate
APTT Activated Partial Thromboplastin Time
AT-III Antithrombin-III
BirA Bacterial biotin ligase from E. Coli
CCSD Complex Carbohydrate Structures Database
CE Capillary Electrophoresis
CFG Consortium for Functional Glycomics
3-[3-(Cholamidopropyl)dimethylammonio]-1 -proanesulfonate;
CHAPS detergent
CS Chondroitin Sulfate
DAPBA Dimethylaminophenylboronic acid
CD209, a C-type lectin receptor present on both macrophages and
DC-SIGN Dendritic cells
DNA Deoxyribonucleic acid
DS Dermatan Sulfate
DVT Deep Vein Thrombosis
EDTA ethylendiaminetetraacetic acid; divalent cation chelator
Ethyleneglycotetraacetic acid; calcium specific divalent cation
EGTA chelator
EIS Electrolyte Insulator Silicon
ELISA Enzyme Linked Immunosorbent Assay
ESI-MS Electrospray Ionization Mass Spectrometry
FAB Fast Atom Bombardment
FACS Fluorescence-activated cell sorter
FET Field Effect Transistor
FGF Fibroblast Growth Factor
FTICR-MS Fourier Transform Ion Cyclotron Resonance Mass Spectrometry
GAG Glycosaminoglycan
Gal Galactose
GBP Glycan Binding Protein
gCOSY Gradient correlated spectroscopy; a two-D NMR technique
GIc Glucose
HA Hyaluronic Acid
HMBC Heteronuclear Multiple Bond Correlation
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HPLC High-performance Liquid Chromatography
HS Heparan Sulfate
HSGAG Heparin/Heparan Sulfate Glycosaminoglycan
HUVEC Human Umbilical Vein Endothelial Cells
ICAM Intercellular Adhesion Molecule
KEGG Kyoto Encyclopedia of Genes and Genomes
KS Keratan Sulfate
LC Liquid Chromatography
LMWH Low Molecular Weight Heparin
MACS Magnet Assisted Cell Sorting
MALDI-MS Matrix Assisted Laser Desorption Ionization Mass Spectrometry
MPS I Mucopolysaccharidosis Type I; Hurler Syndrome
MS Mass Spectrometetry
NAc n-acetyl
NAcPBA 3-acetamidophenylboronic acid
NHS n-hydroxysuccinamide
NMR Nuclear Magnetic Resonance
PBA phenylboronic acid
PBS Phosphate Buffered Saline
PCR Polymerase Chain Reaction
PE R-phycoerythrin
PEG poly-ethylene-glycol
PLL poly-L-lysine
PTM Post Translational Modification
RNA Ribonucleic acid
RPIP Reverse Phase Ion Pairing
scFv Single chain variable fragment
SMR Suspended Microchannel Resonator
TOCSY Total Correlated Spectroscopy
UFH Unfractionated Heparin
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